[
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_0",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Ministry of Health Malaysia\nAcademy of Medicine of Malaysia\nMalaysian Society of Hypertension\nManagement of Hypertension\n(4th Edition)\nCLINICAL  PRACTICE  GUIDELINES\nMOH/P/PAK/272.13(GU)\nISBN 978-967-12406-0-1\nSTATEMENT OF INTENT\nThis guideline was developed to be a guide for best clinical practice in the \nmanagement of hypertension. All efforts were made to ensure references quoted \nwere the most current at the time of printing. Specific attempts were made to use \nlocal data and publications to ensure local relevance. Adherence to this guideline \nmay not necessarily lead to the best clinical outcome in individual patient care. \nEvery health care provider is responsible for the care of his/her unique patient",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_1",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Every health care provider is responsible for the care of his/her unique patient \nbased on the clinical presentation and treatment options available locally. However \nadherence to this guideline is strongly recommended as a starting point in managing \npatients as it constitute the best available evidence at the time of writing.\nREVIEW OF THE GUIDELINES\nThis guideline was issued in 2013 and will be reviewed in 2018 or earlier if important \nnew evidence becomes available.\nThis is an update to the Clinical Practice Guideline on Management of Hypertension \n\u2013 3rd Edition (published 2008) and supersedes the previous.\nElectronic version will be made available on the following websites:\n\t\nwww.moh.gov.my\n\t\nwww.acadmed.org.my\n\t\nwww.msh.org.my\nDISCLOSURE STATEMENT",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_2",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "www.moh.gov.my\n\t\nwww.acadmed.org.my\n\t\nwww.msh.org.my\nDISCLOSURE STATEMENT\nThe panel members had completed disclosure forms. None held shares in \npharmaceutical firms or acted as consultants to such firms (details are available \nupon request from the CPG Secretariat).\nSOURCES OF FUNDING\nThe development of the CPG on Management of Hypertension (4th Edition) \nwas supported via unrestricted educational grant from Merck Sharp & Dohme \n(Malaysia) Sdn. Bhd. The funding body was not involved in and has no influence on \nthe development of the guidelines.\ni\nKEY MESSAGES\nHypertension is defined as persistent elevation of systolic BP of 140mmHg or \ngreater and/or diastolic BP of 90 mmHg or greater.\nThe prevalence of hypertension in Malaysians aged 18 years and above was",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_3",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The prevalence of hypertension in Malaysians aged 18 years and above was \n32.7% and for aged 30 years and above was 43.5% in 2011.\nHypertension is a silent disease; the majority of cases (61%) in the country \nremain undiagnosed. Blood pressure should be measured at every chance \nencounter.\nUntreated or sub-optimally controlled hypertension leads to increased \ncardiovascular, cerebrovascular and renal morbidity and mortality.\nA systolic BP of 120 to 139 and/or diastolic BP of 80 to 89 mmHg is defined as \nprehypertension and should be treated in certain high risk groups.  \nTherapeutic lifestyle changes should be recommended for all individuals with \nhypertension and pre-hypertension. \nDecisions on pharmacological treatment should be based on global vascular",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_4",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Decisions on pharmacological treatment should be based on global vascular \nrisks and not on the level of blood pressure per se. \nIn patients with newly diagnosed uncomplicated hypertension and no \ncompelling indications, choice of first line monotherapy includes ACEIs, ARBs, \nCCBs, diuretics and beta blockers. Beta blockers is now recommended based \non evidence from newer meta analyses since the last edition.\nOnly 35% of Malaysian patients achieved blood pressure control (<140/90 \nmmHg) while on treatment. Every effort should be made to achieve target \nblood pressure. Target blood pressure depends on specific patient groups. \nCombination therapy is often required to achieve target and may be instituted \nearly in patients with stage II hypertension and in high risk stage I hypertension.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_5",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "early in patients with stage II hypertension and in high risk stage I hypertension.\nA patients whose BP is not controlled on three or more drugs (including a \ndiuretic) is by definition having resistant hypertension. \nRenal sympathetic denervation is a treatment option for selected patients with \nresistant hypertension.\nii\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\nFOREWORD\nIn the Name of Allah, the Most Beneficent, the Most Merciful.\nIn 2010 the Ministry of Health launched the National Strategic Plan for Non \nCommunicable Diseases. Diseases of the heart and circulatory system \n(Cardiovascular diseases or CVD) dominates the national health landscape being \nthe number 1 cause of morbidity and mortality for the last few decades and is",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_6",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "the number 1 cause of morbidity and mortality for the last few decades and is \nprojected to do so for the next few. Of all the risk factors contributing to CVD, \nhypertension confer the greatest disease  burden. It is thus pertinent that all health \ncare providers directly or indirectly involved with CVD knows what is latest in the \nmanagement of hypertension. \nI will like to record my utmost appreciation to all the members of the Working \nGroup on Hypertension for their tireless effort in coming up with this latest edition \nof the Hypertension Clinical Practice Guideline (CPG). This is the fourth in the series \nsince it was first launched in 1998. This reflects the rapid evolution of knowledge \nin hypertension driven by major outcome trials for which there were a few since",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_7",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in hypertension driven by major outcome trials for which there were a few since \nthe last edition 5 years ago. The results of the National Health Morbidity Survey \nof 2011 (NHMS 2011) were also instrumental in the drafting of this latest guideline. \nThere are also important local studies quoted which is a testimony of the growing \nresearch interest on the topic nationally. I am happy to report  that in some of the \nlandmark multicentre clinical trials quoted, Malaysian researchers were actively \ninvolved. A special thanks to the Health Technology Assessment Unit of the Ministry \nof Health Malaysia for ensuring that the development of this CPG conforms to the \nhigh standards it had laid down.  \nAlthough the NHMS 2011 showed some improvement in important key indicators",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_8",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Although the NHMS 2011 showed some improvement in important key indicators \non hypertension, there is still a lot of scope for betterment. It is hoped that this latest \nedition of the Hypertension CPG will continue to play an important role in controlling \nthis major CVD risk factor. It is the hope of the Working Group that the release of \nthis new edition will be followed by concerted effort by the various stakeholders to \nmake it implementable on the ground. By so doing, we will have contributed in a \nsignificant way to combat the scourge of CVD particularly pre mature CVD. If that \nhappens, this CPG will have served its purpose, God Willing.\nYours Sincerely\nAbdul Rashid Abdul Rahman \nChairman\nWorking Group on Hypertension CPG 2013 \niii\nRATIONALE AND PROCESS OF GUIDELINES DEVELOPMENT",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_9",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Working Group on Hypertension CPG 2013 \niii\nRATIONALE AND PROCESS OF GUIDELINES DEVELOPMENT\nRATIONALE\nThe Clinical Practice Guideline on the Management of Hypertension was developed \nto provide a clear and concise approach to all health care providers on the current \nconcepts in the management of hypertension. Since hypertension is managed \nby various levels of health care providers in Malaysia, attempts were made to \nensure the different stakeholders will benefit from this CPG. This is reflected by the \nrepresentation of the committee members which developed the guideline. There \nwere three previous guidelines on hypertension; in 1998, 2002 and 2008.This \nedition is the fourth in the series and was deemed necessary due to new evidence",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_10",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "edition is the fourth in the series and was deemed necessary due to new evidence \nwhich has emerged since the last edition. Prior to the publication of this edition, the \nNational Health and Morbidity Survey 2011 was completed and the results have \nsince been made available. The results of the survey showed that the prevalence of \nhypertension has increased with very little difference in awareness rate and rate of \nblood pressure control in the hypertensive population. The rate of blood pressure \ncontrol remained poor despite an increase in the prevalence of diagnosed patients \nwho were prescribed antihypertensive medication. This may reflect the fact that \nclinicians are still not clear of the target blood pressure to achieve in their patients",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_11",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "clinicians are still not clear of the target blood pressure to achieve in their patients \nwhile on treatment. It is hoped that this CPG will contribute towards reversing this \nworrying trend.\nGUIDELINE DEVELOPMENT PROCESS\nThe current edition of the CPG was initiated by the Malaysian Society of \nHypertension. The guideline was developed in 2012/2013. A committee was \nconvened, comprising 4 nephrologists, 4 cardiologists, 3 family physicians, 2 \nobstetrician/gynaecologists, an endocrinologist, a neurologist, a general physician/\nclinical pharmacologist, a paediatrician, an epidemiologist and a pharmacist. \nThe involvement of a pharmacist (an expert in pharmacoeconomy) and an \nepidemiologist is unique, making this CPG more comprehensive in terms of",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_12",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "epidemiologist is unique, making this CPG more comprehensive in terms of \ncommittee membership. Besides being experts in their own fields, some of the \nmembers hold important positions in relevant non-governmental organizations \nand government agencies dealing with hypertension. The development of this \nguideline adheres closely to the methodology outlined in the Guidelines for Clinical \nPractice Guideline 2003 by the Medical Development Division of the Ministry of \nHealth. All attempts were made to ensure references quoted were current and \nrelevant to the issues discussed. Whenever clinical recommendations were made, \nthe best available evidence was used to support the recommendations. Literature \nsearch was carried out at the following electronic databases: International Health",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_13",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "search was carried out at the following electronic databases: International Health \nTechnology Assessment website, PUBMED, MEDLINE, Cochcrane Database of \nSystemic Reviews (CDSR), Journal full text via OVID search engine and Science \nDirect. The chapters were developed based on relevant clinical questions \nfrequently asked by practitioners. The chapters were divided among the \nworkgroup members based on their respective expertise. Literature searched were \nappraised by workgroup members  using the Critical Appraisal Skills Programme \n(CASP) checklist. All statements and recommendations formulated were agreed \nupon by the workgroup members. Where there was insufficient evidence, the \niv\nrecommendations were derived by consensus of the workgroup. Most evidence",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_14",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "iv\nrecommendations were derived by consensus of the workgroup. Most evidence \nquoted especially for treatment recommendation is based on major clinical \noutcome trials irrespective of their year of publications. Many of these are seminal \nand landmark studies which has stood the test of time.\nThe articles quoted were graded by using the US/Canada Preventive Services Task \nForce level of evidence while the grading of recommendations was modified from \nthe Scottish Intercollegiate Guideline Network (SIGN) as shown on page vi and vii \nbelow. \nThe guideline will be posted on the Ministry of Health Malaysia, Academy of Medicine \nMalaysia and the Malaysian Society of Hypertension websites for comment and \nfeedback. This guideline has also been presented to the Technical Advisory",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_15",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "feedback. This guideline has also been presented to the Technical Advisory \nCommittee for Clinical Practice Guidelines, and the Health Technology Assessment \nand Clinical Practice Guidelines Council, Ministry of Health Malaysia for review and \napproval.\nOBJECTIVES, QUESTIONS AND TARGETS\nOBJECTIVES \nThis guideline is intended to provide education and awareness on the \nproper ways to\n1.\t\ndiagnose hypertension\n2.\t\nassess and investigate a patient with hypertension\nThis guideline is intended to provide evidence on the\n1.\t\noptimal management of a patient with hypertension \n2.\t\nlatest therapeutics on subgroups of hypertensive patients\nEXCLUSION\nThis guideline, however, does not cover\n1.\t\nstrategies for hypertension screening \n2.\t\nstrategies to reduce population blood pressure",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_16",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "1.\t\nstrategies for hypertension screening \n2.\t\nstrategies to reduce population blood pressure  \nCLINICAL QUESTIONS\nThe clinical questions to be addressed in this guideline include:\n1.\t\nWhat are the current best practices in the management of a patient with \nhypertension?\n2.\t\nHow can hypertension management be done in tandem with the overall \nstrategy to manage global vascular risk of a patient?\nTARGET POPULATION\nThis guideline is to be applied to adults (including the elderly and pregnant women) \nand children with hypertension. It is also applicable to hypertensive patients with \nvarious concomitant clinical conditions.\nTARGET GROUP \nThis guideline is developed for all levels of health care providers involved in the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_17",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "TARGET GROUP \nThis guideline is developed for all levels of health care providers involved in the \nmanagement of hypertension in adults, elderly, pregnant women and children.\nv\nvi\nCLINICAL INDICATORS FOR QUALITY MANAGEMENT \nTreatment setting: Primary care / Secondary care\nName of indicator: \n1.\t\nRate of anti-hypertensive prescription for newly diagnosed cases of \nhypertension\n2.\t\nRate of blood pressure control among patients who are treated with\n\t\nanti-hypertensive drugs\nDefinition of control: \n\t\n<140/90 mmHg for all\n\t\n<140/80 mmHg for patients with diabetes\n\t\n< 130/80 mmHg for patients with ischaemic heart disease/\t\n\t\n\t\n\t\n   cerebrovascular disease/renal impairment \nNumerator: \n1.\t\nNumber of newly diagnosed cases of hypertension prescribed \n\t\nanti-hypertensive drugs\n2.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_18",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "1.\t\nNumber of newly diagnosed cases of hypertension prescribed \n\t\nanti-hypertensive drugs\n2.\t\nNumber of patients on treatment who achieved blood pressure control\nDenominator: \n1.\t\nTotal number of newly diagnosed cases of hypertension\n2.\t\nTotal number of patients who are diagnosed and on anti-hypertensive drug \n\t\ntreatment\nRate of treatment = (Numerator/Denominator) x 100%\nRate of blood pressure control = (Numerator/Denominator) x 100%\nLEVEL OF EVIDENCE\n\t Level\t\nStudy design\n\t\nI\t\nEvidence from at least one properly randomised controlled trial\n\t\nII-1\t\nEvidence obtained from well-designed controlled trials without \nrandomisation\n\t\nII-2\t\nEvidence obtained from well-designed cohort or case-control \nanalytic studies, preferably from more than one centre or group\n\t\nII-3",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_19",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "analytic studies, preferably from more than one centre or group\n\t\nII-3\t\nEvidence from multiple time series with or without intervention. \nDramatic results in uncontrolled experiments (such as the results of \nthe introduction of penicillin treatment in the 1940s) could also be \nregarded as this type of evidence\n\t\nIII\t\nOpinions of respected authorities based on clinical experience; \ndescriptive studies and case reports; or reports of expert committees\nSource: US/Canada Preventive Services Task Force\nGRADES OF RECOMMENDATION\nA\t\nAt least one meta analysis, systematic review, or RCT, or evidence \nrated as good and directly applicable to the target population\nB\t\nEvidence from well conducted clinical trials, directly applicable to the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_20",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "B\t\nEvidence from well conducted clinical trials, directly applicable to the \ntarget population, and demonstrating overall consistency of results; or \nevidence extrapolated from meta analysis, systematic review, or RCT\nC\t\nEvidence from expert committee reports, or opinions and /or clinical \nexperiences of respected authorities; indicates absence of directly \napplicable clinical studies of good quality\nSource: Modified from the Scottish Intercollegiate Guidelines Network (SIGN)\nNote: The grades of recommendation relates to the strength of the evidence on \nwhich the recommendation is based. It does not reflect the clinical importance of \nthe recommendation.\nvii\nHYPERTENSION GUIDELINE WORKING GROUP\nCHAIRPERSON\nDr. Abdul Rashid Abdul Rahman",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_21",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "vii\nHYPERTENSION GUIDELINE WORKING GROUP\nCHAIRPERSON\nDr. Abdul Rashid Abdul Rahman\nProfessor of Medicine & Clinical Pharmacology and Senior Consultant Physician \nCyberjaya University College of Medical Sciences and An Nur Specialist Hospital \nSelangor\nWORKGROUP MEMBERS\nDr. Sunita Bavanandan\nConsultant Nephrologist\nKuala Lumpur Hospital\nKuala Lumpur\nDr. Chia Yook Chin\nProfessor of Primary Care Medicine and \nSenior Consultant Primary Care Physician\nUniversity Malaya Medical Centre\nKuala Lumpur\nDr. Ghazali Ahmad\nConsultant Nephrologist and \nHead of Department\nDepartment of Nephrology\nKuala Lumpur Hospital\nKuala Lumpur\nDr. Khoo Ee Ming\nProfessor of Primary Care Medicine and \nSenior Consultant Primary Care Physician\nUniversity Malaya Medical Centre\nKuala Lumpur\nDr. Khalid Yusoff",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_22",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "University Malaya Medical Centre\nKuala Lumpur\nDr. Khalid Yusoff\nVice Chancellor\nProfessor of Medicine and \nSenior Consultant Cardiologist\nUCSI University, Kuala Lumpur\nDr. Robaayah Zambahari\nManaging Director\nChief Executive Officer \nand Senior Consultant Cardiologist \nNational Heart Institute\nKuala Lumpur\nviii\nDr. Hj. Azhari Rosman\nConsultant Cardiologist & Electrophysiologist\nNational Heart Institute\nKuala Lumpur\nDr. Chua Chin Teong\nDirector of Medical Services and \nConsultant Nephrologist\nRamsay Sime Darby Health Care\nSelangor\nDr. Faridah Aryani Md. Yusof\nSenior Principal Assistant Director\nPharmaceutical Services Division\nMinistry of Health (Jalan Universiti)\nPetaling Jaya\nDr. Khoo Kah Lin\nConsultant Cardiologist\nPantai Medical Centre\nKuala Lumpur\nDr. Yap Piang Kian",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_23",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Dr. Khoo Kah Lin\nConsultant Cardiologist\nPantai Medical Centre\nKuala Lumpur\nDr. Yap Piang Kian\nConsultant Physician & Endocrinologist\nSime Darby Medical Centre\nSelangor\nDr Mimi Omar\nFamily Medicine Specialist\nKlinik Kesihatan Kelana Jaya\nKelana Jaya\nSelangor\nDr. Zaleha Abdullah Mahdy\nProfessor and Senior Consultant \nObstetrician & Gynaecologist\nPusat Perubataan Universiti \nKebangsaan Malaysia\nKuala Lumpur\nDr. Hj. Md. Hanip Rafi\nConsultant Neurologist and\nHead of Department\nDepartment of Neurology\nKuala Lumpur Hospital\nKuala Lumpur\nDr. Wan Jazilah Wan Ismail\nConsultant Paeditric Nephrologist and \nHead of Department\nDepartment of Paediatric\nHospital Selayang\nSelangor\nEXTERNAL REVIEWERS\nDr. J Ravichandran Jeganathan\nConsultant Obstetrician & Gynaecologist\n& Head of Department",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_24",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Dr. J Ravichandran Jeganathan\nConsultant Obstetrician & Gynaecologist\n& Head of Department\nDepartment of Obstetrics & Gynaecology\nHospital Sultanah Aminah\nJohor\nDr. Husni Hussain \nFamily Medicine Specialist  \nKlinik Kesihatan Putrajaya\nPutrajaya\nAssoc. Prof. Goh Lee Gan\nDepartment of Family Medicine\nNational University Hospital\nSingapore\nProf. Dr. Hj Hamidon Basri\nConsultant Neurologist \nUniversiti Putra Malaysia\nSerdang\nSelangor\nProf. Tariq Abdul Razak\nDean\nProfessor of Clinical Pharmacology\nKulliyah of Medicine\nInternational Islamic University\nKuantan, Pahang\nDr. Yau Weng Keong\nConsultant Geriatrician\nKuala Lumpur Hospital\nKuala Lumpur\nDr. Feisul Idzwan Mustapha\nPublic Health Specialist\nCardiovascular Diseases & Diabetes Unit\nNon-Communicable Disease Section\nDisease Control Division",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_25",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Cardiovascular Diseases & Diabetes Unit\nNon-Communicable Disease Section\nDisease Control Division\nMinistry of Health, Putrajaya\nDr. Ho Bee Kiau\nFamily Medicine Specialist  \nKlinik Kesihatan Kapar\nKlang\nProf. Dr. Wan Azman Bin Wan Ahmad\nConsultant Cardiologist\nUniversity Malaya Medical Centre\nKuala Lumpur\nDr. Adina Abdullah\nPrimary Care Lecturer \nPrimary Care Clinic (RUKA)\nUniversity Malaya Medical Centre\nKuala Lumpur\nProf. Brian Tomlinson \nProfessor of Medicine and Therapeutics \nand Honorary Consultant Physician \nChinese University of Hong Kong\nHong Kong SAR  \nix\nSUMMARY OF RECOMMENDATIONS\nIssues\t\nRecommendations\t\nGrade\nMeasurement\t\nThe mercury sphygmomanometer remains the gold standard\nof Blood\t\nfor measurement.\nPressure\n\t\nAll of the data upon which we base our estimates of risk as",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_26",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "of Blood\t\nfor measurement.\nPressure\n\t\nAll of the data upon which we base our estimates of risk as \nwell as benefits of treatment have been accumulated from \ncasual BP readings taken in the office or clinic setting and \ntherefore ambulatory blood pressure monitoring (ABPM) is \nnot necessary for the diagnosis and management of most \npatients with hypertension.\n\t\nBlood pressure should be measured in both arms and the \nhigher reading is taken as the systemic BP. \n\t\nBlood pressure should be taken both lying and at least one \nminute after standing to detect any postural drop, especially \nin the elderly and in diabetics. \n\t\nOn rising, the BP will transiently rise and then fall. A systolic \ndrop of >20 mmHg is considered a significant postural drop.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_27",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "drop of >20 mmHg is considered a significant postural drop. \n\t\nThe data provided by ABPM does not influence therapeutic \ndecisions in the vast majority of patients and as a result is not \nrecommended as a routine procedure in the initial evaluation \nof the hypertensive patient. \n\t\nHome BP measurement can be useful in monitoring control \nof BP. It empowers the patient with the control of his condition \nand may improve compliance.\nDiagnosis and\t\nRecommendations for follow-up is based on initial BP\nAssessment\t\nmeasurements.\nPre-hypertension\t\nThere should be yearly follow-up in patients with prehyper-\ntension to detect and treat hypertension as early as possible.\n\t\nDecisions regarding pharmacological treatment should be \nbased on the individual patient\u2019s global CVD risk. \nNon-",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_28",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "based on the individual patient\u2019s global CVD risk. \nNon-\nPharmacological \nManagement\nBMI or weight\t\nAs far as possible, aim for an ideal Body Mass Index [Weight \n(kg)/Height2(m)] \u2013 for Asians, the normal range has been \nproposed to be 18.5 to 23.5 kg/m2. However a weight loss \nas little as 4.5kg or 5% of baseline weight can significantly \nreduces BP.\nSalt intake\t\nAn intake of <100 mmol of sodium or 6g of sodium chloride a \nday is recommended (equivalent to <11/4 teaspoonfuls of salt \nor 3 teaspoonfuls of monosodium glutamate).\nAlcohol\t\nPatients with hypertension should refrain from alcohol intake. \n\t\nFor those who want to consume alcohol, standard advice is \nto restrict intake to no more than 21 units for men and 14 units \nfor women per week (1 unit equivalent to 1/2 a pint of beer or",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_29",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "for women per week (1 unit equivalent to 1/2 a pint of beer or \n100ml of wine or 20 ml of proof whisky).\nx\nC\nC\nC\nC\nC\nC\nC\nC\nC\nC\nC\nA\nC\nExercise\t\nGeneral advice on cardiovascular health would be for  \n\u201cmilder\u201d exercise, such as brisk walking for 30 \u2013 60 minutes \n\t\nat least 5 times a week.\nDiet\t\nA diet rich in fruits, vegetables and dairy products with \nreduced saturated and total fat can substantially lower BP \n(11/6mmHg in hypertensive patients and 4/2 mmHg in \npatients with high normal BP).\nSmoking\t\nCessation of smoking is important in the overall management \nof the patients with hypertension in reducing cardiovascular \nrisk.\nPharmacological\t\nFigure 1 (page 17) outlines the management of a patient\nManagement\t\nwith hypertension.\nManagement\nof Severe \nHypertension\nHypertensive",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_30",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Management\t\nwith hypertension.\nManagement\nof Severe \nHypertension\nHypertensive\t\nInitial treatment should aim for about 25% reduction in BP\nUrgencies\t\nover 24 hours but not lower than 160/90 mmHg.\nHypertensive\t\nThe BP needs to be reduced rapidly. It is suggested that the\nEmergencies\t\nBP be reduced by 25% depending on clinical scenario over \n\t\n3 to 12 hours but not lower than 160/90mmHg.\nRapid reduction\t\nSeveral serious side effects have been reported with the \nof Blood\t\nadministration of sublingual fast-acting nifedipine and \nPressure\t\ntherefore this is no longer recommended.\nHypertension\t\nPharmacological treatment should be initiated in patients\nand\t\nwith diabetes when the BP is persistently >140 mmHg \nDiabetes\t\nsystolic and/or >80 mmHg diastolic.\nMellitus",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_31",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Diabetes\t\nsystolic and/or >80 mmHg diastolic.\nMellitus\n\t\nSBP should be targeted to<140 and DBP <80 mmHg\n\t\nBP of <130/80 mmHg is recommended for younger patients\n\t\nwithout systemic complications.\n\t\nThe presence of microalbuminuria or overt proteinuria should \n\t\nbe treated even if the BP is not elevated. An ACEI or ARB is \n\t\npreferred.\n\t\nIn a proportion of patients, microalbuminuria may be \nnormalised by higher doses of ACEIs and ARBs.\n\t\nTight BP control should take precedence over the class of \nantihypertensive drug used.\n\t\nACEIs are drugs of choice based on extensive data attesting \n\t\nto their cardiovascular and renal protective effects in diabetic\n\t\npatients.\n\t\nIf an ACEI is not tolerated, an ARB should be considered.\n\t\nBeta-blockers, diuretics or calcium channel blockers maybe",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_32",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Beta-blockers, diuretics or calcium channel blockers maybe\n\t\nconsidered if either ACEIs or ARBs cannot be used.\nxi\nA\nA\nC\nC\nC\nC\nC\nA\nA\nC\nA\nA\nA\nA\nA\nA\nHypertension\t\nThe combination of ACEIs and ARBs has been proven to\nand\t\nreduce proteinuria more than monotherapy with either agent\nNon-Diabetic \t\nin non-diabetic renal disease. This combination should only be\nRenal Disease\t\ninitiated by a nephrologist.\n\t\nIf there is a persistent rise of serum creatinine of 30% from \nbaseline over a two month period, ACEIs should be stopped. \nSimilar caution should be exercised with the use of ARBs.\n\t\nIn patients with renal disease and hypertension with an \nelevated serum creatinine of >200 \u00b5mol/L, thiazide diuretics \nmay not be effective anti-hypertensive agents and therefore \nloop diuretics are preferred.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_33",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "may not be effective anti-hypertensive agents and therefore \nloop diuretics are preferred.\n\t\nIn those with proteinuria, the non-dihydropyridine group \nof calcium channel blockers (CCBs) namely diltiazem or \nverapamil are preferred as \u201cadd-on\u201d therapy as they have an \nadditional antiproteinuric effect.\nHypertension\t\nIn post-infarction patients, ACEIs and beta-blockers (especially \nand\t\nin patients with LV dysfunction), help to reduce future cardiac\nCardiovascular\t\nevents which include cardiac failure, cardiac mortality and \nDisease\t\nmorbidity.\nHypertension\t\nBlood pressure is the most consistent and powerful predictor \nand\t\nof stroke and is also the most important modifiable cause from \nStroke\t\nstroke.\n\t\nBeta-blockers, diuretics, CCBs, ACEIs and ARBs have been",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_34",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Stroke\t\nstroke.\n\t\nBeta-blockers, diuretics, CCBs, ACEIs and ARBs have been \nshown to reduce the risk and mortality from stroke.\n\t\nCalcium channel blockers in particular, provided significantly \nbetter primary protection against stroke compared with \ndiuretics and/or beta-blockers in Asian and Caucasian \npopulations.\n\t\nCombination of an ACEI and diuretic has been shown \nto reduce stroke recurrence in both normotensive and \nhypertensive patients when treatment was started at least \ntwo weeks after the stroke.\n\t\nThe morbidity and mortality from further strokes were also \nshown to be significantly lower in patients receiving ARBs \ncompared to CCBs for the same level of BP control.\n\t\nIn Ischaemic stroke, in general, it is best to avoid lowering BP",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_35",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "In Ischaemic stroke, in general, it is best to avoid lowering BP \nin the first few days after a stroke unless there is evidence of \naccelerated hypertension or patients presenting concurrently \n\t\nwith hypertensive emergencies.\n\t\nIn acute haemorrhagic stroke , recent evidence suggest that\n\t\nlowering SBP< 140mmHg is safe.  \n\t\nHypertension in\t\nThe goals of treatment in older patients should be the same\nthe elderly and\t\nas in younger patients.\nthe very elderly\n\t\nIn those patients with marked systolic hypertension and not \ntolerating treatment well, reducing SBP to below 160mmHg \ninitially is acceptable. Subsequently, attempts should be made \nto reduce BP to target levels.\nxii\nA\nC\nC\nA\nA\nA\nA\nA\nA\nA\nC\nB\nA\nC\n\t\nIn the very elderly (>80 years old) who can tolerate treatment,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_36",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "xii\nA\nC\nC\nA\nA\nA\nA\nA\nA\nA\nC\nB\nA\nC\n\t\nIn the very elderly (>80 years old) who can tolerate treatment, \na target of <150 mmHg/90 mmHg is acceptable.\n\t\nWeight loss and modest salt reduction maybe especially \neffective in the elderly because of their greater sensitivity to \nsodium intake.\n\t\nThe five major classes of drugs (diuretics, b-blockers, CCBs, \nACEIs and ARBs) have been shown to reduce cardiovascular \n\t\nevents in the elderly.\n\t\nIn the very elderly, thiazide-like diuretics based treatment \nwith or without ACEIs  reduced not only stroke but also total \nmortality. \n\t\nAngiotensin converting enzyme inhibitors are the drugs of \nchoice for those with concomitant left ventricular systolic \ndysfunction, post myocardial infarction or diabetes mellitus.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_37",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "dysfunction, post myocardial infarction or diabetes mellitus.\n\t\nStanding BP should be measured to detect postural \nhypotension.\nHypertension\t\nKorotkoff  V should now be used as the cut-off point for \nand\t\ndiastolic BP, and Korotkoff  IV utilized only when Korotkoff V is\nPregnancy\t\nabsent.\n\t\nPregnant women with hypertension should be referred to an \nobstetrician for further management.\n\t\nEarly diagnosis and referral to an obstetrician for further \nmanagement may prevent progression to eclampsia.\n\t\nThe drugs of choice in pregnancy are still methyldopa and \nlabetalol.\n\t\nIn the event of an acute hypertensive crisis, IV hydrallazine \n(2.5-5 mg bolus or infusion)or IV labetalol (10-20 mg slow \nbolus over 5 minutes or infusion), or oral nifedipine (10mg stat \ndose), may be used to lower the BP.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_38",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "dose), may be used to lower the BP.\n\t\nSublingual nifedipine is no longer recommended.\n\t\nParenteral magnesium sulphate is currently the drug of choice \nfor the prevention of eclampsia and to abort an eclamptic fit.\n\t\nPregnant women who are at high risk of developing \npreeclampsia should be referred to an obstetrician. Specialist \nmanagement will include Doppler ultrasonography and aspirin \npharmacoprophylaxis.\n\t\nHigh calcium supplementation of 1.5 g/day significantly \nreduces the risk of eclampsia, severe gestational hypertension \nand severe preeclamptic complication index in pregnant \nwomen with low dietary calcium intake.\nHypertension\t\nA woman who develops hypertension while using combined\nand Oral\t\noral contraceptives (COC) should be advised to stop taking\nContraceptives\t\nthem \nand",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_39",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and Oral\t\noral contraceptives (COC) should be advised to stop taking\nContraceptives\t\nthem \nand \nshould \nbe \noffered \nalternative \nforms \nof \n \ncontraception.\n\t\nBlood pressure should be reviewed regularly, at least every six \nmonths.\nxiii\nA\nA\nA\nA\nA\nC\nC\nC\nB\nC\nA\nC\nA\nA\nA\nC\nC\nHypertension\t\nAll women treated with HRT should have their BP monitored\nand Hormone\t\nevery six months.\nReplacement\nTherapy\t\nGreater caution and closer monitoring is required for \nhypertensive patients on conjugated equine estrogen (CEE).\nHypertension in\t\nOnce a child is diagnosed with hypertension, he should be \nChildren and \t\nreferred to a paediatrician for further evaluation and\nAdolescents\t\nmanagement.\n\t\nNon-pharmacologic management particularly weightreduction",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_40",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Adolescents\t\nmanagement.\n\t\nNon-pharmacologic management particularly weightreduction \nin those who are obese is recommended in all children with \nhypertension as well as those with BP in the 90th to 95th \npercentile. \n\t\nThe goal of pharmacologic therapy is to reduce BP to lower \nthan 95th percentile in uncomplicated primary hypertension \nand <90th percentile for children with TOD, CKD and diabetes \nmellitus.\nPharmaco-\t\nTreating hypertension to target is very cost effective. \neconomics\t\nHypertension pharmacotherapy should not be judged by the \ndirect cost of the drug alone.\n\t\nPublic \neducation \nshould \ninclude \ninformation \non \ncost \neffectiveness and drug compliance.\nResistant\t\nPatient whose BP did not reach target despite taking 3\nHypertension",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_41",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Resistant\t\nPatient whose BP did not reach target despite taking 3\nHypertension\t\ndrugs (including a diuretics) are by definition having resistant \nhypertension\n\t\nMedication \nnon-compliance \nand \npossible \nsecondary \nhypertension must be considered.\n\t\nPatients with eligible criteria may be considered for renal \ndenervation.\nAntiplatelet\t\nAll hypertensive for secondary prevention must receive\nand\t\nantiplatelet and antilipid therapy\nAntilipid therapy\t\n\t\nAntiplatelet for primary prevention is recommended for patient \nwith higher baseline BP but BP must be treated to target \nbefore starting antiplatelet\n\t\nStatin should be intiated  for primary prevention in patients with \nmildly elevated cholesterol (LDL-C >2.6mmol/L in high risk, \n>3.4mmol/L in medium risk patient)\nxiv\nC\nC\nC\nC\nC\nB\nC\nC\nC\nC\nA\nB",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_42",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": ">3.4mmol/L in medium risk patient)\nxiv\nC\nC\nC\nC\nC\nB\nC\nC\nC\nC\nA\nB\nA\nxv\nTABLE OF CONTENTS \n\t Chapter\t\nTopic\t\nPage\n\t\n1\t\nDefinition and Classification of Hypertension\t\n1\n\t\n2\t\nMeasurement of Blood Pressure\t\n3\t\n\t\n\t\n3\t\nDiagnosis and Assessment\t\n7\n\t\n4\t\nPre-Hypertension\t\n11\n\t\n5\t\nNon-Pharmacological Management\t\n13\n\t\n6\t\nPharmacological Management\t\n15\n\t\n7\t\nManagement of Severe Hypertension\t\n21\n\t\n8\t\nHypertension in Special Groups:\t\n24\n\t\n8.1\t\n\t\nHypertension and Diabetes Mellitus\t\n24\n\t\n8.2\t\n\t\nHypertension and the Metabolic Syndrome\t\n26\n\t\n8.3\t\n\t\nHypertension and Non-Diabetic Renal Disease\t\n27\n\t\n8.4\t\n\t\nRenovascular Hypertension\t\n28\n\t\n8.5\t\n\t\nHypertension and Heart Disease\t\n30\n\t\n8.6\t\n\t\nHypertension and Stroke\t\n32\n\t\n8.7\t\n\t\nHypertension in the Elderly\t\n35\n\t\n8.8\t\n\t\nHypertension in Pregnancy\t\n36\n\t\n8.9",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_43",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "32\n\t\n8.7\t\n\t\nHypertension in the Elderly\t\n35\n\t\n8.8\t\n\t\nHypertension in Pregnancy\t\n36\n\t\n8.9\t\n\t\nHypertension and Oral Contraceptives\t\n42\n\t\n8.10\t\n\t\nHypertension and Hormone Replacement Therapy\t\n42\n\t\n8.11\t\n\t\nHypertension in Children and Adolescents\t\n42\n\t\n9\t\nPharmacoeconomics of Hypertension\t\n46\n\t\n10\t\nTypes of Anti-Hypertensive Agents\t\n47\n\t\n10.1\t\n\t\nDiuretics\t\n47\n\t\n10.2\t\n\t\nBeta-Blockers\t\n48\n\t\n10.3\t\n\t\nCalcium Channel Blockers\t\n49\n\t\n10.4\t\n\t\nACE Inhibitors\t\n49\n\t\n10.5\t\n\t\nAngiotensin Receptor Blockers\t\n50\n\t\n10.6\t\n\t\nDirect Renin Inhibitors\t\n51\n\t\n10.7\t\n\t\nMiscellaneous Drugs\t\n52\n\t\n11\t\nResistant Hypertension\t\n55\n\t\n12\t\nAspirin in Hypertension\t\n57\n\t\n13\t\nLipid Lowering in Hypertension\t\n58\n\t\n\t\n\t\nAppendices\t\n59 \u2013 60\n\t\n\t\n\t\nReferences\t\n61 \u2013 75\nxvi\nLIST OF TABLES & FIGURE\n\t Table No\t\nTitle\t\nPage\n\t\n1",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_44",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "59 \u2013 60\n\t\n\t\n\t\nReferences\t\n61 \u2013 75\nxvi\nLIST OF TABLES & FIGURE\n\t Table No\t\nTitle\t\nPage\n\t\n1\t\nClassification and Prevalence of Elevated Blood \n\t\n\t\nPressure for Adults Age \u226518 Years in Malaysia (2006)\t\n1\n\t\n2\t\nCriteria for Staging Hypertension based on Clinic, Home\n\t\n\t\nand Ambulatory Blood Pressure Monitoring\t\n6\n\t\n3\t\nSecondary Causes of Hypertension\t\n7\n\t\n4\t\nManifestations of Target Organ Damage (TOD) / Target \n\t\n\t\nOrgan Complication (TOC)\t\n7\n\t\n5\t\nConcomitant Cardiovascular Risk Factors\t\n8\n\t\n6\t\nRisk Stratification\t\n9\n\t\n7\t\nRecommendations for Follow-Up based on Initial\n\t\n\t\nBlood Pressure Measurements for Adults\t\n10\n\t\n8\t\nChoice of Anti-Hypertensive Drugs in Patients with\n\t\n\t\nConcomitant Conditions\t\n18\n\t\n9\t\nEffective Anti-Hypertensive Combinations Used in \n\t\n\t\nOutcome Trials\t\n19\n\t\n10",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_45",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "18\n\t\n9\t\nEffective Anti-Hypertensive Combinations Used in \n\t\n\t\nOutcome Trials\t\n19\n\t\n10\t\nDrug Combinations in Hypertension: Recommendations\t\n19\n\t\n11\t\nCommon Causes of Severe Hypertension\t\n21\n\t\n12\t\nOral Treatment for Hypertensive Urgencies \t\n22\n\t\n13\t\nTreatment Options for Hypertensive Emergencies\t\n23\n\t\n14\t\nNCEP ATP III and IDF Criteria for the Metabolic Syndrome\t\n27\n\t\n15\t\nCurrent Guideline for The Management of Blood \n\t\n\t\nPressure in Acute Phase of Ischaemic Stroke and\n\t\n\t\nIntracerebral Haemorrhage\t\n33\n\t\n16\t\nAnti-Hypertensive Drugs Commonly Used in Pregnancy\t\n40\nxvii\n\t Table No\t\nTitle\t\nPage\n\t\n17\t\nAnti-Hypertensive Drugs for Severe Preeclampsia with\n\t\n\t\nAcute Hypertensive Crisis\t\n41\n\t\n18\t\nAnti-Convulsant for Eclampsia (and Severe Preeclampsia).\t\n41\n\t\n19",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_46",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "41\n\t\n18\t\nAnti-Convulsant for Eclampsia (and Severe Preeclampsia).\t\n41\n\t\n19\t\nCOC and HRT Preparations containing Drospirenone\t\n42\n\t\n20\t\nClassification and Management of Hypertension in\n\t\n\t\nChildren and Adolescents\t\n44\n\t\n21\t\nRecommended Dosing for Diuretics \t\n47\n\t\n22\t\nRecommended Dosing for \u00df-blockers\t\n48\n\t\n23\t\nRecommended Dosing for CCBs \t\n49\n\t\n24\t\nRecommended Dosing for ACEIs \t\n50\n\t\n25\t\nRecommended Dosing for ARBs \t\n51\n\t\n26\t\nRecommended Dosing for DRI\t\n52\n\t\n27\t\nRecommended Dosing for \u2202-blockers\t\n52\n\t\n28\t\nRecommended Dosing for \u2202, \u00df-blockers\t\n53\n\t\n29\t\nRecommended Dosing for Centrally Acting Agent\t\n53\n\t\n30\t\nRecommended Dosing for Centrally Acting Agents\t\n54\n\t\n31\t\nRecommended Dosing for Direct Vasodilators\t\n54\n\t\nFigure\t\nTitle\t\nPage\n\t\n1\t\nAlgorithm for the Management of Hypertension\t\n17\n1\n1.0",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_47",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "54\n\t\nFigure\t\nTitle\t\nPage\n\t\n1\t\nAlgorithm for the Management of Hypertension\t\n17\n1\n1.0\t\nDEFINITION, CLASSIFICATION AND TYPES OF HYPERTENSION\nHypertension is defined as persistent elevation of systolic BP of 140 mmHg or greater \nand/or diastolic BP of 90 mmHg or greater.\nHypertension is an increasingly important medical and public health issue. The \nNational Health and Morbidity Survey (NHMS) 2011 has shown that the prevalence of \nhypertension in Malaysia for adults \u226518 years has increased from 32.2% in 2006 to 32.7% \nin 2011. For those >30 years old, the prevalence has increased from 42.6% to 43.5% \nUnfortunately, 60.6% of total hypertensive were \u201cundiagnosed\u201d.1 Hence BP should be \nmeasured at every opportunity.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_48",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "measured at every opportunity.\nNo significant difference between gender was observed. In terms of the main ethnic \ngroups, the Bumiputera from Sabah & Sarawak have the highest prevalence at 36.4%, \nfollowed by the Malays at 34.0%, Chinese at 32.3% and lastly the Indians at 30.6%.1\nAn analysis of NHMS 3 (2006) data has shown that 63% of Malaysians had at least one \ncardiovascular risk factor, 33% had two risk factors and 14% had three or more risk \nfactors. Hypertension remains the number one risk factor with a prevalence rate of 42.6% \nin adults above 30 years of age, followed by central obesity (37%), hypercholesterolaemia \n(24%) and hyperglycaemia (15%).2\nThe relationship between BP and risk of cardiovascular events is continuous, consistent",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_49",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The relationship between BP and risk of cardiovascular events is continuous, consistent \nand independent of other risk factors. The higher the BP, the greater the chance \nof myocardial infarction, heart failure, stroke and kidney diseases. The presence of \neach additional risk factor, such as dyslipidaemia, diabetes mellitus or smoking status, \ncompounds the risk. Therefore the main aim of identifying and treating high BP is to \nreduce these risks of end organ damage or end organ complications. \nTable 1.\t Classification and Prevalence of Elevated Blood Pressure for Adults \t\n\t\nAge \u226518 years in Malaysia (NHMS 3, 2006)3\nClassification*\t\nSBP\t\nDBP\t\nPrevalence in\t\n\t\n\t\n(mmHg)\t\n(mmHg)\t\nMalaysia3\nOptimal\t\n<120 and\t\n<80\t\n32%\nNormal\t\n<130 and\t\n<85\t\n20%\nHigh Normal\t\n130 \u2013 139 and/or\t\n85 \u2013 89\t\n17%",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_50",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Optimal\t\n<120 and\t\n<80\t\n32%\nNormal\t\n<130 and\t\n<85\t\n20%\nHigh Normal\t\n130 \u2013 139 and/or\t\n85 \u2013 89\t\n17%\nHypertension\t\n\t\n\t\nStage I\t\n140 \u2013 159 and/or\t\n90 \u2013 99\t\n20%\nStage II\t\n160 \u2013 179 and/or\t\n100 \u2013 109\t\n8%\nStage III\t\n\u2265180 and/or\t\n\u2265110\t\n4%\n* Adapted from JNC VI\n\u2022 \nHypertension is defined as persistent elevation of systolic BP of 140 mmHg or \ngreater and/or diastolic BP of 90 mmHg or greater.\n\u2022 \nThis definition is based on the average of two or more properly measured, \nseated, BP readings on each of two or more clinic visits. When SBP and DBP \nfall into different categories, the higher category should be selected to classify \nthe individual\u2019s BP.\n2\nIsolated Systolic Hypertension \nIsolated systolic hypertension (ISH) is defined as SBP of \u2265140 mmHg and DBP <90",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_51",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Isolated systolic hypertension (ISH) is defined as SBP of \u2265140 mmHg and DBP <90 \nmmHg. It is common after the age of 50, and carries with it a poor prognosis. Clinical trials \nhave demonstrated that control of ISH reduces total mortality, cardiovascular mortality, \nstroke and heart failure events.4,5,6\nChanging patterns of BP occur with increasing age. The rise in SBP continues throughout \nlife in contrast to DBP, which rises until approximately age 50, tends to level off over \nthe next decade, and may remain the same or fall later in life.7,8 Diastolic hypertension \npredominates before age 50, either alone or in combination with SBP elevation. The \nprevalence of systolic hypertension increases with age, and above 50 years of age,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_52",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "prevalence of systolic hypertension increases with age, and above 50 years of age, \nsystolic hypertension represents the most common form of hypertension. DBP is a \nmore potent cardiovascular risk factor than SBP until age 50; thereafter, SBP is more \nimportant.9\nIsolated Office (\u201cwhite-coat\u201d) Hypertension \nIsolated office hypertension is characterised by an elevation in clinic blood pressure \nbut normal home or ambulatory blood-pressure values. In these subjects the clinic BP \nis persistently above 140/90 mmHg but the home or 24-hour ambulatory systolic/\ndiastolic BP measurements are lower than 130/80 mmHg. It is still debatable whether \nisolated office hypertension is an innocent phenomenon or whether it carries an\nincreased cardiovascular risk.10\nMasked Hypertension",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_53",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "increased cardiovascular risk.10\nMasked Hypertension \nPatients with masked hypertension have normal clinic blood pressure but elevated 24-\nhour ambulatory or home blood-pressure load (\u2265135/85 mmHg). Prognosis of masked \nhypertension is worse than isolated office hypertension.11\nFor both isolated office and masked hypertension, once diagnosed, first-line therapeutic \ninterventions should be non-pharmacological and aim at lifestyle changes. However, \ndrug treatment is indicated, particularly when the patient\u2019s cardiovascular risk profile \nis elevated or when target-organ damage (TOD) is detected.12 (Refer to chapter on \nDiagnosis and Assessment)\n3\n2.0\t\nMEASUREMENT OF BLOOD PRESSURE \nBlood pressure should be measured correctly. It can be measured directly or",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_54",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Blood pressure should be measured correctly. It can be measured directly or \nindirectly. There are four common devices used for the indirect measurement of BP \nnamely:  \n\u2022 \nmercury column sphygmomanometer \n\u2022 \nelectronic devices\n\u2022 \naneroid sphygmomanometer\n\u2022 \nautomated ambulatory BP devices. \nThere are many calibrated electronic or ambulatory BP devices available in the market. \nOnly professionally validated electronic models should be used.   \nVarious countries have their own validating bodies for devices e.g. British Hypertension \nSociety, American Association for the Advancement of Medical Instrumentation (AAMI) \nand German Hypertension Society. The mercury sphygmomanometer remains the gold \nstandard for non invasive measurement.13 (Level III) However, it is gradually being replaced",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_55",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "standard for non invasive measurement.13 (Level III) However, it is gradually being replaced \nby the electronic blood pressure measurement device due to environmental and health \nconcerns. \n2.1\t\nTHE MERCURY COLUMN SPHYGMOMANOMETER\nThe following points should be noted: \n\t\na.\t The key to the reservoir should be turned open\n\t\nb.\t The mercury meniscus should be at zero. \n\t\nc.\t The calibrated glass tube must be clean \u2013 a dirty tube can cause inaccurate \t\n\t\n\t\n\t\nreadings.\n\t\nd.\t The cuff size should be appropriate\n \n \n\u2022 Both the length and width of the inflatable bladder are important. The bladder \nlength should encircle at least 80% of the circumference whilst the width \nshould be at least 40% of the circumference of the arm. Standard bladder",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_56",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "should be at least 40% of the circumference of the arm. Standard bladder \nsize is 13 cm x 24 cm13 too small a cuff will give a falsely higher reading and vice \nversa.\n  \ne. Inflation-deflation bulb \n \n \n\u2022 It is important to ensure that inflation-deflation device functions properly. The \nfollowing may indicate malfunction of the device: \n\t\n\t\n\t\n\u2014\t Failure to achieve a pressure of 40 mmHg above the estimated SBP or 200 \nmmHg after 3 \u2013 5 seconds of rapid inflation. \n \n \n \n\u2014 The inability of the equipment to deflate smoothly at a rate of 1 mmHg per \nsecond or at each pulse beat.13\n\t\nf.\t Auscultatory measurement of systolic and diastolic pressures\n \n \n\u2022 The following technique is recommended for the measurement of BP using a \nsphygmomanometer:",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_57",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 The following technique is recommended for the measurement of BP using a \nsphygmomanometer:\n\t\n\t\n\t\n\u2014\t Patients should be adequately rested and seated with their arms supported. \n\t\n\t\n\t\n\u2014\t The cuff and the mercury reservoir should be at the level of the heart.  \n\t\n\t\n\t\n\u2014\t They should not have smoked or ingested caffeine within 30 minutes of \nmeasurement. \n\t\n\t\n\t\n\u2014\t The SBP should be estimated initially by palpation. While palpating the \nbrachial/radial artery, the cuff is inflated until the pulse disappears. The \ncuff should then be inflated to a further 20 mmHg. The cuff is then slowly \ndeflated and the pressure at which the pulse is palpable is the estimated \nSBP. \n \n \n \n\u2014 The bladder is again inflated to 20 mmHg above the previously estimated",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_58",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "SBP. \n \n \n \n\u2014 The bladder is again inflated to 20 mmHg above the previously estimated \nSBP and the pressure reduced at 1-2 mmHg per second whilst auscultating \nwith the bell of the stethoscope.13 The bell should not be placed under \nthe cuff. The point at which repetitive, clear tapping sounds first appears \n(Korotkoff Phase I) gives the SBP.  \n4\n\t\n\t\n\t\n\u2014\t Phase I sounds sometimes disappear as pressure is reduced and \nreappears again at a lower reading (the auscultatory gap), resulting in under \nestimation of the SBP.  \n\t\n\t\n\t\n\u2014\t The complete disappearance of sound (Korotkoff Phase V) should be taken \nas the diastolic reading. \n\t\n\t\n\t\n\u2014\t Check BP in both arms in the first consultation. Use the higher reading for \nmaking diagnosis.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_59",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2014\t Check BP in both arms in the first consultation. Use the higher reading for \nmaking diagnosis. \nIn some groups, (e.g. anaemic or elderly patients) the sounds may continue until the \nzero point. In such instances the muffling of the repetitive sounds (Korotkoff Phase IV) is \ntaken as the diastolic pressure. The point of muffling is usually higher than the true arterial \ndiastolic pressure. If Korotkoff Phase IV is used, this should be clearly recorded. \nBlood Pressure should be measured in both arms on the first visit and the higher reading \nis taken as the systolic BP.13 At least 3 readings preferably 1-2 minutes apart should be \ntaken in the same arm with the patient in the same position. The first reading should be",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_60",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "taken in the same arm with the patient in the same position. The first reading should be \ndiscarded and the latter two averaged.13 Blood pressure measurements should not be \ndone on the arm with arterio-venous fistula in haemodialysis patients. \nIf the difference in BP between the two arms is >20/10 mmHg, there may be an arterial \nanomaly which requires further evaluation. \nThe BP should be taken both lying/sitting and at least 1 minute after standing (with arm \nsupported) to detect any postural drop, especially in the elderly and in diabetics.13 On \nrising, the BP will transiently rise and then fall. A systolic drop of >20 mmHg after one \nminute of standing is considered a significant postural drop.13\n2.2\t\nELECTRONIC BP SETS",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_61",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "minute of standing is considered a significant postural drop.13\n2.2\t\nELECTRONIC BP SETS\nThis is now increasingly being used. The best are those validated by a reputable body, \ne.g., national hypertension societies such as British Hypertension Society (www.bhsoc.\norg) or American Association for the Advancement of Medical Instrumentation (www.\naami.org). A list of validated machines is available from their websites. \nThese electronic machines are generally less accurate in patients with atrial fibrillation. \nDiastolic blood pressure also tends to be lower than mercury sphygmomanometer. They \nshould not be used in pregnancy as the BP reading may be underestimated.\nThe use of home devices that measure the blood pressure in the fingers or the wrists is \nnot recommended.\n2.3",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_62",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "not recommended.\n2.3\t\nHOME BP MEASUREMENT (HBPM) USING ELECTRONIC DEVICES\nHome BP measurement is a useful adjunct in the diagnosis and management of \nhypertension especially in selected patients. If properly performed, it has good prognostic \nvalue.14,15 (Level II-2)\nSystematic review has shown that HBPM is superior compared to office measurements in \ndiagnosing uncontrolled hypertension, assessing antihypertensive treatment, improving \npatients compliance and provides potential cost saving.16 (Level I) \nAdditionally, some studies have shown that HBPM measurements can be an alternative \nto ABPM and may have similar prognostic value.17,18 (Level I)\n5\nIndications for HBPM 19\n \n\u2022 At initial assessment \n \n\u2022 To diagnose isolated office hypertension\n \n\u2022 To diagnose masked hypertension",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_63",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 To diagnose isolated office hypertension\n \n\u2022 To diagnose masked hypertension\n \n\u2022 To assess treatment effects\n \n\u2022 To diagnose true resistant hypertension\n \n\u2022 To improve compliance with long term treatment\n \n\u2022 To optimize blood pressure control in high CV risk patients and pregnancy\nHBPM Interpretation19\n \n\u2022 Average BP from several monitoring days (at least 3 days) should be used\n \n\u2022 BP values measured on the first monitoring day should be discarded\n \n\u2022 Mean home systolic BP >135 mmHg and/or diastolic BP >85 mmHg should be \nconsidered as elevated\n \n\u2022 Systolic and diastolic home BP <130 and <80 mmHg respectively, should be \nconsidered normal\nHome BP is generally lower than clinic BP by approximately 10-20 mmHg systolic and \n5-10 mmHg diastolic.  \n\t\nRecommendations",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_64",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "5-10 mmHg diastolic.  \n\t\nRecommendations\n\t\nBP Measuring Technique\n\t\nFor Clinic BP, patients should be\n \n\u2022 seated for at least 5 mins, without smoking, meal, caffeine intake or physical  \n \n\t\n\t\nexercise for at least 30 mins\n \n\u2022 seated position in a quiet room, back supported, arm supported (for example,   \n\t\n\t\nresting on the table)\n \n\u2022 seated with legs uncrossed, not talking and relaxed\n \n\u2022 the correct cuff bladder must be placed at heart level\n\t\n\t\nFor home measurements, besides the above ;\n \n\u2022 a minimum measurement for 3 days and ideally 7 days should be performed\n \n\u2022 should be done at about the same time once in the morning and evening \n \n\u2022 morning (before drug intake if treated) and evening (before meal) readings\n\t\n\t\nshould be taken with two measurements per occasion (1\u20132 mins apart)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_65",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "should be taken with two measurements per occasion (1\u20132 mins apart)\n \n\u2022 the results must be  immediately recorded in a specific logbook or stored in \n\t\n\t\ndevice memory\n2.4\t\nAMBULATORY BLOOD PRESSURE MONITORING (ABPM)\nMost of the data upon which estimates of risk are based, as well as benefits of treatment \nhave been accumulated from office BP readings and therefore ABPM is not essential for \nthe diagnosis and management of most patients with hypertension.\nThe data provided by ABPM does not influence therapeutic decisions in the vast majority \nof patients. The current cost of ABPM devices will also limit its widespread usage.\nHowever the latest NICE Guideline suggests a possible role of ABPM in confirming the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_66",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "However the latest NICE Guideline suggests a possible role of ABPM in confirming the \ndiagnosis of hypertension when the clinic blood pressure is 140/90mmHg or higher, in \nselected patients.20 (Level III)\n6\nABPM is useful in selected clinical situations. These include21 (Level III): \n \n\u2022 diagnosis of isolated office hypertension\n \n\u2022 diagnosis of masked hypertension\n \n\u2022 patients with borderline or labile hypertension\n \n\u2022 the detection of nocturnal hypertension\n \n\u2022 patients with resistant hypertension \n \n\u2022 evaluation of suspected hypotensive symptoms, especially in the elderly\n\t\nRecommendations\n\t\nABPM Technique\n \n\u2022 15-30 min needed for fitting and setup\n \n\u2022 Relax patient in a quiet room\n \n\u2022 Enter patient\u2019s details into monitor\n \n\u2022 Measure BP in both arms",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_67",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 Enter patient\u2019s details into monitor\n \n\u2022 Measure BP in both arms\n \n\u2022 If SBP difference <20 mmHg and/or DBP difference <10 mmHg, use non-\ndominant arm\n \n\u2022 If SBP difference >20 mmHg and/or DBP difference >10 mmHg, use arm with \ngreater pressure\n \n\u2022 Select appropriate cuff\n \n\u2022 Select frequency of measure (usually every 15-20 min during day and every \n30 min at night, ideally every 15 min over the 24 hours)\n \n\u2022 Give patient written instructions and a diary card\n \n\u2022 Instruct patient how to remove and inactivate monitor after 24 hour\nTable 2.\t Criteria for Staging Hypertension Based on Clinic, Home and \t\n\t\n\t\nAmbulatory Blood Pressure Monitoring\nCategory\t\nClinic BP (mmHg)\t\nHome BP Monitoring Average\n\t\n\t\nor\n\t\n\t\nAmbulatory BP Daytime Average \n \t\n\t\n(mmHg)\nStage I Hypertension\t\n\u2265140/90\t\n\u2265135/85",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_68",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "or\n\t\n\t\nAmbulatory BP Daytime Average \n \t\n\t\n(mmHg)\nStage I Hypertension\t\n\u2265140/90\t\n\u2265135/85\nStage II Hypertension\t\n\u2265160/100\t\n\u2265150/95\nSevere Hypertension\t\nSBP \u2265180 or DBP \u2265110\n* Adapted from National Institute for Health and Clinical Excellence (NICE) Hypertension, 2011. \n  [Available at: www.nice.org.uk/guidance/CG127 (accessed 8th September 2013)]\n7\n3.0\t\nDIAGNOSIS AND ASSESSMENT\nEvaluation of patients with documented hypertension has three objectives: \n1.\t\nTo exclude secondary causes of hypertension. (Table 3)\n2.\t To ascertain the presence of target organ damage or complication (Table 4)\n3.\t To assess lifestyle and identify other cardiovascular risk factors (Table 5) or \t\n\t\n\t\ncoexisting condition that affect prognosis and guide treatment. (Table 6)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_69",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "coexisting condition that affect prognosis and guide treatment. (Table 6)\nSuch information is obtained from adequate history, physical examination, laboratory \ninvestigations and other diagnostic procedures.\nTable 3.\t Secondary Causes of Hypertension\n \n\u2022 Parenchymal kidney disease\n \n\u2022 Renovascular disease\n \n\u2022 Primary aldosteronism\n \n\u2022 Sleep apnoea\n \n\u2022 Drug-induced or drug-related \n\t\n\t\n\u2014\t\nOral contraceptives\n\t\n\t\n\u2014\t\nSteroids\n \n \n\u2014 \nNon-Steroidal Anti-inflammatory Drugs / Cyclooxygenase 2 Inhibitors\n\t\n\t\n\u2014\t\nErythropoeitin\n \n\u2022 Cushing syndrome\n \n\u2022 Phaeochromocytoma\n \n\u2022 Acromegaly\n \n\u2022 Thyroid disease\n \n\u2022 Parathyroid disease \n \n\u2022 Coarctation of the aorta\n \n\u2022 Takayasu Arteritis\nTable 4.\t Manifestations of Target Organ Damage (TOD) / Target Organ \t\n\t\n\t\nComplication (TOC)\nOrgan\t\nManifestations",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_70",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Complication (TOC)\nOrgan\t\nManifestations\nHeart\t\nLeft ventricular hypertrophy, coronary heart disease, heart failure\nBrain\t\nTransient ischaemic attack, stroke\nPeripheral \t\nAbsence of one or more major pulses in extremities (except\nvasculature\t\ndorsalis pedis) with or without intermittent claudication\nKidney\t\nGFR < 60 ml/min/1.73m2, proteinuria (1+ or greater) microalbuminuria\n\t\n(2 out of 3 positive tests over a period of 4-6 months)\nRetina\t\nHaemorrhages or exudates, with or without papilloedema\nTOD = Target organ damage (LVH, retinopathy, proteinuria) \nTOC = Target organ complication (heart failure, renal failure)\nA complete history should include:\n \n\u2022 duration and level of elevated BP if known\n \n\u2022 symptoms of secondary causes of hypertension",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_71",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 duration and level of elevated BP if known\n \n\u2022 symptoms of secondary causes of hypertension\n \n\u2022 symptoms of target organ complications (i.e. renal failure and heart failure)\n \n\u2022 symptoms of cardiovascular disease (e.g. CHD and cerebrovascular disease)\n \n\u2022 symptoms of concomitant disease that will affect prognosis or treatment e.g. \ndiabetes mellitus, heart failure, renal disease and gout\n8\n \n\u2022 family history of hypertension, CHD, stroke, diabetes, renal disease or dyslipidaemia\n \n\u2022 dietary history including salt caffeine, liquorice and alcohol intake\n \n\u2022 drug history of either prescribed or over-the-counter medication (NSAIDs, nasal \ndecongestants) and traditional or complementary medicine treatment\n \n\u2022 lifestyle and environmental factors that will affect treatment and outcome (e.g.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_72",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 lifestyle and environmental factors that will affect treatment and outcome (e.g. \nsmoking, physical activity, work stress and excessive weight gain since childhood)\n \n\u2022 presence of snoring and or day time somnolence which may indicate sleep \napnoea \nPhysical examination should include the following:\n \n\u2022 general examination including height, weight and waist circumference\n \n\u2022 two or more BP measurements separated by 1-2 minutes with the patient either \nsupine or seated; and after standing for at least one minute  \n \n\u2022 take standing BP at 2 minutes and again at 5 minutes in the elderly, diabetics and \nother conditions where postural hypotension is frequent or suspected\n \n\u2022 measure BP on both arms\n \n\u2022 fundoscopy",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_73",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 measure BP on both arms\n \n\u2022 fundoscopy\n \n\u2022 examination for carotid bruit, abdominal bruit, presence of peripheral pulses and \nradio-femoral delay\n \n\u2022 cardiac examination \n \n\u2022 abdominal examination for renal masses and bruit, aortic aneurysm and \nabdominal obesity\n \n\u2022 neurological examination to look for evidence of stroke\n \n\u2022 signs of endocrine disorders (e.g. Cushing syndrome, acromegaly and thyroid \ndisease)\n \n\u2022 Ankle brachial index (where available)\nThe minimum initial investigations aim to screen for presence of secondary causes of \nhypertension, determine the presence of CV risk factors, target organ damage (TOD) \nand target organ complication (TOC). They should include the following:22 (Level III)\n \n\u2022 Urinalysis (dip stick: albuminuria/microalbuminuria & microscopic haematuria)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_74",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 Urinalysis (dip stick: albuminuria/microalbuminuria & microscopic haematuria)\n \n\u2022 Renal function tests (creatinine, eGFR, serum electrolytes)\n \n\u2022 Blood glucose\n \n\u2022 Lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides)\n \n\u2022 Electrocardiogram (ECG)\nIf the examination or investigations suggest the presence of a secondary cause, the \npatient should be referred for specialist evaluation. If there is evidence of TOD or TOC \n(Table 4), further tests should be considered. \nTable 5.\t Concomitant Cardiovascular Risk Factors\n \n\u2022 Diabetes mellitus\n \n\u2022 Dyslipidaemia\n \n\u2022 Cigarette smoking\n \n\u2022 Central obesity (waist circumference >90 cm for men, >80 cm for women) \n \n\u2022 Microalbuminuria/Proteinuria \n \n\u2022 Estimated GFR <60 mL/min/m2",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_75",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 Microalbuminuria/Proteinuria \n \n\u2022 Estimated GFR <60 mL/min/m2\n \n\u2022 Age (>55 years for men, >65 years for women) \n \n\u2022 Family history of premature cardiovascular disease \n\t\n\t\n(men <55 years or women <65 years)\n \n\u2022 Physical inactivity (Refer to chapter 5 on Non-Pharmacological \n\t\n\t\nManagement)\n9\nAccording to a study in Malaysia as many as 54% patients with essential hypertension \ndid not have their cardiovascular risks adequately assessed.23 (Level III)\nFollowing initial clinical evaluation and investigations, the patient should be risk stratified. \nTable 6 stratifies the risk of developing major cardiovascular events, which includes \nstroke, myocardial infarction and total mortality.\nTable 6.\t Risk Stratification\n     Co-existing\t\n\t\n\t\nTOC\t\nPrevious MI\n       Condition\t\n\t\n\t\nor\t\nor",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_76",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Co-existing\t\n\t\n\t\nTOC\t\nPrevious MI\n       Condition\t\n\t\n\t\nor\t\nor\n\t\n\t\nTOD\t\nRF(\u22653)\t\nPrevious\nBP\t\nNo RF\t\nor\t\nor\t\nstroke\nLevels\t\nNo TOD\t\nRF (1-2)\t\nClinical\t\nor\n(mmHg)\t\nNo TOC\t\nNo TOC\t\natherosclerosis\t\nDiabetes\nSBP 130 \u2013 139\nand/or\t\nLow\t\nMedium\t\nHigh\t\nVery high\nDBP 80 \u2013 89\nSBP 140 \u2013 159\nand/or\t\nLow\t\nMedium\t\nHigh\t\nVery high\nDBP 90 \u2013 99\nSBP 160 \u2013 179\nand/or\t\nMedium\t\nHigh\t\nVery high\t\nVery high\nDBP 100 \u2013 109\nSBP >180\nand/or\t\nHigh\t\nVery high\t\nVery high\t\nVery high\nDBP >110\nRisk Level\t\nRisk of Major CV Event\t\nManagement\n\t\nin 10 years\nLow\t\n< 10%\t\nLifestyle changes\nMedium\t\n10 \u2013 20%\t\nDrug treatment and lifestyle changes\nHigh\t\n20 \u2013 30%\t\nDrug treatment and lifestyle changes\nVery high\t\n> 30%\t\nDrug treatment and lifestyle changes\nTOD = Target organ damage (LVH, retinopathy, proteinuria)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_77",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Drug treatment and lifestyle changes\nTOD = Target organ damage (LVH, retinopathy, proteinuria) \nTOC = Target organ complication (heart failure, renal failure)\nRF    =  additional risk factors (smoking, TC > 6.5mmol/L, family history of premature vascular disease) \nClinical atherosclerosis (CHD, carotid stenosis, peripheral vascular disease, transient ischaemic attack, stroke)\nFollowing initial clinical evaluation, investigations and risk stratification, patients need to \nbe re evaluated at subsequent visits as recommended below. \n10\nTable 7.\t Recommendations for Follow-Up Visit based on Initial Blood \t\n\t\n\t\nPressure Measurements for Adults\n\t\n\t Initial BP (mmHg)\t\t\nFollow-up recommended to\n\t\nSystolic\t\n\t\nDiastolic\t\nconfirm diagnosis \n\t\n<130\t\n and\t\n<85\t\nRecheck in one year\n\t\n130 \u2013 139\t\nand",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_78",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Systolic\t\n\t\nDiastolic\t\nconfirm diagnosis \n\t\n<130\t\n and\t\n<85\t\nRecheck in one year\n\t\n130 \u2013 139\t\nand\t\n85 \u2013 89\t\nRecheck within 3 \u2013 6 months\n\t\n40 \u2013 159\t\nand/or\t\n90 \u2013 99\t\nConfirm within two months\n\t\n160 \u2013 179\t\nand/or\t 100 \u2013 109\t\nEvaluate within one month and treat\t\n\t\n\t\n\t\n\t\n\t\nif confirmed\n\t\n180 \u2013 209\t\nand/or\t\n110 \u2013 119\t\nEvaluate within one week and treat \t\n\t\n\t\n\t\n\t\n\t\nif confirmed\n\t\n\u2265210\t\nand/or\t\n\u2265120\t\nInitiate drug treatment immediately\nModified from JNC-VII 24 (Level III)\n11\n4.0\t\nPRE-HYPERTENSION\nPre-hypertension is defined as SBP of 120 to 139 or DBP 80 to 89 mmHg, based on 2 or \nmore seated BP readings on each of 2 or more clinic visits.24\nThe term \u201cpre-hypertension\u201d replaces former categories \u201chigh-normal\u201d (130\u2013139/85\u201389",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_79",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The term \u201cpre-hypertension\u201d replaces former categories \u201chigh-normal\u201d (130\u2013139/85\u201389 \nmmHg) and \u201cabove optimal\u201d (120\u2013129/80\u201384 mmHg). The term \u201cborderline hypertension\u201d \nis discouraged from use as it is imprecise and inconsistently defined.\nRationale for highlighting this category of BP include: \n1.\t\nTo emphasize the excess cardiovascular risk associated with BP in this range. It has \nbeen estimated that almost a third of BP-related deaths from coronary heart disease \noccur in individuals with SBP between 110 and 139.25\n2.\t To increase clinical and public health awareness on the prevention of hypertension. \n4.1\t\nEPIDEMIOLOGY OF PRE-HYPERTENSION\nIn Malaysia, data from the National Health and Morbidity Survey (NHMS III) indicates that \n37% of our population has pre-hypertension.3",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_80",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "37% of our population has pre-hypertension.3\nPatients with pre-hypertension are at increased risk for progression to hypertension. In \nthe Framingham study, the high-normal BP group conversion rate was 37% in 4 years.26 \nThis conversion rate was even higher in the Trial of Preventing Hypertension (TROPHY) \nstudy in which over a period of 4 years, stage I hypertension developed in nearly \ntwo thirds of patients with untreated pre-hypertension.27 Predictors of conversion to \nhypertension include baseline BP, increasing age, obesity and weight gain.\nPre-hypertension tends to cluster with other CVD risk factors such as dyslipidaemia, \nglucose abnormalities and obesity.28-30 However, the weight of evidence suggests that",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_81",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "glucose abnormalities and obesity.28-30 However, the weight of evidence suggests that \npre-hypertension itself is an independent CVD risk factor.30,31 (Level II-2)\n4.2\t\nMANAGEMENT OF PRE-HYPERTENSION\n \n\u2022 Patients should be managed with non-pharmacologic interventions/therapeutic \nlifestyle modifications to lower BP. (Refer to Chapter 5). Major challenges to this \napproach will be  the lack of clinical symptoms, the extremely long latent period \nbefore target organ damage becomes clinically apparent as well as psychological \nand practical barriers (time, cost, etc) to lifestyle modification.          \n \n\u2022 There should be 6-12 monthly follow-up in patients with pre-hypertension to \ndetect and treat hypertension as early as possible.24 (Level III)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_82",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "detect and treat hypertension as early as possible.24 (Level III)\n \n\u2022 Decision regarding pharmacological treatment should be based on the individual \npatient\u2019s global CV risk. In diabetes mellitus with proteinuria or patients with chronic \nkidney disease (with proteinuria >1g/day), medical treatment is required if BP is \nabove 130/80.32-34 (Level I) This also applies to other high risk subjects such as those \nwith previous CVA or CAD.35-37 (Level I)\n12\n \n\u2022 All patients with pre-hypertension should have full cardiovascular risk \nassessment. There is presently inadequate evidence for pharmacological \nintervention in pre-hypertensive patients at moderate or low total CV risk. \nTwo trials i.e. the Trial of Preventing Hypertension (TROPHY) study27 and the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_83",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Two trials i.e. the Trial of Preventing Hypertension (TROPHY) study27 and the \nPrevention of Hypertension with the Angiotensin Converting Enzyme inhibitor \nRamipril in Patients with High-normal pressure (PHARAO) study38 have shown \nthat treatment with either an ARB or an ACEI monotherapy significantly reduce \nthe risk of developing hypertension. \n\t\n\t\n\t\n\t\nPre-hypertension is defined as systolic BP 120 to 139 or diastolic BP 80 to\n\t\n\t\n89 mmHg, based on 2 or more seated BP readings on each of 2 or more\n\t\n\t\noffice visits.\n\t\n\t\nRecommendations\n \n \n\u2022 \nNon-pharmacological intervention is the mainstay of management. \n\t\n\t\n\t\n(Grade C)\n \n \n\u2022 \nPatient at high CV risk may require pharmacological intervention.\n\t\n\t\n\t\n(Grade A)\n13\n5.0\t\nNON-PHARMACOLOGICAL MANAGEMENT\nNon-pharmacological \nmanagement",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_84",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "(Grade A)\n13\n5.0\t\nNON-PHARMACOLOGICAL MANAGEMENT\nNon-pharmacological \nmanagement \n(therapeutic \nlifestyle \nmodification) \nplays \nan important role in the management of hypertension and in improving overall \ncardiovascular health.39 However evidence from randomized controlled trials on lifestyle \nintervention and blood pressure came from small trials with short duration of intervention \nand poor in quality. In an overview of 98 trials including 7,993 participants, statistically \nsignificant reductions in blood pressure were found in the short term for improved \ndiet and exercise, relaxation therapies, sodium and alcohol reduction.20 (Level I) When \nrecommending lifestyle modification, it is important to know that these interventions",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_85",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "recommending lifestyle modification, it is important to know that these interventions \nrequire a concerted effort from both the patient and the doctors.\n5.1\t\nWEIGHT REDUCTION\nWeight-reducing diets in overweight hypertensive persons can result in modest weight \nloss in the range of 3-9% of body weight 40 (Level I) and are associated with blood pressure \nreduction of about 3-6 mmHg. It is advisable for overweight hypertensive patients to lose \nat least 5% of their weight. \n5.2\t\nSODIUM INTAKE\nHigh salt intake is associated with significantly increased risk of stroke and total \ncardiovascular disease.41 (Level I) Evidence from published systematic review and meta \nanalyses showed that restricting sodium intake in people with elevated blood pressure",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_86",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "analyses showed that restricting sodium intake in people with elevated blood pressure \nin the short term leads to reductions in blood pressure of up to 10.5 mmHg systolic and \n2 mmHg diastolic.41-43 (Level I) An intake of <100 mmol of sodium or 6g of sodium chloride \na day is recommended (equivalent to <1\u00bc teaspoonfuls of salt or 3 teaspoonfuls of \nmonosodium glutamate).44,45,46 (Level I)\nIn society with a high salt intake, such as in Malaysia, salt reduction should be \nemphasized.47 (Level III)\n5.3\t\nAVOIDANCE OF ALCOHOL INTAKE\nAlcohol consumption elevates BP acutely. For those who consume alcohol, intake should \nbe restricted to no more than 21 units for men and 14 units for women per week (1 unit",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_87",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "be restricted to no more than 21 units for men and 14 units for women per week (1 unit \nis equivalent to one half-pint of beer or 100 ml of wine or 20 ml of \u201cproof whisky\u201d). Meta \nanalyses have shown that, interventions to reduce alcohol consumption caused a small \nbut significant reduction (3.3/2 mmHg) in both systolic and diastolic blood respectively.48 \n(Level I) Hypertensives who are heavy drinkers are also more likely to have hypertension \nresistant to drug treatment. The only way to reduce these patients\u2019 BP effectively is by \nreducing or stopping their alcohol intake.49\n5.4\t\nREGULAR PHYSICAL EXERCISE\nAerobic exercise is more effective than resistance training (e.g., weight lifting).50  Exercise",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_88",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Aerobic exercise is more effective than resistance training (e.g., weight lifting).50  Exercise \nlike walking-jogging can result in a reduction of 13/18 mmHg in SBP/DBP.51 (Level I) More \nrecent evidence showed that resistant exercise is effective in lowering blood pressure \namong normotensives and pre-hypertensives but not among hypertensives.52  However \nisometric resistant exercise can reduce BP by 10.4/6.7 mmHg as shown by a recent \nmeta analysis.53 (Level I) General advice on cardiovascular health would be for modest \nexercise, such as brisk walking for a total of at least 150 mins per week.54,55 (Level I)\n14\n5.5\t\nHEALTHY EATING\nA diet rich in fruits, vegetables and low fat dairy products with reduced saturated and",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_89",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "A diet rich in fruits, vegetables and low fat dairy products with reduced saturated and \ntotal fat can substantially lower BP (11/6 mmHg in hypertensive patients and 4/2 mmHg \nin patients with high normal BP).55 (Level I) More recently, diet high in L-Arginine has been \nshown to be able to reduce BP by 5.4/2.3 mmHg56 (Level I)\n5.6\t\nCESSATION OF SMOKING\nSmoking can raise BP acutely. However the effect of chronic smoking on BP is less clear. \nNevertheless smoking cessation is important in reducing overall cardiovascular risk.  \n5.7\t\nRELAXATION THERAPY\nRelaxation interventions were shown to be associated with statistically significant \nreductions in systolic and diastolic blood pressure of about 3 mmHg.55 However, another",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_90",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "reductions in systolic and diastolic blood pressure of about 3 mmHg.55 However, another \nsystematic review of studies on the effect of stress reduction on blood pressure found \nsmall and non-significant effect on blood pressure.57 (Level I) It is not recommended for \nroutine provision in primary care. \n5.8\t\nOTHERS\nThese include micronutrient alterations, caffeine reduction and dietary supplementation \nwith fish oil, potassium, calcium, magnesium and fibre. However the evidence for its \nbeneficial effect is limited.58-61 (Level I)\nIn summary while weight reducing diet, regular exercise, alcohol and salt restriction have \nbeen consistently shown to be beneficial in reducing BP in patients, the evidence thus",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_91",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "been consistently shown to be beneficial in reducing BP in patients, the evidence thus \nfar has not been consistent for relaxation therapies and supplementations with calcium, \nmagnesium or potassium.62 (Level I)\n\t\nRecommendations\n \n\u2022 Lifestyle modification must be instituted as an integral role in reducing blood  \n \n\t\n\t\npressure (Grade C)\n \n\u2022 Patients must be advised to  lose weight, do regular exercise, restrict alcohol  \n \n\t\n\t\nintake and reduce salt consumption (Grade A)\n15\n6.0\t\nPHARMACOLOGICAL MANAGEMENT\n6.1\t\nGENERAL GUIDELINES\nAll patients must be risk stratified to guide management. Decision to initiate \npharmacologic treatment depends on the total cardiovascular risk (Table 6). It is \nthe reduction of BP which provides the main benefits in the general hypertensive",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_92",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "the reduction of BP which provides the main benefits in the general hypertensive \npopulation.63 (Level I) The choice of drug should be individualized. Appendix 3 shows the \ndrugs currently available in Malaysia.\n6.1a\t\nInitiating Treatment\nFor patients with Stage I hypertension with low cardiovascular risk, advice should be \ngiven on lifestyle modification for a period of three to six months. The patient should \nbe seen two to three times during this period to assess the efficacy of the above \nintervention. Stage I patients with medium or higher risk should be offered drug \ntreatment upon diagnosis (Figure 1).(Level III)\n6.1b\t\nChoosing Antihypertensive Drug Treatment\nIn patients with newly diagnosed uncomplicated hypertension and no compelling",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_93",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "In patients with newly diagnosed uncomplicated hypertension and no compelling \nindications, choice of first line monotherapy includes ACEIs, ARBs, CCBs and diuretics \nwhich have all been shown to reduce cardiovascular morbidity and mortality.64-68 (Level I) \nBeta-blockers are not recommended as first line monotherapy in this group of patients \naccording to the one guideline.20 (Level III) This is mainly based on an earlier meta analysis \nwhich  showed that it is not as effective in lowering blood pressure and in the prevention \nof stroke compared to the other anti-hypertensive agents.69-72 However more recent \nmeta analyses73,74 including updated versions of earlier meta analysis75,76  have vindicated",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_94",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "meta analyses73,74 including updated versions of earlier meta analysis75,76  have vindicated \nbeta-blockers even as first line agent. Aside from the NICE guideline and the latest JNC \nguideline 77 all other guidelines continue to recommend beta-blockers as first line agent \neven in uncomplicated newly diagnosed hypertension.22,78,79 However, all guidelines \nrecommend that beta-blockers should be considered in younger patients in particular:\n \n\u2022 those with an intolerance or contraindication to ACE inhibitors and angiotensin   \n\t\n\t\nreceptor blockers or\n \n\u2022 women of child-bearing potential or\n \n\u2022 patients with evidence of increased sympathetic drive.\nIdeally, individualisation should be based on scientific evidence of reduction in endpoints",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_95",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Ideally, individualisation should be based on scientific evidence of reduction in endpoints \nand co-morbidities (Table 8). Contraindications to the use of these drugs must also be \nconsidered. \nIn patients with stage I hypertension, treatment should be started with monotherapy at \nlow dose. Monotherapy can lower BP to <140/90 mmHg in approximately 40\u201360% of \npatients with mild to moderate hypertension. If after a sufficient period of treatment (up to \nsix weeks) with monotherapy BP is still not controlled, three options are available;\n \n\u2022 the dose of the initial drug can be increased\n \n\u2022 the drug can be substituted with another class of drug\n \n\u2022 a second drug can be added \n\t\n\t\n\t\nChoices of combination therapy is as shown in Table 9 & 10.\n16",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_96",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 a second drug can be added \n\t\n\t\n\t\nChoices of combination therapy is as shown in Table 9 & 10.\n16\nWhen target BP is not achieved after initiation of an anti-hypertensive, either increase \nthe dose of the initial anti-hypertensive agent or add a second anti-hypertensive. The \nformer may however give rise to dose-related adverse effects. Properly selected anti-\nhypertensive combinations may also mitigate the adverse effects of each other. If the \npatient does not show response or does not tolerate the initial drug, substituting with \na drug from another class is recommended.(Level III) In patients presenting with stage II \nhypertension or beyond, combination therapy as first line is recommended.(Level III) (Refer \nto Figure 1)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_97",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "to Figure 1)\nSingle Pill Combinations (SPC) is very convenient to use and promote treatment \nadherence 80  by reducing pill burden and simplifying the treatment regimen.81,82  \nIn addition, it takes less time to achieve BP control using a combination than \nmonotherapy.83,84 (Level I)\nIt should be emphasized that simplification of the treatment regimen is only one strategy \nfor improving adherence. For many patients, cost is a critical issue. In Malaysia, generic \nSPC are generally not available. Patented SPC are available but are more expensive. \nThis may adversely affect adherence especially for self paying patients. Free drug \ncombination is the obvious choice in such circumstances It is however worth noting",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_98",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "combination is the obvious choice in such circumstances It is however worth noting \nthan available evidence showed SPC is associated with not only improved adherence, \nbut also lower overall health care cost.85 (Level II-2)\n17\nFigure 1.\tAlgorithm for the Management of Hypertension\nBLOOD PRESSURE\n(Repeated Readings)\nSBP < 140 mmHg\nAND/OR\nDBP < 90 mmHg\nMedium / High /\nVery High\n6-monthly follow up\nLow\n3 \u2013 6 monthly follow-up with advice on \nnon-pharmacological management\nAssess global \ncardiovascular risk\n(Table 6)\nSBP \u2265 140 mmHg\nAND/OR\nDBP \u2265 90 mmHg\nDrug treatment\nDrug treatment,\n(combination therapy\npreferred)*\n* either free or single pill combination\nSBP = 130 \u2013 159 mmHg\nAND/OR\nDBP = 80 \u2013 99 mmHg\nSBP \u2265 160 mmHg\nAND/OR\nDBP \u2265 100 mmHg\n18",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_99",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "SBP = 130 \u2013 159 mmHg\nAND/OR\nDBP = 80 \u2013 99 mmHg\nSBP \u2265 160 mmHg\nAND/OR\nDBP \u2265 100 mmHg\n18\nTable 8.\t Choice of Anti-Hypertensive Drugs in Patients with Concomitant \t \t\n\t\nConditions \nConcomitant\t\nDiuretics\t\n\u00df-blockers\t\nACEIs\t\nCCBs\t\nPeripheral  \t\nARBs\nCondition \t\n\t\n\t\n\t\n\t\n\u2202-blockers\nDiabetes mellitus\n(without nephropathy)\t\n+\t\n +/-\t\n+++\t\n+\t\n+/-\t\n++\nDiabetes mellitus\n(with nephropathy)\t\n++\t\n+/-\t\n+++\t\n++*\t\n+/-\t\n+++\nGout\t\n+/-\t\n+\t\n+\t\n+\t\n+\t\n++\nDyslipidaemia\t\n+/-\t\n+/-\t\n+\t\n+\t\n+\t\n+\nCoronary heart\ndisease\t\n+\t\n+++\t\n+++\t\n++\t\n+\t\n+++\nHeart failure\t\n+++\t\n+++\t\n+++#\t\n+@\t\n+\t\n+++\nAsthma\t\n+\t\n-\t\n+\t\n+\t\n+\t\n+\nPeripheral vascular\ndisease\t\n+\t\n+/-\t\n+\t\n+\t\n+\t\n+\nNon-diabetic\nrenal impairment\t\n ++\t\n+\t\n+++\t\n+*\t\n+\t\n++\nRenal artery stenosis\t\n+\t\n+\t\n++$\t\n+\t\n+\t\n++$\nElderly with no\nco-morbid conditions\t\n+++\t\n+\t\n+\t\n+++\t\n+/-\t\n+",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_100",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "+\t\n+\t\n++$\t\n+\t\n+\t\n++$\nElderly with no\nco-morbid conditions\t\n+++\t\n+\t\n+\t\n+++\t\n+/-\t\n+\nVery elderly (>80 yrs) \nwith no co-morbid\nconditions\t\n+++\t\n+\t\n+++\t\n++\t\n+/-\t\n++\nThe grading of recommendation from (+) to (+++) is based on increasing levels of evidence \nand/or current widely accepted practice\n+/-\t Use with care\n- \t\nContraindicated\n*\t\nOnly non-dihydropyridine CCB\n#\t\nMetoprolol, bisoprolol, carvedilol, nebivolol \u2013 dose needs to be gradually titrated\n@\t\nCurrent evidence available for amlodipine and felodipine only\n$\t\nContraindicated in bilateral renal artery stenosis\n19\nTable 9.\t Effective Anti-Hypertensive Combinations Used in Outcome Trials \nEffective combination\t\nPatients studied\nACEI + thiazide-like diuretics 86\t\nPost stroke\nARB  + thiazide87\t\nHypertensive with Left Ventricular Hypertrophy",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_101",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Post stroke\nARB  + thiazide87\t\nHypertensive with Left Ventricular Hypertrophy\nCCB + ACEIs or \u00df-blocker\t\nPatients with Coronary Artery Disease\n+ thiazide88\t\nARB + thiazide or CCB + thiazide89\t\nHigh risk hypertensives\nCCB + ACEI90\t\nMedium risk hypertensives with no overt \t\n\t\n\t\nvascular diseases\nACEI + thiazide-like diuretics91\t\nHigh risk hypertensives with diabetes\nACEI + CCB92\t\nHigh risk hypertensives\nthiazide-like diuretics + ACEI93\t\nVery elderly (>80 years old )\nTable 10.\tDrug Combinations in Hypertension: \nPreferred (based on outcome trials)86-93\nACEI / thiazide or thiazide-like diuretics \nARB / thiazide diuretics\nACEI / CCB\n\u00df-Blocker / thiazide diuretics\nthiazide diuretics / K+ sparing diuretics\nAcceptable (no outcome trial evidence yet) \nARB / CCB\n\u00df-Blocker / thiazide-like diuretics",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_102",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Acceptable (no outcome trial evidence yet) \nARB / CCB\n\u00df-Blocker / thiazide-like diuretics\nDRI/diuretic\nARB\t = angiotensin receptor blocker\nACEI\t= angiotensin-converting enzyme inhibitor\nCCB\t= calcium channel blocker\nDRI\t = direct renin inhibitor\n6.1c\t\nTarget Blood Pressure\nEfforts must be made to reach target BP.  For patients <80 years old, the target SBP \nshould be <140 mmHg and DBP <90 mmHg.20,78 For patients aged 80 years and above, \naim for a target of <150/90 mmHg (Refer to chapter 8 on Hypertension in the Elderly). \nFor high/very high risk individuals the target is <130 or 140 mmHg / 80 mmHg (Refer to \nchapter 8 on Hypertension in Special Groups).  \nIf BP is still >140/90 mmHg with three drugs, including a diuretic at optimal doses, there",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_103",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "If BP is still >140/90 mmHg with three drugs, including a diuretic at optimal doses, there \nis a need to exclude medication non-compliance and isolated office hypertension. After \nexcluding these causes of uncontrolled hypertension, the patient is then defined as \nhaving resistant hypertension94 (Refer to chapter on Resistant Hypertension). A quick \ncheck on the possible causes of resistant hypertension is required. These include:\n \n\u2022 secondary hypertension\n \n\u2022 excessive sodium intake, excessive liquorice intake, drugs and drug interactions.\n \n\u2022 complications of long standing hypertension such as nephrosclerosis, loss of  \n \n\t\n\t\naortic distensibility and atherosclerotic renal artery stenosis.\n20\n6.2\t\nFOLLOW\u2013UP VISITS",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_104",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "aortic distensibility and atherosclerotic renal artery stenosis.\n20\n6.2\t\nFOLLOW\u2013UP VISITS\nFollow up intervals should be individualised based on global CV risk, pre-treatment BP \nlevels and drugs used. For high and very high risk patients, it is advisable to bring the \nBP to target within 3 to 6 months.89 Once target BP is achieved, follow-up at three to \nsix-month intervals is appropriate. As a rule, once the BP is controlled, most patients will \nrequire life-long treatment.\n6.3\t\nSTEP-DOWN THERAPY\nStep-down therapy is discouraged in the vast majority of patients. However in patients \nwho insist on it, the patient must fulfil the following criteria:\n \n\u2022 BP well-controlled for at least 1 year on the same medication\n \n\u2022 patients\u2019 BP must not be higher than stage I hypertension with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_105",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 patients\u2019 BP must not be higher than stage I hypertension with \n\t\n\t\nlow global CV risk \n \n\u2022 must agree to be followed-up at least 3-6 monthly\n \n\u2022 must be motivated to continue life-style modification\n6.4\t\nWHEN TO REFER\nMost patients can be effectively managed by primary care practitioners. Patients with \nthe following conditions should be referred to the appropriate specialist for further \nassessment. Indications for referral to the appropriate specialist include:\n \n\u2022 accelerated or malignant hypertension\n \n\u2022 suspected secondary hypertension\n \n\u2022 resistant hypertension\n \n\u2022 recent onset of target organ damage\n \n\u2022 pregnancy\n \n\u2022 isolated office hypertension\n \n\u2022 children <18 years old\n\t\n\t\nRecommendations\n \n\u2022 For the majority of hypertensive patients, treatment is life-long (Grade C)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_106",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Recommendations\n \n\u2022 For the majority of hypertensive patients, treatment is life-long (Grade C)\n \n\u2022 Choice of treatment should be individualised (Grade C)\n \n\u2022 Target BP should be SBP<140 mmHg and DBP<90 mmHg for most  (Grade A)\n \n\u2022 For high / very high risk patients, target SBP is  <130 or <140 mmHg and DBP\n\t\n\t\n<80 mmHg (Grade A)\n \n\u2022 Combination therapy (free or single pill) is required is most patients to achieve\n\t\n\t\nBP control (Grade B )\n21\n7.0\t\nMANAGEMENT OF SEVERE HYPERTENSION\nSevere hypertension is defined as persistent elevated SBP >180 mmHg and/or DBP >110 \nmmHg. \nThese patients may present in the following manner:\n\u2022 \nincidental finding in an asymptomatic patient\n\u2022 \nnon-specific symptoms like headache, dizziness, lethargy\n\u2022",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_107",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 \nnon-specific symptoms like headache, dizziness, lethargy\n\u2022 \nsymptoms and signs of acute target organ damage. These include acute heart\n\t\nfailure, acute coronary syndromes, acute renal failure, dissecting aneurysm, \t\n\t\n\t\nsubarachnoid haemorrhage and hypertensive encephalopathy. \nPatients are then categorised as having:-\n\t\n(a)\t\t\nasymptomatic severe hypertension,\n\t\n(b)\t\nhypertensive urgencies, or\n\t\n(c)\t\t\nhypertensive emergencies\n\t\n(b) and (c) are also referred to as hypertensive crises.95\nIn a recent large series, only a minority of patients admitted (5.1%) had hypertensive \ncrises. Of those more than three quarters (76.6%) constitute hypertensive \nemergencies.96 (Level III)\nManagement of these patients depends on the clinical presentation and laboratory",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_108",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Management of these patients depends on the clinical presentation and laboratory \ninvestigations. The evaluation of these patients should include a thorough history and \nphysical examination, particularly looking for signs of acute target organ damage / \ncomplication and causes of secondary hypertension. (Table 11) \nThe commonest reason of severe hypertension is long-standing poorly controlled \nessential hypertension.97 Other causes are as listed in Table 11. \nTable 11.\tCommon Causes of Severe Hypertension\nCauses\t\nExample\nParenchymal renal disease \t\nChronic Kidney Disease\n\t\nPrimary glomerulonephritis\nRenovascular disease\t\nAtherosclerotic disease\n\t\nFibromuscular dysplasia\n\t\nPolyarteritis nodosa\nSystemic disorders with renal\t\nSystemic lupus erythematosus\ninvolvement\t\nSystemic sclerosis",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_109",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Systemic disorders with renal\t\nSystemic lupus erythematosus\ninvolvement\t\nSystemic sclerosis\n\t\nVasculitides\nEndocrine\t\nConn syndrome (primary hyperaldosteronism)\n\t\nPhaeochromocytoma\n\t\nCushing syndrome\nDrugs\t\nNSAIDs \n\t\nCOX-2  inhibitors\n\t\nOral Contraceptives\n\t\nAmphetamines\n\t\nCyclosporin\n\t\nCocaine \n\t\nOther Illicit Drugs\n\t\nPhencyclidine\n\t\nClonidine withdrawal\nCongenital disease\t\nCoarctation of Aorta\n\t\nPolycystic kidney disease\nPregnancy related\t\nPreeclampsia/eclampsia\n22\n7.1\t\nSPECIFIC MANAGEMENT\nThe aim of management is to reduce BP in a controlled, predictable and safe manner, \nin order to avoid the onset or aggravating acute coronary syndrome, cerebral or renal \nischaemia. \n7.1.1\t\nAsymptomatic Severe Hypertension",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_110",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ischaemia. \n7.1.1\t\nAsymptomatic Severe Hypertension \nAdmission may be necessary in the newly diagnosed, or where drug adherence may be \na problem.  Patients already on treatment need to have their drug regime reviewed. Oral \ncombination therapy should be preferred. \n7.1.2\t\nHypertensive Urgencies \nThese include patients with grade III or IV retinal changes (also known as accelerated \nand malignant hypertension), but no overt acute target organ damage/complication. \nThese patients should be admitted. BP measurement should be repeated after 30 \nminutes of bed rest. Initial treatment should aim for about 25% reduction in BP over 24 \nhours but not lower than 160/90 mmHg.95,98 (Level III) Oral drugs proven to be effective are",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_111",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hours but not lower than 160/90 mmHg.95,98 (Level III) Oral drugs proven to be effective are \noutlined in Table 12. Combination therapy is necessary. There is no role for intravenous \nBP lowering drugs.\nTable 12.\t Oral Treatment for Hypertensive Urgencies \nDrug\t\nDose (mg)\t\nOnset of\t\nDuration\t\nFrequency\t\t\n\t\n\t\naction (hr)\t\n(hr)\t\n(prn)\nCaptopril\t\n25 mg\t\n0.5\t\n6\t\n1 \u2013 2 hrs\nNifedipine\t\n10 \u2013 20 mg\t\n0.5\t\n3 \u2013 5\t\n1 \u2013 2 hrs\nLabetalol\t\n200 \u2013 400 mg\t\n2.0\t\n6\t\n4 hrs\n7.1.3\t\nHypertensive Emergencies \nThese include patients with complications of severe hypertension such as acute heart \nfailure, dissecting aneurysm, acute coronary syndromes, hypertensive encephalopathy, \nsubarachnoid haemorrhage and acute renal failure. These may occur in patients with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_112",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "subarachnoid haemorrhage and acute renal failure. These may occur in patients with \nBP < 180/110 mmHg, particularly if the BP has risen rapidly. \nAll these patients should be admitted. The BP needs to be reduced rapidly. It is \nsuggested that the BP be reduced by 25% depending on clinical scenario over 3 to 12 \nhours but not lower than 160/90 mmHg.99,100 (Level III)\nThis is best achieved with parenteral drugs. (Table 13)\nThere has been very few head to head comparative trials is the management of \nhypertensive crises especially hypertensive emergencies. A recent meta analysis \nshowed that IV labetalol have comparable efficacy and safety compared to nicardipine \nwith the later showing more predictable and consistent BP control 101 (Level I)\n23",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_113",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "with the later showing more predictable and consistent BP control 101 (Level I)\n23\nTable 13.\t Treatment Options for Hypertensive Emergencies98-100\nDrugs\t\nDose\t\nOnset of\t\nDuration\t\nRemarks\n\t\n\t\naction\nSodium\t\n0.25\u201310 \u03bcg/kg/min\t\nseconds\t\n1 \u2013 5 min\t\nCaution in heart \nnitroprusside\t\n\t\n\t\n\t\nfailure\t\nLabetalol\t\nIV bolus 50 mg \t\n\u22645 min\t\n3 \u2013 6 hrs\t\nCaution in heart \n\t\n(over at least 1 minute)\t\n\t\n\t\nfailure \n\t\nrepeating if necessary \n\t\nat 5 minute intervals to \n\t\na max of 200 mg then \n\t\n2 mg/min IVI\nNitroglycerine\t\n5 \u2013 100 \u03bcg /min\t\n2 \u2013 5 min\t\n3 \u2013 5 min\t\nPreferred in acute\t\n\t\n\t\n\t\n\t\n\t\ncoronary syndrome\t \t\n\t\n\t\n\t\n\t\nand acute\n\t\n\t\n\t\n\t\npulmonary oedema\nHydralazine*\t\nIV 5\u201310 mg maybe\t\n10 \u2013 30 min\t\n3 \u2013 8 hrs \t\nCaution in acute\n\t\nrepeated after 20\u201330\t\n \t\n\t\ncoronary syndromes,\t\t\n\t\nminutes.\t\n\t\n\t\ncerebrovascular",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_114",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Caution in acute\n\t\nrepeated after 20\u201330\t\n \t\n\t\ncoronary syndromes,\t\t\n\t\nminutes.\t\n\t\n\t\ncerebrovascular\n\t\nIVI 200\u2013300 mcg/min\t\n\t\n\t\naccidents and\n\t\ninitially. Maintenance\t\n\t\n\t\ndissecting aneurysm \t\n\t\n50\u2013150 \u03bcg/min\nNicardipine\t\nIV bolus 10\u201330 mcg/kg\t\n5 \u2013 10 min\t\n1 \u2013 4 hrs\t\nCaution in acute \n\t\nover 1 minute \t\n\t\n\t\nheart failure and\n\t\nIVI 2\u201310 \u03bcg/kg/min\t\n\t\n\t\ncoronary ischaemia\nEsmolol\t\nIV bolus \t\n1 min\t\n10 \u2013 20 min\t Used in peri-\n\t\n250\u2013500 \u03bcg/kg over \t\n\t\n\t\noperative situations\t\n\t\n\t\n1 min\t\n\t\n\t\nand\n\t\nIVI 50\u2013200 \u03bcg/kg/min\t\n\t\n\t\ntachyarrhythmias\n\t\nfor 4 min.\t\n\t\n\t\n\t\nMay repeat sequence\t\n\t\n\t\nIn pregnancy, 200 mg labetalol in 50 ml normal saline and start infusion at 4 ml/hour.\n* In pregnancy, the initial dose is 25 \u03bcg/min IV infusion (25 mg in 500 ml normal saline at 30 ml/hour).\n7.2",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_115",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "7.2\t\nDANGERS OF RAPID REDUCTION IN BLOOD PRESSURE\nRapid reduction of BP (within minutes to hours) in asymptomatic severe hypertension or \nhypertensive urgencies is best avoided as it may precipitate ischaemic events.102\nOral or sublingual drugs with rapid onset of action can result in an uncontrolled BP \nreduction. Several serious side effects have been reported with the administration of \nsublingual fast-acting nifedipine and therefore this is no longer recommended.103 (Level III) \nHowever oral nifedipine retard can be used and has been recommended as first line \ntherapy for hypertensive urgencies.95 (Level III)\nFollowing stabilization of patient\u2019s BP, subsequent management is tailored towards \nachieving optimal control.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_116",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "achieving optimal control.\nFor management of patients with severe hypertension and stroke, refer to chapter 8.6 on \non Hypertension and Stroke.\n\t\nRecommendations\n \n\u2022 Do not reduce BP rapidly in asymptomatic severe hypertension. (Grade C)\n \n\u2022 Treat hypertensive urgencies with combination oral therapy targeting BP to  \n \n\t\n\t\nreduce by around 25% within 24 hours. (Grade C)\n \n\u2022 Treat hypertensive emergencies with intravenous drugs targeting BP to reduce     \n\t\n\t\nby around 25% within 3 to 12 hours. (Grade C)\n24\n8.0\t\nHYPERTENSION IN SPECIAL GROUPS\n8.1\t\nHYPERTENSION AND DIABETES MELLITUS\nHypertension is common in patients with diabetes mellitus. Its presence increases the \nrisk of morbidity and mortality. The Hypertension in Diabetes Study Group reported a",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_117",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "risk of morbidity and mortality. The Hypertension in Diabetes Study Group reported a\n39% prevalence of hypertension among newly diagnosed patients. \nHypertension should be treated early in diabetics to prevent both microvascular, \nmacrovascular complications and CV death.\n8.1.1\t\nThreshold for Treatment\nPharmacological treatment should be initiated in patients with diabetes when the BP\nis persistently >140 mmHg systolic and/or >80 mmHg diastolic.            \nThe presence of microalbuminuria or overt proteinuria should be treated even if the BP \nis <140/80 mmHg. An ACEI or ARB is preferred.104-111 (Level I) In a proportion of patients, \nmicroalbuminuria may be normalised by high doses of ACEIs108 or ARBs109-110 (Level I) even",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_118",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "microalbuminuria may be normalised by high doses of ACEIs108 or ARBs109-110 (Level I) even \nif the BP is optimally controlled. The combination of ACEI and ARBs may further reduce \nproteinuria but should be instituted by a specialist.112 Normalisation of microalbuminuria is \nassociated with a reduction in the rate of decline in glomerular filtration rate.113\n8.1.2\t\nTarget Blood Pressure\nTight BP control should take precedence over the class of anti-hypertensive drug \nused.114,115 (Level I) This will often require combination therapy. There are suggestions that a \nlower target BP may be necessary to maximally protect against the development and \nprogression of cardiovascular and diabetic renal disease. In general, the SBP should be",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_119",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "progression of cardiovascular and diabetic renal disease. In general, the SBP should be \ntargeted to <140 mmHg22,91,104 (Level I) and diastolic pressure <80 mmHg.91 (Level I) In a subset \nof patients especially the younger patients, a systolic target of <130 mmHg can be \nconsidered116-117 (Level I)\nIn the ACCORD Study, diabetic patients at high risk of cardiovascular events who were \nrandomised to a target systolic blood pressure (SBP) of <120 mmHg, did not show a \nreduction in the rate of composite outcome of fatal and nonfatal major cardiovascular \nevents as compared with <140 mmHg.118 (Level I)This could possibly be due to the J-curve \nphenomenon seen in this particular cohort of patients who had underlying cardiovascular",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_120",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "phenomenon seen in this particular cohort of patients who had underlying cardiovascular \ndisease at baseline. However, subgroup analysis showed the more intensive SBP-\nlowering group had significantly lower stroke rate. The ACCORD Study however is under \npowered as acknowledged by the authors.\nThe J-curve phenomenon was also noted in the diabetic subgroup in the INVEST \nStudy.119 This however is a subanalysis of the study.\nThere was no reported increase in cardiovascular events in the ADVANCE Study with \npatients whose systolic blood pressures were lowered to <120 mmHg.91 On the other \nhand, renal protection was seen with baseline or achieved BP down to <120/70 mmHg. \nNo BP threshold could be identified below which renal benefit was lost.119",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_121",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "No BP threshold could be identified below which renal benefit was lost.119\nGenerally the target BP should be aimed at <140/80 mmHg and <130/80 mmHg in the \nyounger patients. However in diabetics with known CAD further lowering BP beyond \n120/80 mmHg does not confer additional cardiovascular benefit.  \n8.1.3\t\nManagement\nThe approach to managing patients with hypertension and diabetes should be along \nthe guidelines for treatment of hypertension in general including emphasis on non-\npharmacological management. \n25\n8.1.3.1\t\nNon-pharmacological Management\nThis cannot be over emphasised. Dietary counselling should target at optimal body \nweight, glycaemic and dyslipidaemic control. \nModerate dietary sodium restriction is advisable. It enhances the effects of BP lowering",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_122",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Moderate dietary sodium restriction is advisable. It enhances the effects of BP lowering \ndrugs especially ACEIs and the ARBs. Further sodium restriction, with or without a diuretic, \nmay be necessary in the presence of nephropathy or when the BP is difficult to control.115\n8.1.3.2\t\nPharmacological Management\nThe use of certain classes of anti-hypertensive drugs may be disadvantageous to the \ndiabetic patient by virtue of their modes of action or adverse effects. Diabetic control may \nbe compromised and various diabetic complications aggravated, for example:\n \n\u2022 decreased insulin responsiveness with higher doses of diuretics\n \n\u2022 masking of early symptoms of hypoglycaemia with \u00df-blockers and slowing of  \n \n\t\n\t\nrecovery from hypoglycaemia with non-selective \u00df-blockers",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_123",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "recovery from hypoglycaemia with non-selective \u00df-blockers\n \n\u2022 aggravation of symptoms of peripheral vascular disease with \u00df-blockers\n \n\u2022 dyslipidaemia with most \u00df-blockers and diuretics\n \n\u2022 worsening of orthostatic hypotension with peripheral \u2202-blockers or centrally  \n \n\t\n\t\nacting drugs. \nAngiotensin-converting enzyme inhibitors are drugs of choice based on extensive \ndata attesting to their cardiovascular and renal protective effects in patients with \ndiabetic kidney disease.120 (Level I) They have also been reported to prevent the onset of \nnephropathy in normoalbuminuric diabetic patients with or without hypertension.121-123 \n(Level I) In addition they do not have adverse effects on lipid and carbohydrate metabolism.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_124",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "(Level I) In addition they do not have adverse effects on lipid and carbohydrate metabolism. \nHowever it\u2019s routine use in normotensive normoalbuminuric diabetic patients is currently \nnot recommended. If an ACEI is not tolerated, an ARB should be considered.\nAngiotensin receptor blockers have been reported to be superior to conventional non-\nACEI anti-hypertensive drugs in terms of slowing the progress of nephropathy at the \nmicroalbuminuric stage109 as well as the overt nephropathy stage in type 2 diabetic \npatients.110,111 In addition, ARB has been shown to prevent or delayed the onset of \nmicroalbuminuria in normoalbuminuric patients with type 2 diabetes with or without \nhypertension.124,125 (Level I) However the data is too limited for ARBs to be recommended",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_125",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hypertension.124,125 (Level I) However the data is too limited for ARBs to be recommended \nroutinely in normotensive normoalbuminuric diabetic patients.\nAngiotensin receptor blockers have been shown to be of similar efficacy as ACEIs but \nbetter tolerated.121 (Level I) There have been no reports of adverse effects on carbohydrate \nand lipid metabolism.109-111\nThiazide and thiazide-like diuretics can be used as initial therapy or as add-on when \nmonotherapy is inadequate. Single Pill Combinations of a thiazide-like diuretic \n(indapamide) with ACEI reduced overall mortality.91\nCalcium channel blockers do not have significant adverse metabolic effects. They do not \ncompromise glycaemic control in diabetic patients. They can be effectively combined",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_126",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "compromise glycaemic control in diabetic patients. They can be effectively combined \nwith a RAAS blocker to lower blood pressure in general as well as in hypertensive \ndiabetics. Combination of amlodipine with perindopril was superior to the combination of \natenolol with bendroflumethiazide in the reduction of cardiovascular events in the overall \nstudy population as well as the diabetic subgroup.90\nBeta-blockers may be used when ACEIs, ARBs or CCBs cannot be used or when there \nare concomitant compelling indications. However, they should be used with caution, \nespecially in patients with type 1 diabetes.\n26\n\t\nRecommendations\n \n\u2022 ACEIs are the agents of choice for patients with diabetes without proteinuria.\n\t\n\t\nFor ACEI intolerant patients, ARBs should be used. (Grade A)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_127",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "For ACEI intolerant patients, ARBs should be used. (Grade A)\n \n\u2022 ACEIs or ARBs are the agents of choice for patients with diabetes and  \n \n\t\n\t\nproteinuria. (Grade A)\n \n\u2022 Calcium channel blockers, diuretics or \u00df-blockers may be considered if\n\t\n\t\neither of the above cannot be used. (Grade B)\n \n\u2022 Target BP in the diabetic is <140/80 mmHg for all. (Grade A)\n \n\u2022 A target BP of <130/80 mmHg is recommended for the younger patients\n\t\n\t\n(Grade C)\n8.2 \t\nBLOOD PRESSURE AND THE METABOLIC SYNDROME\nThe metabolic syndrome is a cluster of risk factors predisposing to cardiovascular disease \nand diabetes. Since the last guideline was formulated, several key medical organisations \nhave agreed on a common definition.126 However the American Diabetes Association",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_128",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "have agreed on a common definition.126 However the American Diabetes Association \nand the European Association for the Study of Diabetes have not subscribed to it. \nThe diagnostic criteria are listed in the table below. More recently, the Harmonised \nInternational Diabetes Federation (IDF) has agreed that waist circumference no longer \nneeds to be a compulsory criterion, but it should be country and ethnic-specific. The \npresence of any three out of the five criteria would lead to a diagnosis of the Metabolic \nSyndrome.126 The IDF definition is in line with the American National Cholesterol Education \nProgramme Adult Treatment Panel III (NCEP ATP III) criteria127 and that which is modified \nfor Asian128 and other populations129 (Table 14).",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_129",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "for Asian128 and other populations129 (Table 14).\nAn elevated blood pressure is one of the criteria for the diagnosis of the Metabolic \nSyndrome. In these high risk patients, the cut-off point has been set at 130/85 mmHg. \nDespite disagreement over the usefulness of making a diagnosis of the Metabolic \nSyndrome, the consensus is that various components of the metabolic syndrome should \nbe treated vigorously. For blood pressure, the target should be <130/85 mmHg.129,130 \nBlood pressure associated with the Metabolic Syndrome should be treated according\nto standard clinical practice guidelines. Drugs which are metabolically neutral, like the \nRAAS blockers and CCBs are preferred. \u00df-blockers and thiazide diuretics have the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_130",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "RAAS blockers and CCBs are preferred. \u00df-blockers and thiazide diuretics have the \npotential to increase the incidence of new onset diabetes131,69 and thus should be used \nwith caution in these patients. \nIn Malaysia, the overall prevalence of the Metabolic Syndrome using the original NCEP \nATP III and the Harmonised IDF criteria was 34.3% and 42.5% respectively.132,133 These \nprevalence rates are among the highest in the world. The prevalence of the Metabolic \nSyndrome in Malaysia was higher in urban areas, among females and those of Indian \nethnicity. Among the criteria used for metabolic syndrome, abdominal obesity was \nmost prevalent (57.4%); being higher in females (64.2%) and among Indians (68.8%). \nHypertension was higher in males (56.5%) and among Malays (52.2%). In contrast, the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_131",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Hypertension was higher in males (56.5%) and among Malays (52.2%). In contrast, the \nChinese had the highest prevalence of hypertriglyceridaemia (47.4%).\n\t\nThe prevalence of the Metabolic Syndrome in Malaysia is among the highest\n\t\nin the world. \n\t\n\t\nRecommendations\n \n\u2022 In the presence of one component of Metabolic Syndrome, other components   \n\t\n\t\nof the syndrome must be screened for (Grade C)\n \n\u2022 Treat each component of the Metabolic Syndrome optimally. (Grade B)\n \n\u2022 Chose treatment which will not aggravate other components of the syndrome.  \n\t\n\t\n(Grade C)\n27\nTable 14.\t NCEP ATP III and IDF Criteria for the Metabolic Syndrome 126,127\nComponents of\t\nWaist\t\nBP\t\nFBS\t\nTG\t\nHDL\nmetabolic syndrome\t\n(cm)\t\n(mm Hg)\t\n(mmol/L)\t\n(mmol/L)\t\n(mmol/L)\nNCEP 2001\t\n> 102  (M)\t\n\u2265130/85\t\n\u2265 5.6\t\n\u2265 1.7",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_132",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "(cm)\t\n(mm Hg)\t\n(mmol/L)\t\n(mmol/L)\t\n(mmol/L)\nNCEP 2001\t\n> 102  (M)\t\n\u2265130/85\t\n\u2265 5.6\t\n\u2265 1.7\t\n< 1.0 (M)\n3 out of 5 criteria\t\n> 88  (F)\t\n\t\n\t\n\t\n< 1.3 (F)\nIDF Task Force 2009\t\nCountry\t\n\u2265130/85\t\n\u2265 5.6\t\n\u2265 1.7\t\n< 1.0 (M)\n3 out of 5 of criteria\t\nand\t\n\t\n\t\n\t\n< 1.3 (F)\n\t\nEthnic-specific\n8.3\t\nHYPERTENSION AND NON-DIABETIC RENAL DISEASE \nHypertension may be a cause or consequence of renal failure.134,135 Renal disease is one \nof the commonest cause of secondary hypertension. \nHypertension in renal disease is often associated with an elevated serum creatinine, \nproteinuria and/or haematuria. Approximately 50-75% of individuals with GFR <60 ml/\nmin/1.73m2 (CKD stages 3\u20135) have hypertension.136 Hypertension accelerates the \nprogression of renal disease and may lead to end stage renal disease (ESRD). Tight",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_133",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "progression of renal disease and may lead to end stage renal disease (ESRD). Tight \ncontrol of BP in patients with CKD is therefore important. The target BP should be \n<140/90 mmHg for patients with CKD33,137,138 (Level I) and <130/80 mmHg for those with \nproteinuria of \u22651g/24 hours.34 (Level I) All anti-hypertensive drug classes can be used to \nachieve this goal.\nIn the management of hypertension in renal disease, control of BP and proteinuria are \nthe most important factors in terms of retarding the progression of renal disease. Anti-\nhypertensive agents that reduce proteinuria thus have an advantage. Meta analyses of \ncomparative trials concluded that ACEI conferred an anti-proteinuric effect greater than",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_134",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "comparative trials concluded that ACEI conferred an anti-proteinuric effect greater than \nother anti-hypertensive drugs.139 Overall 30% reduction in incidence of ESRD with ACEI \ncan be expected.140 The anti-proteinuric effect and reduction in ESRD was beyond that \nattributable to the BP lowering effect.138,141 (Level I) This anti-proteinuric effect of ACEI was \nmost prominent in patients on a low sodium diet or those treated with diuretics. Patients \nwith proteinuria >3g/24 hours benefit the most.138,141 The advantage of ACEI is most \napparent in patients with rapid progression of renal disease associated with proteinuria. \nARBs are similar to ACEI in lowering BP and reducing proteinuria.142,143  The combination of",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_135",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ARBs are similar to ACEI in lowering BP and reducing proteinuria.142,143  The combination of \nACEIs and ARBs has also been proven to reduce proteinuria more than monotherapy.144 \nHowever consultation with a specialist is advised prior to initiation of this combination.\nRenal insufficiency should not be a contraindication to starting ACEI or ARB therapy, nor \nshould it be a reason for discontinuing therapy. Serum creatinine level should be checked \nwithin the first two weeks of initiation of therapy and also after every increase in dose. If \nthere is a persistent rise of serum creatinine of >30% from baseline within two months, \nACEIs145 (Level I) or ARBs should be reduced or stopped after excluding other precipitating",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_136",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ACEIs145 (Level I) or ARBs should be reduced or stopped after excluding other precipitating \nfactors. These patients should be referred to a nephrologist or physician.\nIn patients with renal disease and hypertension with an elevated serum creatinine of \n>200 \u03bcmol/L (GFR <30 ml/min/1.73m2), thiazide diuretics may not be effective anti-\nhypertensive agents and therefore loop diuretics are preferred.146 (Level III) Concurrent \ndiuretic therapy will often be necessary in patients with renal insufficiency since salt and \nwater retention is an important determinant of hypertension in this setting.\nCalcium channel blockers may be used in renal disease. In those with proteinuria, the \nnon-dihydropyridine group of CCBs namely diltiazem or verapamil are preferred, as they",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_137",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "non-dihydropyridine group of CCBs namely diltiazem or verapamil are preferred, as they \nhave an additional anti-proteinuric effect.139 (Level I) Dihydropyridine CCBs can be considered \nif optimal BP is not achieved but should not be used as monotherapy. The combination of \nan ACEI and a non-dihydropyridine CCB is more anti-proteinuric than either drug alone.147\n28\nMore recently, aldosterone antagonists have been shown to have additive anti-\nproteinuric effects when administered with ACEI and/or ARB in patients with CKD.148,386 \nHowever, larger randomised prospective trials are needed to confirm the efficacy and \nsafety of aldosterone antagonists in reduction of CKD progression and mortality. Currently \nthere is not enough evidence for these agents to be used routinely.\n\t\nRecommendations",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_138",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "there is not enough evidence for these agents to be used routinely.\n\t\nRecommendations\n \n\u2022 Target BP should be <140/90 mmHg for those with proteinuria of <1g/24 hours   \n\t\n\t\nand <130/80 mmHg for those with proteinuria of >1 g/24 hours (Grade A)\n \n\u2022 ACEIs are recommended as initial anti-hypertensive therapy (Grade A)\n \n\u2022 ARBs should be used in patients intolerant to ACEIs (Grade C)\n \n\u2022 Dietary salt and protein restriction is important  (Grade A)\n \n\u2022 Concurrent diuretic therapy is useful in patients with fluid overload (Grade A)\n \n\u2022 Non-dihydropyridine CCBs can be added on if the BP goal is still not achieved   \n\t\n\t\nand there is persistent proteinuria (Grade A)\n8.4\t\nRENOVASCULAR HYPERTENSION\nRenovascular hypertension is defined as a rise in arterial pressure attributable",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_139",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Renovascular hypertension is defined as a rise in arterial pressure attributable \nto reduced perfusion of the kidney(s).149 It is important to diagnose renovascular \nhypertension as it is potentially reversible. Treatment also has the potential to restore \nor preserve renal function. The aetiology of renovascular hypertension includes the \nfollowing:\n \n\u2022 atherosclerotic renovascular disease\n \n\u2022 fibromuscular dysplasia \n \n\u2022 Takayasu\u2019s arteritis\n \n\u2022 transplant renal artery stenosis\nAtherosclerotic renal artery stenosis (ARAS) is an important cause as it can lead to \nESRD. It is also associated with coronary heart disease, cerebrovascular disease \nand peripheral vascular disease. In patients with ARAS older than 60 years, the five-",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_140",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and peripheral vascular disease. In patients with ARAS older than 60 years, the five-\nyear-survival is 45% in patients with bilateral ARAS and 18% in those requiring dialysis \ntherapy151,152\nThe presence of a stenotic renal vessel in a patient with hypertension does not \nnecessary equate to renovascular hypertension. \nSome clinical features suggestive of renovascular hypertension includes:\n \n\u2022 onset of hypertension before 30 years, especially without family history\n \n\u2022 recent onset of hypertension after 55 years or deterioration in BP control in a  \n \n\t\n\t\npreviously well-controlled patient \n \n\u2022 resistant hypertension \n \n\u2022 abdominal bruit; particularly if associated with a unilateral small kidney\n \n\u2022 flash pulmonary oedema",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_141",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 flash pulmonary oedema\n \n\u2022 renal failure of uncertain cause in the presence of normal urine sediment\n \n\u2022 renal failure induced by ACEIs or ARBs\n \n\u2022 coexisting diffuse atherosclerotic vascular disease\nRenal angiography including measurement of the pressure gradient remains the gold \nstandard in the diagnosis of renovascular hypertension.152 Non-invasive investigations \ncommonly recommended include spiral CT angiography (CTA), and magnetic resonance \nangiography (MRA) in patients with normal renal function.153\n29\nThe management of renal artery stenosis includes conservative treatment, angioplasty \nwith or without stenting and surgery. Conservative treatment can be considered for \npatients with stenosis less than 70% or those with stable renal function and good",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_142",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "patients with stenosis less than 70% or those with stable renal function and good \nBP control despite radiological evidence of stenosis >70%. These lesions should \nbe monitored for progression using colour duplex sonography. Medical treatment \nof patients with ARAS include statins, low dose aspirin, cessation of smoking and \nmanagement of diabetes when present. \nPharmacologic management of renovascular hypertension follows the general principles \nof all antihypertensive therapy but is especially dependant on effective blockade of the \nRAAS. Angiotensin converting enzyme inhibitors or ARB can be used in patients with \nsuspected ARAS if renal function is carefully monitored. A persistent rise in creatinine of",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_143",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "suspected ARAS if renal function is carefully monitored. A persistent rise in creatinine of \n>30% over 2 months warrants cessation of ACEI/ARB drug therapy. This is best done \nunder specialist\u2019s supervision.\nRevascularisation has been shown in case series and non-randomised trials to alleviate \nrenovascular hypertension as well as to salvage renal function.154,155 It should be \nconsidered under the following circumstances.156\n \n\u2022 flash pulmonary oedema\n \n\u2022 rapidly deteriorating renal function especially if leading to dialysis\n \n\u2022 resistant hypertension\n \n\u2022 transplant renal artery stenosis\n \n\u2022 fibromuscular dysplasia (FMD) associated with hypertension\n \n\u2022 Takayasu\u2019s arteritis\nOstial ARAS is best treated with angioplasty with stenting due to problem of recoil",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_144",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Ostial ARAS is best treated with angioplasty with stenting due to problem of recoil \npost angioplasty. In patients with deteriorating renal function or global obstructive \natherosclerotic renovascular disease, renal artery stenting improves or stabilizes renal \nfunction and preserves kidney size.157 Patients with complex renovascular disease such \nas renal artery aneurysm or failed endovascular procedures may benefit from renal artery \nsurgery.\nDoctors have to distinguish patients with a high likelihood of treatment benefit \nfrom those with incidental ARAS. The presence of refractory hypertension, recent \ndeterioration of renal function and evidence of progression of the stenotic lesion will \nhelp to determine the plan of management for these patients. For those in whom",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_145",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "help to determine the plan of management for these patients. For those in whom \nindications are uncertain, prospective randomised trials including the Stent Placement \nin Patients with Atherosclerotic Renal Artery Stenosis and impaired Renal Function study \n(STAR)158 and Angioplasty and Stent for Renal Artery Lesions study (ASTRAL)159 have \nnot demonstrated compelling benefits either with endovascular stents or surgery when \nadded to effective medical therapy. These trials are subject to several limitations including \nbeing underpowered in the former, and inconsistency in defining \u2018critical\u201d vascular \nocclusion and the degree of stenosis in the latter. More recently, the Cardiovascular \nOutcomes in Renal Atherosclerotic Lesions (CORAL) study160 shows renal artery stenting",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_146",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Outcomes in Renal Atherosclerotic Lesions (CORAL) study160 shows renal artery stenting \nonly achieved a modest difference in SBP favouring intervention, with no  benefits in renal \nor cardiovascualr outcomes when added to comprehensive multifactorial medical \ntherapy in people with atherosclerotic renal artery stenosis and hypertension or CKD.\nDuplex Doppler examination is ideal for screening and follow-up monitoring of patients \nwith renal transplant artery stenosis. These lesions should only be treated if there is a \nrecent worsening of renal function as there is a possibility of spontaneous reversal of \nstenosis.161 Percutaneous Renal Angioplasty (PTRA) is the treatment of choice where \nindicated. Further studies comparing intervention and conservative treatment are \nneeded. \n30",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_147",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "indicated. Further studies comparing intervention and conservative treatment are \nneeded. \n30\nPatients with fibromuscular dysplasia rarely have excretory dysfunction, and \nhypertension in these patients generally responds to ACEIs.162 Given the typical patient \nwith FMD (young female with lower angioplasty-related risks, the need for many years of \nanti-hypertensive treatment plus limitations of RAAS blockers during pregnancy), most \nclinicians would probably favour angioplasty for patients with FMD.163 It is important to \nrecognise that benefits of angioplasty may be limited. The chance of achieving normal \nBP without anti-hypertensive agents is less than 30%, although some improvement in BP \nmay be expected in an additional 50% or more.163\n8.5\t\nHYPERTENSION AND HEART DISEASE \n8.5.1",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_148",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "may be expected in an additional 50% or more.163\n8.5\t\nHYPERTENSION AND HEART DISEASE \n8.5.1\t\nHypertension and Coronary Heart Disease\nHypertension is a known risk factor for atherosclerosis. As prevention for atherosclerotic \ndisease, blood pressure control is important especially in the presence of other risk \nfactors. In patients with symptomatic angina, the treatment of choice should be a \n\u00df-blocker or CCB. Clinical studies have also shown that coronary events in hypertensive \npatients with coronary heart disease are reduced in those whose blood pressure are \ncontrolled.164,165 Based on the many studies using different groups of antihypertensives, \nit appears that the benefits are achieved predominantly by lowering the blood pressure",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_149",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "it appears that the benefits are achieved predominantly by lowering the blood pressure \nrather than the use of any specific class of antihypertensive agent. 73,166\nFollowing any coronary event, patients will be at high risk of subsequent events, \nespecially if the hypertension is not controlled. There are clinical trials showing morbidity \nand mortality benefits of anti-hypertensive agents like \u00df-blockers,167 ACEIs168 and ARBs,169 \nfollowing myocardial infarction.\n8.5.2\t\nHypertension and Heart Failure\nChronic, uncontrolled hypertension can cause heart failure, even in the presence of \nnormal systolic function. Anti-hypertensive agents including \u00df-blockers,170-172 ACEIs,172 \nand aldosterone antagonist,173 have shown mortality benefits and reduction in the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_150",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and aldosterone antagonist,173 have shown mortality benefits and reduction in the \nnumber of hospitalizations, in patients with systolic heart failure. The evidence for ARB \nis less convincing174 except for ACEI intolerant patients.175 However for patients having \nheart failure with preserved systolic function, results with ARB has been mixed176,177 while \nmeta analysis with ACEI has shown a modest effect on diastolic dysfunction.178 Should \nhypertension be persistent in spite of ACEI, ARB and/or \u00df-blocker, CCBs which are not \nnegatively inotropic, such as amlodipine, can be added. These patients should also be on \nloop diuretics for symptomatic relief.\n\t\nRecommendations\n \n\u2022 \u00df-blockers, ACEIs or ARBs should be used post myocardial infarction to reduce",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_151",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 \u00df-blockers, ACEIs or ARBs should be used post myocardial infarction to reduce  \n\t\n\t\nrecurrent myocardial infarction and death. (Grade A)\n \n\u2022 \u00df-blockers, ACEIs and Aldosterone antagonists should be given to patients with  \n\t\n\t\nsystolic heart failure to reduce morbidity and mortality. (Grade A)\n \n\u2022 Angiotensin receptor blockers or ACEIs should be used on heart failure patients  \n\t\n\t\nwith preserved ejection fraction. (Grade B)\n \n\u2022 Blood pressure in post myocardial infarction and heart failure patients should \n\t\n\t\nbe lowered to <130 / <80 mmHg. (Grade C)\n31\n8.5.3\t \t\nHypertension and Atrial Fibrillation\nHypertension is one of the risk factors for atrial fibrillation.179 Atrial fibrillation increases the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_152",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "risk of thromboembolic stroke, and the role of anticoagulants to reduce this risk, is well \nestablished. Uncontrolled hypertension increases the risk of haemorrhagic stroke and \nhence it is imperative that patients with hypertension and atrial fibrillation should have \ntheir blood pressure well controlled, more so if they are on anticoagulant. The blood \npressure target is <130 / <80 mmHg.180\nA few small studies181,182 and sub-analysis of larger trials183,184 have reported that ARB \ncan reduce the incidence of recurrent atrial fibrillation or help maintain patient in sinus \nrhythm. Both ARB and ACEI have been shown to reduce the incidence of atrial fibrillation\nin patients with paroxysmal atrial fibrillation and to prevent new onset atrial fibrillation.185",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_153",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in patients with paroxysmal atrial fibrillation and to prevent new onset atrial fibrillation.185 \nWhile both ACEI and ARB can prevent onset of atrial fibrillation, there is no significant \nreduction in new onset atrial fibrialltion in the subset of patients with underlying \nhypertension.186 However for hypertensive patients with paroxysmal atrial fibrillation, \nACEI and ARB are the preferred choice. For elderly patients (>75 years old) who are on \nanticoagaulation for atrial fibrillation, both ACEI and ARB reduce mortality.187 (Level II-2)\nFor rate-control of permanent atrial fibrillation, \u00df-blockers and non-dihydropiridine \nCCBs (verapamil and diltiazem) should be considered.188\n8.5.4\t\nHypertension and Peripheral Arterial Disease",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_154",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "8.5.4\t\nHypertension and Peripheral Arterial Disease\nThe risk factors for peripheral arterial disease (PAD) include hypertension, diabetes, \ncurrent smoking and hypercholestrolaemia.189 As atherosclerosis is a \u2018global\u2019 vascular \ndisease, diffuse atherosclerosis, CAD, and renovascular disease often coexist in these \npatients. PAD is associated with an increased risk of death from CVD. It is appropriate \nthat these patients are also screened for the presence of atherosclerotic disease of \nthe other systems. Control of hypertension in patients with peripheral arterial disease \nis poor.190 The aim of treatment in peripheral arterial disease is both symptom relief and \nprevention of cardiovascular event. There is no consensus on the treatment of choice",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_155",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "prevention of cardiovascular event. There is no consensus on the treatment of choice \nfor hypertensive patients with peripheral artery disease,191 although sub-analysis of major \ntrials showed benefits of ACEI in patients with both symptomatic and asymptomatic \nperipheral arterial disease.36 Although \u00df-blockers may cause vasoconstriction and \nmay worsen the frequency of intermittent claudication, they may be used with caution \nin patients with compelling indications (CHD and/or HF). Should patients present with \nRaynaud\u2019s phenomenon, consider a vasodilator such as CCBs. Cilostazol has been \nshown to be useful especially in the elderly with disabling peripheral arterial diease.192 \nIn addition to these medications, patients should stop smoking. Other therapy including",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_156",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "In addition to these medications, patients should stop smoking. Other therapy including \nLDL-cholesterol lowering and better control of diabetes is also recommended. \n\t\nRecommendations\n \n\u2022 Treat blood pressure in hypertensives with peripheral arterial disease to\n\t\n\t\n<130 / <80 mmHg (Grade C)\n \n\u2022 Any antihypertensive can be used as first choice (Grade C)\n \n\u2022 Give ACEI to patients with PAD to prevent vascular events (Grade B)\n \n\u2022 Consider cilostazol in the elderly patients with symptomatic CAD (Grade B)\n \n\u2022 Other aspects of management must include smoking cessation, optimal  \n \n\t\n\t\ntreatment of concurrent diabetes, dyslipidaemia and antiplatelet agent\n32\n8.5.5\t\nHypertension and Left Ventricular Hypertrophy (LVH)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_157",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "32\n8.5.5\t\nHypertension and Left Ventricular Hypertrophy (LVH)\nLeft Ventricular Hypertrophy is characterized by increased left ventricular mass index\nand may be associated with increased wall thickness. In LVH due to hypertension, the \nhypertrophy is usually concentric, and is sometimes associated with echocardiographic \n\u2018impaired relaxation\u2019. This is often described as \u201cdiastolic dysfunction\u201d, and may \ncause heart failure with preserved systolic function. While LVH can be detected on \nelectrocardiography (ECG), echocardiography is much more sensitive for detection of \nLVH. Those with LVH are at risk of premature cardiovascular events or death. Several \nstudies have suggested that LVH regression is associated with a lower overall CVD risk.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_158",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "studies have suggested that LVH regression is associated with a lower overall CVD risk. \nRegression of LVH can be achieved by weight reduction, salt restriction and BP lowering. \nFor LVH regression, it is the blood pressure reduction rather than the class of anti-\nhypertensive that is important.193 However, in the LIFE study, ECG LVH and cardiovascular \noutcome (especially stroke) was reduced significantly more by a losartan-based than \natenolol-based regimen despite equivalent BP lowering.87 This is supported by a recent \nmeta analysis which showed that ARB has the best effect on LVH regression with \n\u00df-blockers the least.194\n8.6\t\nHYPERTENSION AND STROKE\nHigh blood pressure is the most important modifiable risk factor for stroke,195 both",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_159",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "High blood pressure is the most important modifiable risk factor for stroke,195 both \nIschaemic Stroke (IS) and Intracerebral Haemorrhage (ICH). Blood Pressure levels are \ncontinuously associated with the risk for stroke.25,196 Although both SBP and DBP are \nassociated with stroke, SBP is more predictive.197  In the Asia Pacific region, up to 66% of \nCV events can be attributed to hypertension. Moreover, the burden of stroke is higher \namong Asian compared to Caucasian population in the region.198\nWorldwide, 15 million people suffer from stroke annually. Of these, 5 million die and \nanother 5 million are left permanently disabled.199 It is presently among the top four \nleading causes of death in ASEAN countries.200 In Malaysia, stroke is the fifth leading",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_160",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "leading causes of death in ASEAN countries.200 In Malaysia, stroke is the fifth leading \ncause of death in government hospitals in 2009, accounting for 8.43 % of all deaths.201\n8.6.1\t\nPrimary Prevention of Stroke\nSystemic reviews of 17 primary prevention trials involving a total of 47,000 participants \nshowed that lowering SBP by 10\u201312 mmHg and DBP by 5\u20136 mmHg leads to a 38% \nreduction in the risk of stroke. 202\nThe benefits have been shown in both systolic-diastolic hypertension and in isolated \nsystolic hypertension.90,196,203-205 Beta-blockers, diuretics, CCBs, ACEIs and ARBs have \nbeen shown to reduce risk and mortality from stroke.90,176,203-206 Calcium channel blockers \nin particular, provided significantly better protection against stroke compared with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_161",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in particular, provided significantly better protection against stroke compared with \ndiuretics and/or \u00df-blockers in Asian 207 and Caucasian 204 populations.\n8.6.2\t\nTreatment of Hypertension in Acute Stroke\nTreatment of elevated BP in acute stroke is still controversial.208 Stress-related high BP \nvalues (>140/90 mmHg) are present in up to 80% of patients with acute stroke209,210 \nwhile almost 25% of patient presents with markedly raised SBP values >180 mmHg. In a \nmajority of patients, a decline in blood pressure without any specific medical treatment will \noccur within days or weeks.211,212 A slightly higher systemic BP is required to maintain the \ncerebral perfusion in the situation of increased intracranial pressure, partial thrombosis \nand disturbed cerebral perfusion.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_162",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and disturbed cerebral perfusion.\nCurrent guidelines recommend that treatment of hypertension in acute IS should be \ndelayed for several days or up to 2 weeks after an IS unless there is hypertensive \nencephalopathy, severe left ventricular failure, acute renal failure, acute myocardial \ninfarction, aortic dissection, acute pulmonary oedema or repeated BP readings reveal \nSBP values >220 mmHg and DBP >120 mmHg.213-214 (Table 15)\n33\nCurrent recommendations for treatment of elevated BP levels in patients with acute \nICH are more aggressive than those with IS (Table 15). For ICH, BP levels should be \nmaintained <180/105 mmHg.215 However, if unable to differentiate between IS or ICH, it\nis recommended NOT to lower BP <180/105 mmHg.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_163",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "is recommended NOT to lower BP <180/105 mmHg.\nIn cases where acute BP reduction is indicated, BP lowering should be done cautiously \ntargeting BP reduction of no more than 10 to 20% from baseline BP over 24 hours.  More \nprofound BP reductions (>20%) have been associated with neurological and functional \nworsening.216\nParenteral agents such as labetalol or nicardipine that are easily titrated and \nhave minimal vasodilatory effects on cerebral blood flow are preferred. In cases \nwith excessive DBP levels (>140 mmHg), intravenous administration of sodium \nnitroprusside is recommended for adequate BP control. The use of sublingual nifedipine \nshould be avoided because of the risk of abrupt BP reduction and possible worsening \nischaemia.213,217",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_164",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ischaemia.213,217\nTable 15.\tCurrent Guideline for the Management of Blood Pressure in Acute \t\n\t\nPhase of Ischaemic Stroke and Intracerebral Haemorrhage\nAcute phase of ischaemic stroke 213,214,217\nBP level, mmHg\t\nTreatment\nSBP \u2264220 or DBP \u2264120\t\ndefer anti-hypertensive therapy\nSBP >220 or  DBP 121\u2013140\t\ni.\t\nlabetalol 10\u201320 mg IV over 1\u20132 min, may repeat\n       \t\n\t\nor double every 10 min (maximum 300 mg)\n\t\nii.\t\nnicardipine 5 mg/h IV infusion as initial dose,\n       \t\n\t\ntitrate to desired effect by increasing 2.5 mg/h\n      \t\n\t\nevery 5 min (maximum 15 mg/h)\n\t\niii.\t captopril 6.25\u201312.5 mg p.o. or i.m.\n\t\niv.\t dihydralazine 5 mg IV plus metoprolol 10 mg IV\n\t\nTarget: Not more than 10\u201320% reduction from \t\n\t\n\t\nbaseline BP over 24 hours\nDBP >140\t\ni.\t\nnitroprusside 0.5 \u03bcg/kg/min as initial dose with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_165",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "baseline BP over 24 hours\nDBP >140\t\ni.\t\nnitroprusside 0.5 \u03bcg/kg/min as initial dose with\n     \t\n\t\ncontinuous BP monitoring\n\t\nii.\t\nnitroglycerin 5 mg IV, followed by 1\u20134 mg/h IV\n\t\nTarget: Not more than 10\u201320% reduction from \t\n\t\n\t\nbaseline BP over 24 hours\nAcute phase of intracerebral haemorrhage 217\nSBP <180 and  DBP <105\t\ndefer antihypertensive therapy\nSBP 180 \u2013 230 or\t\ni.\t\nlabetalol 5\u2013100 mg IV by intermittent bolus\nDBP 105 \u2013 140\t\n\t\ndoses of 10\u201340 mg or continuous infusion drip \n(2 readings 20 mins apart)     \t\n\t\n(2\u20138 mg/min)\n\t\nii.\t\nesmolol 500 \u03bcg/kg IV loading dose;\n       \t\n\t\nmaintenance use 50\u2013200 \u03bcg/kg/min\n\t\niii.\t enalapril 0.625\u20131.2 mg IV\n\t\niv.\t other easily titratable IV medications\n      \t\n\t\n(diltiazem, verapamil, nicardipine) \n\t\nTarget: Not more than 10\u201320% reduction from",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_166",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "(diltiazem, verapamil, nicardipine) \n\t\nTarget: Not more than 10\u201320% reduction from \t\n\t\n\t\nbaseline BP over 24 hours\n34\nSBP >230 or DBP >140 \t\n(i)\t nitroprusside 0.5\u20131.0 \u03bcg/kg/min IV\n(2 readings 5 mins apart)\n\t\nTarget: Not more than 10\u201320% reduction from \t\n\t\n\t\nbaseline BP over 24 hours\nTwo recent studies in acute blood pressure lowering in patients with acute \nhaemorrhagic stroke shed useful information on this controversial issue. A relatively \nsmall Japanese study showed that clinical outcome is worst if the achieved systolic \nblood pressure is higher.218 A much bigger international study showed that a target \nSBP of <140 mmHg improves functional outcome and is safe. There was however no \ndifference in the primary outcome of death or severe disabilities compared to achieved",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_167",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "difference in the primary outcome of death or severe disabilities compared to achieved \nSBP <180 mmHg.219\n8.6.3\t\nSecondary Prevention of Stroke\nPatients who have had a stroke or a Transient Ischaemic Attack (TIA) are at increased \nrisk of future stroke, especially in the following few months.220 Annual recurrence rate is \n12.5% per year.221 Survival rates decreased from 63.7%, 42.8% and 24% at 1, 5 and 10 \nyears respectively. Of those who survived at 10 years, almost a third had poor range of \nclinical outcomes.222\nLowering BP has been shown to reduce the risk of subsequent strokes.35,223 Meta \nanalyses of randomized controlled trials confirm approximately 30\u201340% reduction in \nstroke risk with blood pressure lowering.224",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_168",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "stroke risk with blood pressure lowering.224\nCombination of ACEI and thiazide-like diuretic has been shown to reduce stroke \nrecurrence in both normotensive and hypertensive patients when treatment was \nstarted at least two weeks after the stroke.35\nThree additional large-scale randomized trials of anti-hypertensive medications after \nstroke have been published. In one such trial, patient with hypertension and a stroke \nor TIA within 2 years of the event were randomized to an ARB or CCB. Despite similar \nBP reductions, recurrent total strokes and TIAs were less frequent among those \nrandomized to ARB. There was a reduction in primary composite events which were \nsignificantly lower with ARB, with reduction in TIAs accounting for most of the benefit",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_169",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "significantly lower with ARB, with reduction in TIAs accounting for most of the benefit \nof ARB.225 However in a bigger trial, patients with Ischaemic stroke were randomized to \nARB or placebo within 90 days of an event with no clear benefits of ARB in preventing \nrecurrent stroke after 2.5 years of follow-up.226 In another placebo control trial involving \nARB, patients with IS were randomised within 30 hours following onset of symptoms.227 \nAt 6 months follow-up, there were no significant difference in the composite primary \nendpoint (stroke, myocardial infarction, or vascular death). Taken together, a specific\nrole for ARB in secondary stroke prevention can not been confirmed.228\nThe target BP after a stroke is less clear. More recent guidelines suggested a target",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_170",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The target BP after a stroke is less clear. More recent guidelines suggested a target \nof <140/90 mmHg 22 but the most recent major outcome trial suggest that for patients \nwith recent lacunar stroke, a target of <130/80 mmHg is beneficial229 especially for \nprevention of intracranial haemorrhage.\n35\n\t\nRecommendations\n \n\u2022 Lower blood pressure to prevent both primary and secondary stroke \n\t\n\t\n(Grade A)\n \n\u2022 In acute ischaemic stroke, do not lower SBP <180 mmHg in the first 2 weeks  \n \nunless hypertensive emergencies co-exist (Grade C)\n \n\u2022 In acute haemorrhagic stroke lower SBP to <140 mmHg. This approach is both   \nbeneficial and safe (Grade A) \n \n\u2022 Avoid lowering BP abruptly with sublingual nifedipine in acute stroke (Grade C)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_171",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 Avoid lowering BP abruptly with sublingual nifedipine in acute stroke (Grade C)\n \n\u2022 Blood Pressure can be safely lowered in both normotensive and hypertensive \npatients for secondary prevention (Grade A) \n \n\u2022 Lower BP to <130/80 mmHg for secondary prevention in lacunar stroke\n\t\n\t\n(Grade A)\n \n\u2022 The benefit seen in secondary stroke prevention is most likely due to BP  \n \n\tlowering per se rather than specific drug effect (Grade B)\n8.7\t\nHYPERTENSION IN THE ELDERLY\nThe definition of hypertension in the elderly (>65 years old) is the same as in the general \nadult population. Hypertension in the elderly is an increasingly important public health \nconcern as our population ages. Hypertension magnifies the risk for cardiovascular \ndisease and dementia especially in the elderly.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_172",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "disease and dementia especially in the elderly.\nSystolic BP, unlike DBP, increases linearly with age leading to an increase in prevalence \nof ISH in the elderly. It is a better predictor of cardiovascular events than DBP.230 The \nprevalence of hypertension in the elderly in Malaysia has been reported to be 62.4% of \nwhich 55% is ISH.1\nSeveral randomized controlled trials have shown that treatment of hypertension in \nthe elderly up to the age of 84 years reduces cardiovascular morbidity and mortality, \nparticularly stroke.5,64,87,90,204,207,231-235 (Level I) A more recent RCT has shown that active \ntreatment significantly reduces the risks of death from stroke and death from any cause \nin very elderly (>80 years old) patients. There was also a significant reduction in stroke.93",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_173",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in very elderly (>80 years old) patients. There was also a significant reduction in stroke.93 \n(Level I) A systematic review also showed that BP reduction in the elderly prevented vascular \ndementia.236 (Level I)\n8.7.1\t\nDetection and Evaluation\nRecommendations for BP measurements in the elderly patients are similar to those for \nthe general population. Postural hypotension i.e., a drop in systolic BP of >20 mmHg \nupon 1-2 mins standing, is a common problem in the elderly. Blood pressure should \ntherefore be measured in both the seated/lying and standing positions. If there is a \nsignificant postural drop, the standing BP is used to guide treatment decisions.\nEvaluation of elderly patients with hypertension should not differ from that of younger",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_174",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Evaluation of elderly patients with hypertension should not differ from that of younger \nadult populations. Particular attention should be paid to detect atheromatous renal artery \ndisease as the cause of secondary hypertension.  \n8.7.2\t\nTreatment\nThe goals of treatment in older patients should be the same as in younger patients.\nIn healthier patients over 80 years a target SBP of around 150 mmHg is acceptable.93 \nAny further reductions need to be established in future research. In those patients with \nmarked systolic hypertension and not tolerating treatment well, reducing SBP to below \n160 mmHg initially is acceptable.(Level III)\n36\nNon-Pharmacological Management\nAttempts at lifestyle modifications while beneficial may not be practical in the elderly.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_175",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Attempts at lifestyle modifications while beneficial may not be practical in the elderly. \nHowever weight loss and modest salt reduction may be especially effective in the \nelderly because they are more likely to have salt sensitive hypertension.237 (Level I)\nPharmacological Management\nThe five major classes of drugs (diuretics, \u00df-blockers, CCBs, ACEIs and ARBs) have been \nshown to reduce cardiovascular events in the elderly.5,65,68,87,207,234 (Level I) In older patients \nwith ISH, diuretics are preferred because they have been shown to significantly reduce \nmultiple endpoints5 including dementia.236 Several trials using dihydropyridine CCBs have \nshown benefits particularly in stroke reduction.90,207,210,232 Angiotensin converting enzyme",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_176",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "shown benefits particularly in stroke reduction.90,207,210,232 Angiotensin converting enzyme \ninhibitors are the drugs of choice for those with concomitant left ventricular systolic \ndysfunction, post myocardial infarction or diabetes mellitus.235 (Level I) Angiotensin receptor \nblockers have also been shown to reduce fatal and non-fatal strokes in hypertensive \npatients aged 65 years or older.87\nWhen initiating pharmacological treatment, the principle is to go \u2018slow and start low\u2019 \n(about half the dose that of younger patients) to minimise side effects. Drug dosage \nshould be gradually titrated to reach BP target. Drugs which can cause or exaggerate \npostural hypotension, (alpha-blockers and high dose diuretics) or drugs that cause",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_177",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "postural hypotension, (alpha-blockers and high dose diuretics) or drugs that cause \ncognitive dysfunction (central alpha-2-agonists) should be used with caution. The \nreduction in BP should be gradual to minimise the risk of symptomatic ischaemia \nespecially in patients with postural hypotension.\n \n\u2022 Definition of hypertension in the elderly is similar to that of younger patients\n \n\u2022 Prevalence of ISH increases with age\n \n\u2022 BP measurement in the elderly should include assessment for postural  \n \n\t\n\t\nhypotension\n\t\nRecommendations\n \n\u2022 Do not neglect therapeutic lifestyle modification though difficult to achieve\n\t\n\t\n(Grade A)\n \n\u2022 When choosing pharmacological agent, take into account any co morbid\n\t\n\t\nstate and contraindication especially postural hypotension (Grade C)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_178",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "state and contraindication especially postural hypotension (Grade C)\n \n\u2022 Treat  BP <140/90 mmHg for patients <80 years old and < 150/90 mmHg for  \n \n\t\n\t\npatients >80 years old (Grade A)\n8.8\t\nHYPERTENSION IN WOMEN\n8.8.1\t\nHypertension in Pregnancy\nHypertension in pregnancy is also defined as a systolic blood pressure (BP) \u2265140 mmHg \nand/or a diastolic BP \u2265 90 mmHg.238\nAn increase of 15 mmHg and 30 mmHg diastolic and systolic BP levels above baseline \nBP respectively is no longer recognised as hypertension if absolute values are below \n140/90 mmHg. Nevertheless, this warrants close observation, especially if proteinuria \nand hyperuricaemia are also present.239\nKorotkoff V should now be used as the cut-off point for diastolic BP, and Korotkoff IV",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_179",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Korotkoff V should now be used as the cut-off point for diastolic BP, and Korotkoff IV \nutilized only when Korotkoff V is absent.238(Level III) Measurement of BP is similar to that of \nthe general population, as stated earlier.  \n37\n8.8.1.1\t\nProteinuria\nSignificant proteinuria in pregnancy is defined as \u2265300 mg protein in a 24 hour urine \nsample, or a spot urine protein-creatinine ratio \u226530 mg/mmol.238 If the dipstick is the \nonly test available, 1+ (30 mg/dl) is often, but not always, associated with \u2265300 mg/day \nproteinuria.238 Significant proteinuria reflects advanced disease and is associated with \npoorer prognosis.\n8.8.1.2\t\nClassification\nThere are various classifications for Hypertension in Pregnancy. The most recent is  by the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_180",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "There are various classifications for Hypertension in Pregnancy. The most recent is  by the \nAustralasian Society for the Study of Hypertension in Pregnancy (ASSHP) and endorsed \nby the International Society for the Study of Hypertension in Pregnancy (ISSHP).238,239\n1.\t\nPreeclampsia-eclampsia: clinically diagnosed in the presence of de novo \t\n\t\n\t\nhypertension after gestational week 20, and one or more of the following:\n\t\ni.\t\nSignificant proteinuria.\n\t\nii.\t\nRenal insufficiency: serum creatinine \u2265 90 micromol/l or oliguria.\n\t\niii.\t\nLiver disease: raised transaminases and / or severe right upper quadrant or \nepigastric pain.\n \niv. Neurological problems: convulsions (eclampsia), hyperreflexia with clonus or \nsevere headaches, persistent visual disturbances (scotoma).\n\t\nv.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_181",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "severe headaches, persistent visual disturbances (scotoma).\n\t\nv.\t\nHaematological disturbances: thrombocytopenia, coagulopathy, haemolysis.\n\t\nvi.\t Fetal growth restriction.\n\t\nThis is followed by normalization of the BP by three months postpartum.\n\t\nOedema is no longer part of the definition of preeclampsia.240 Excessive weight gain \t\n\t\nor failure to gain weight in pregnancy may herald the onset of preeclampsia.241\n2.\t Gestational hypertension is defined as hypertension detected for the first time after \t\n\t\n20 weeks pregnancy. The definition is changed to \u201ctransient\u201d when pressure \t\n\t\n\t\nnormalizes postpartum.\n3.\t Chronic hypertension is hypertension diagnosed prior to gestational week 20 or \t\n\t\n\t\npresence of hypertension preconception, or de novo hypertension in late gestation",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_182",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "presence of hypertension preconception, or de novo hypertension in late gestation \t\n\t\nthat fails to resolve postpartum.  \n4.\t Preeclampsia superimposed on chronic hypertension is diagnosed in the presence \t\n\t\nof any of the following, in a woman with chronic hypertension:\n\t\ni.\t\nDe novo proteinuria after 20 week gestation\t\n\t\nii.\t\nA sudden increase in the severity of hypertension\n\t\niii.\t Appearance of features of preeclampsia-eclampsia, and\n\t\niv.\t A sudden increase in proteinuria in women who have pre-existing proteinuria \nearly in gestation\n38\n8.8.1.3\t\nKey Points in Primary Care Practice\nAlthough women with hypertensive disorders of pregnancy should be managed by \nan obstetrician, the primary care physician plays an important role in the prevention",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_183",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "an obstetrician, the primary care physician plays an important role in the prevention \nof preeclampsia and its complications, both during the preconceptional and antenatal \nperiods:\n1.\t\nPreconception counseling and adjustment of treatment in women with \t\n\t\n\t\nchronic hypertension.\n\t\nWomen with chronic hypertension may require a change in the type of anti- \nhypertensive agent used pre-pregnancy.242 (Level III) The drugs of choice in pregnancy \nare still methyldopa and labetalol (Table 16). Atenolol has been shown to lead \nto fetal growth restriction. The use of ARBs, ACEIs and thiazide diuretics are \nassociated with fetal anomaly243 and are therefore contraindicated in pregnancy. \n\t\nIt should be noted that the treatment of hypertension in pregnancy is solely for",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_184",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "It should be noted that the treatment of hypertension in pregnancy is solely for \nmaternal safety. It does not reduce the risk of development of preeclampsia or \nperinatal mortality, nor improve fetal growth.243 Pregnant women with uncomplicated \nchronic hypertension should have their BP kept lower than 150/100 mmHg. In the \npresence of target organ damage secondary to chronic hypertension, the aim is\n\t\nto maintain the BP below 140/90 mmHg.243\n2.\t Recognition of women at risk of preeclampsia for commencement of \t\n\t\n\t\nprophylaxis.\n\t\nHigh risk factors for development of preeclampsia are:\n\t\ni.\t\nhypertensive disease during a previous pregnancy\n\t\nii.\t\nchronic kidney disease\n\t\niii.\t\nautoimmune disease such as Systemic Lupus Erythematosus (SLE) or             \nanti-phospholipid syndrome (APS)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_185",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "anti-phospholipid syndrome (APS)\n\t\niv.\t\ntype 1 or type 2 diabetes mellitus, and\n\t\nv.\t\nchronic hypertension.\n\t\nHigh risk patients should be prescribed aspirin (75mg\u2013100mg daily) from 12 weeks \ngestation until delivery.243,244 The same treatment should also be prescribed if they \nhave two or more of the following moderate risk factors:\n \n \n\u2022 \nprimigravida\n \n \n\u2022 \nage >40 years\n \n \n\u2022 \npregnancy interval >10 years\n \n \n\u2022 \nbody mass index of >35 kg/m2 at first visit\n \n \n\u2022 \nfamily history of preeclampsia\n \n \n\u2022 \nmultiple pregnancy.\n\t\nFor optimal effectiveness in moderate risk patients, aspirin prophylaxis must be \ncommenced before 16 weeks gestation.244,245 Ideally, women at moderate or high \nrisk should be referred in the first trimester for more detailed risk assessment in a",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_186",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "risk should be referred in the first trimester for more detailed risk assessment in a \nfetomaternal specialist unit.246\n39\n3.\t Nutritional supplementation for prevention of preeclampsia and / or its \t\n\t\n\t\ncomplications.\n\t\nIn pregnant women with low dietary calcium intake (less than 600 mg day), high \ncalcium supplementation of 1.5g/day significantly reduces the risk of eclampsia, \nsevere gestational hypertension, and severe preeclamptic complication index.247 \nA recent meta analysis of RCTs in developing countries showed that calcium \nsupplementation produces significant reduction in the risk of gestational \nhypertension and preeclampsia.248 Other supplements in pregnancy such as marine \noil, garlic and pyridoxine have no proven benefits.249-251",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_187",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "oil, garlic and pyridoxine have no proven benefits.249-251\n\t\nCombined vitamins C and E (i.e. tocopherol from soybean) should be avoided \nbecause they significantly increase the incidence of low birth weight without any \npreventive effect against preeclampsia.252\n4.\t Prevention of eclampsia and other complications of preeclampsia\n\t\nPatient and health professional education on the importance of signs and \nsymptoms of preeclampsia for early diagnosis and referral for further management \nmay prevent progression to eclampsia.253,254(Level II-2)\n8.8.1.4\t\nSevere Preeclampsia\nSevere preeclampsia must be promptly identified so that the patient can be urgently \nadmitted to hospital for close observation and timely delivery. The Royal College of",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_188",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "admitted to hospital for close observation and timely delivery. The Royal College of \nObstetrician and Gynecology (RCOG) defines severe preeclampsia as follows:255\n1.\t\nSystolic BP \u2265170 mmHg or diastolic BP \u2265110 mmHg (acute hypertensive crisis in \npregnancy) on two occasions, with proteinuria of \u22651 g/day.\n2.\t Diastolic BP \u2265100 mmHg on two occasions, with significant proteinuria (1+ on \ndipstick), with two or more signs or symptoms of imminent eclampsia, which include:\n\t\na.\t\nsevere headache\n\t\nb.\t\nvisual disturbance\n\t\nc.\t\nepigastric pain and / or vomiting\n\t\nd.\t\nclonus\n\t\ne.\t\npapilloedema\n\t\nf.\t\nliver tenderness\n\t\ng.\t\nplatelet count below 100,000/cm3\n\t\nh.\t\nabnormal liver enzymes (elevated ALT or AST)\n\t\ni.\t\nHELLP syndrome (haemolysis, elevated liver enzymes, low platelets)\n\t\nj.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_189",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "i.\t\nHELLP syndrome (haemolysis, elevated liver enzymes, low platelets)\n\t\nj.\t\nintrauterine growth restriction (IUGR)\n\t\nk.\t\npulmonary oedema and / or congestive cardiac failure\nDiagnosis of severe preeclampsia should not rely precisely on the above criteria. If in \ndoubt, it is better to over rather than under diagnose. This will prevent delay in referral.\nAnti-hypertensive treatment should be initiated if diastolic BP is persistently \u2265100 mmHg. \nThe target BP to achieve is DBP between 80-100 mmHg.243\nIn the event of an acute hypertensive crisis, IV hydralazine, IV labetalol, or oral nifedipine, \nmay be used to lower the BP.256,257 (Level I) Sublingual nifedipine is no longer recommended\n258 (Level III)(Table 17).",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_190",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "258 (Level III)(Table 17).\nDiuretics are generally contraindicated as they reduce plasma volume, may cause IUGR \nand may possibly increase perinatal mortality. Their only use is in the treatment of acute \npulmonary oedema.241 (Level III)\n40\n8.8.1.5\t\nAnticonvulsants in Preeclampsia-Eclampsia\nParenteral magnesium sulphate is currently the drug of choice for the prevention \nof eclampsia and to abort an eclamptic fit 258,259 (Level I) (Table 18). The alternative is\nintravenous diazepam, bearing in mind that it is inferior in efficacy compared to \nmagnesium sulphate. Magnesium sulphate also provides fetal neuroprotection following \npreterm birth with a significant reduction in the incidence of cerebral palsy.260\n8.8.1.6\t\nPostpartum Care",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_191",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "8.8.1.6\t\nPostpartum Care\nPostpartum, women with hypertensive disorders in pregnancy are advised to have \ntheir BP checked regularly at local clinics if there is a significant delay in their scheduled \nhospital follow-up. In these patients, the dose of anti-hypertensive should be tailed down \ngradually and not stopped suddenly. On average, anti-hypertensive agents are required \nfor longer in women with preeclampsia (approximately two weeks) compared with those \nwith gestational hypertension (approximately one week) although there is substantial \nvariability among women that cannot be predicted reliably.261\nDe novo onset of hypertension or aggravation of BP levels during the postpartum period, \ncan occur.262 These patients should be promptly referred to hospital especially if there is",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_192",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "can occur.262 These patients should be promptly referred to hospital especially if there is \nsignificant proteinuria.(Level III) Eclampsia may occur in the postpartum period.\nChronic hypertension is diagnosed when the hypertension and/or proteinuria persist \nafter three months postpartum.238,239\n8.8.1.7\t\nLong Term Follow-up\nEvidence suggests that up to 13% of women with preeclampsia will have underlying \nessential hypertension that was not suspected antenatally.255 In addition, the same \nfactors which predispose to preeclampsia also predispose to cardiovascular disease in \nlater life.245 Long-term follow-up of patients with a history of hypertension in pregnancy is \ntherefore advisable. (Level III)\n8.8.1.8\t\nReducing Mortality",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_193",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "therefore advisable. (Level III)\n8.8.1.8\t\nReducing Mortality\nA substantial reduction in preeclampsia/eclampsia related mortality can occur in low \nincome countries by widespread screening for hypertension and proteinuria, together \nwith early delivery of women with severe preeclampsia. Early referral is very important.263\nTable 16.\t Anti-hypertensive Drugs Commonly Used in Pregnancy\nDrug\t\nRemarks\nMethyldopa\t\nOral 250 mg tds, doubling every 48 hours (up to 1 gm tds) \nuntil BP well controlled. Oldest anti-hypertensive agent used in \npregnancy, with best safety profile.\nLabetalol\t\nOral 100 mg bd, doubling every 48 hours (up to 400mg bd) until \nBP well controlled.\nNifedipine\t\nOral 10 mg tds, up to 20 mg tds, usually as second line anti-\nhypertensive, when BP poorly controlled despite maximum",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_194",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hypertensive, when BP poorly controlled despite maximum \ndoses of methyldopa \u00b1 labetalol.\n41\nTable 17.\t Anti-Hypertensive Drugs for Severe Preeclampsia with Acute \t\n\t\n\t\nHypertensive Crisis264\nDrug\t\nRemarks\nHydralazine*\t\n5 mg IV bolus or IM, then 5\u201310 mg every 20\u201340 minutes up to 30 \nmg, or IV infusion of 0.5-10 mg per hour.\nLabetalol\t\n20 mg IV bolus, then 40 mg 10\u201315 minutes later, then 80 mg \nevery 10\u201315 minutes, up to 220 mg; or continuous IV infusion of \n1\u20132 mg/minute until BP stabilizes, then stop or reduce to 0.5 mg/\nminute. May cause fetal bradycardia.\nNifedipine\t\nOral 5\u201310 mg stat (repeat in 30 minutes if necessary), especially \nprior to transferring a patient from a peripheral clinic to hospital. \nAfter the initial emergency dose, 10\u201320 mg can be given every",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_195",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "After the initial emergency dose, 10\u201320 mg can be given every \n3\u20136 hours until BP stabilizes.\n* Hydralazine is no longer recommended as first line treatment for acute hypertensive crisis in pregnancy.255\nTable 18.\tAnti-convulsant for Eclampsia (and Severe Preeclampsia)\nDrug\t\nRemarks\nMagnesium \t\nIV: 4g slow bolus over 10 minutes, followed by 1-2 g/hour\nSulphate265,266\t\nmaintenance infusion given via a controlled infusion pump.\n\t\nIM: 4g IV slow bolus over 10 minutes, followed immediately by \n10g IM, then 5 g IM every 4 hours in alternate buttock.\n\t\nClinical monitoring is of utmost importance, looking for signs \nof toxicity (especially loss of deep tendon reflexes, respiratory \ndepression with rate <16/minute) and renal impairment (hourly \nurine output <30 ml/hour).\nDiazepam266",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_196",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "urine output <30 ml/hour).\nDiazepam266\t\n10 mg IV bolus, followed by 40 mg in 5% dextrose slow infusion \nso that patient remains sedated.\n  Recommendations\n \n\u2022 Diagnose and treat hypertension in pregnancy based on Korotkoff V \n\t\n\t\n(Grade C)\n \n\u2022 Appropriately counsel and manage women with chronic hypertension prior \nto pregnancy (Grade C)\n \n\u2022 Refer pregnant women with hypertension to the obstetrician for further \nmanagement (Grade C)\n \n\u2022 Commence aspirin in pregnant women with one or more high risk factor \nor two or more moderate risk factors for preeclampsia from 12 weeks \nonwards (Grade A)\n \n\u2022 Provide calcium supplementation from early pregnancy to prevent \npreeclampsia (Grade A)\n \n\u2022 Oral nifedipine 10 mg stat dose can be used to rapidly control BP in an",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_197",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "preeclampsia (Grade A)\n \n\u2022 Oral nifedipine 10 mg stat dose can be used to rapidly control BP in an \nacute hypertensive crisis prior to transfer to hospital (Grade C)\n42\n8.9\t\nHYPERTENSION AND ORAL CONTRACEPTIVES\nCombined oral contraceptives (COC) can induce significant increases in BP with chronic \nuse, which is nearly always reversible after 4 weeks of discontinuation.267 Hypertension \nhas been reported even with low-dose-oestrogen monophasic pills.268 A woman who \ndevelops hypertension while using COC should be advised to stop taking them and \nshould be offered alternative forms of contraception.269 (Level III) Low dose combined \nhormonal contraceptives should only be used if no other method is suitable, even for \nwomen with controlled hypertension.270",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_198",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "women with controlled hypertension.270\nDrospirenone (a progestin), has anti-mineralocorticoid diuretic effects, and can lower BP \nwhen combined with oestrogen in COCs.271  It is a recommended alternative for patients \nwith hypertension or who developed hypertension but wish to continue oral contraception. \nAll progestogen-only methods are appropriate except in women whose BP is higher than \n160/100 mmHg. In these patients, the injectable depot medroxyprogesterone acetate \n(DMPA) is contraindicated, along with all oestrogen-containing contraceptives.270\nBaseline BP must be assessed before initiating hormonal contraceptives. Blood \npressure should then be measured at least every six months.(Level III) The same applies to \nusage of the combined contraceptive patch and the vaginal ring.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_199",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "usage of the combined contraceptive patch and the vaginal ring. \n8.10\t\nHYPERTENSION AND HORMONE REPLACEMENT THERAPY\nThe presence of hypertension is not a contraindication to oestrogen-based hormonal \nreplacement therapy (HRT). It is recommended that all women treated with HRT should \nhave their BP monitored every six months.(Level III) The decision to continue or discontinue \nHRT in these patients should be individualised.\nTwo large trials on women aged 50-79 years, concluded that the use of HRT increased \ncardiovascular events.272,273 Conjugated equine estrogen (CEE), alone or in combination \nwith medroxyprogesterone acetate, was used in the study. In view of this, greater \ncaution and closer monitoring is required for hypertensive patients on CEE.(Level III)",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_200",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "caution and closer monitoring is required for hypertensive patients on CEE.(Level III) \nDrospirenone when used as progestin in HRT, showed improvement in BP control.267,274\nTable 19:\t COC and HRT Preparations Containing Drospirenone*\n\t\nHormonal\t\nTrade\t\n\t\nActive Ingredients\n\t Preparation\t\nName\t\nOestrogen\t\n\t\nProgestin\n\t\n\t\nYasmin\u00ae /\t\nEthinyl oestradiol\t\n\t\nDrospirenone\t\n\t\n\t\nCOC\t\nLiza\u00ae\t\n0.03 mg\t\n\t\n3 mg\n \t\n\t\nYaz\u00ae / Liz\u00ae /\t\nEthinyl oestradiol\t\n\t\nDrospirenone\n\t\n\t\nLizelle\u00ae\t\n0.02 mg\t\n\t\n3 mg\n\t\nHRT\t\nAngeli\u00ae\t\nEstradiol 1 mg\t\n\t\nDrospirenone 0.5 mg\n* Referenced from 132th Edition, MIMS, 2013\n8.11\t\nHYPERTENSION IN NEONATES, CHILDREN AND ADOLESCENTS\nHypertension in Neonates and Infants \nThe reported incidence of hypertension in neonates admitted to modern Neonatal",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_201",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The reported incidence of hypertension in neonates admitted to modern Neonatal \nIntensive Care Unit is 0.8%.275 It is more common in neonates and infants with antenatal \nsteroids, bronchopulmonary dysplasia, patent ductus arteriosus or in those with \nindwelling umbilical arterial catheters.275 Catheter related hypertension is related to \nthrombus formation at the time of line placement.276\n43\nMeasurement of BP\nHealthy term neonates rarely have hypertension. Routine BP measurements are not \nadvocated in this group. The gold standard of BP measurement in neonates is by direct \nmeasurement of arterial pulse pressure wave form. \nStandardized Protocol for BP Measurement in Neonates: 277,278\n \n\u2022 measure by oscillometric device\n \n\u2022 lie prone or supine\n \n\u2022 use appropriate sized BP cuff",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_202",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "\u2022 measure by oscillometric device\n \n\u2022 lie prone or supine\n \n\u2022 use appropriate sized BP cuff\n \n\u2022 use right upper arm\n \n\u2022 measured when infant is asleep or in quiet awake state\n \n\u2022 3 successive BP reading at 2 min intervals\nA reference table for BP values after two weeks of age in infants from 26 to 44 weeks has \nbeen derived after taking into consideration gestational age at birth, postconceptional \nage and size for gestational age. The 95th and 99th percentile values are intended to serve \nas reference to identify infants with persistent hypertension that may require treatment. \n277 (Refer to Appendix 1)\nTreatment is recommended when BP is consistently above the 99th percentile. There are \nfew published case series that used diuretics, ACEI, \u00df\u0003\u0003-blockers and CCB.277",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_203",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "few published case series that used diuretics, ACEI, \u00df\u0003\u0003-blockers and CCB.277\nThere is concern over the use of ACEI in preterm neonates.279 It has been reported to \ncause an exaggerated fall in BP and may impair the final stages of nephron maturation.280\nHypertension in Children and Adolescents\nPrevalence of hypertension in children and adolescents is increasing in tandem with\nthe increasing prevalence of obesity in this group.281,282\nThe definition of hypertension in children and adolescents is based on age, \ngender and height. Hypertension is defined as average systolic or diastolic BP \n> 95th percentile for age, gender and height percentiles on at least 3 separate \noccasions. \nThe Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_204",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in \nChildren and Adolescents has provided normative tables of BP based on age and gender \nadjusted for height percentiles from the National Centre for Health Statistics (NCHS) \ngrowth chart (Refer to Appendix 1).283 This is to allow for a more precise classification of \nBP and avoids mislabeling children who are either too tall or too short.\nMeasurement of BP in children follows the same principles as set out in the section on BP \nmeasurement. Special attention needs to be paid in the selection of an appropriate cuff \nsize in relation to the child\u2019s right upper arm. \nBP should be measured in all children and adolescents >3 years old at all medical",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_205",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "BP should be measured in all children and adolescents >3 years old at all medical \nencounters and in selected children <3 years old who are at high risk.283\nTo assist clinicians in the further evaluation and management of hypertensive children \nand adolescents, blood pressure in this group has been arbitrarily divided into normal, \npre-hypertension, stage I and stage II hypertension. (Table 20)\n44\nTable 20.\t Classification and Management of Hypertension in Children and \t \t\n\t\nAdolescents283\n\t\nSBP or DBP\t\nFrequency of BP\t\nWhen to start \t\n\t\n\t\n\t\npercentile\t\nmeasurement\t\npharmacologic treatment*\nNormal\t\n< 90th\t\nNo data available\t\nNo treatment\nPre-\t\n> 90th to <95th or if BP \t\nRecheck in\t\nNo treatment unless having\nhypertension\t\n> 120/80 mmHg (even if \t 6 months\t\ncompelling indications e.g.,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_206",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hypertension\t\n> 120/80 mmHg (even if \t 6 months\t\ncompelling indications e.g.,\n\t\n< 90th percentile) & up\t\n\t\nCKD, DM, heart failure\n\t\nto 95th percentile\nHypertension\t\nSBP and/or DBP >95th percentile >3 occasions\nStage I\t\n95th to 99th percentile \nRecheck in 1\u20132 wk, \n\u2022 Secondary hypertension  \nhypertension \nplus 5 mmHg** ) \nsooner if  \n\u2022 Symptomatic hypertension*** \n \n \nsymptomatic, refer \n\u2022 Presence of TOD \n \n \nwithin 1 month \n\u2022 Failed non-pharmacologic\n\t\n\t\n\t\n   measures\nStage II\t\n> 99th percentile\t\nImmediately if\t\nInitiate therapy\nhypertension\t\nplus 5 mmHg**\t\nsymptomatic; refer\t\n\t\n\t\nwithin a week\n*\t\nnon-pharmacologic measures recommended in all pre-hypertensives and hypertensive children.\n**\t\nTo diagnose stages of hypertension, add 5 mmHg to the respective percentile value. \n***",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_207",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "**\t\nTo diagnose stages of hypertension, add 5 mmHg to the respective percentile value. \n***\t\nSymptoms associated with hypertension include headache, nausea, vomiting, seizures and visual \t\n\t\n\t\ndisturbances.\nA patient with BP levels >95th percentile in a doctor\u2019s office but who is normotensive \noutside a clinical setting has \u201cisolated office hypertension\u201d. Isolated office hypertension \nis seen in up to 60% of children and adolescents and is not associated with target organ \ndamage. Ambulatory blood pressure measurement is necessary to confirm hypertension \nin otherwise healthy children.\nIdentifiable causes of hypertension particularly of renal parenchymal and renovascular \norigin account for about 80\u201390% of hypertension in children <10 years of age. Children",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_208",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "origin account for about 80\u201390% of hypertension in children <10 years of age. Children \nwith primary hypertension tend to be obese and have positive family history of \nhypertension.284\nOnce a child is diagnosed with hypertension, he should be referred to a paediatrician for \nfurther evaluation and management.285 (Level III)\nTreatment of Paediatric Hypertension\nGoals of Therapy283\nChildren with uncomplicated primary\t\nAim for BP <95th percentile for age, \nhypertension without hypertensive TOD\t\nsex and height \nChildren with secondary hypertension,\t\nAim for BP <90th percentile for age, \ndiabetes mellitus or hypertensive TOD\t\nsex and height \nNon-pharmacologic Treatment\nNon-pharmacologic management including dietary changes, exercise and weight",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_209",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Non-pharmacologic management including dietary changes, exercise and weight \nreduction (if obese) is recommended in all children with hypertension as well as those \nwith BP in the 90th to 95th percentile.283 (Level III)  \nPharmacologic Treatment\nDefinite indications for initiating pharmacotherapy include:283\n\t\n \n\u2022 Diabetes Mellitus Type 1 and 2\n \n\u2022 Hypertension with TOD\n \n\u2022 Stage II hypertension\n \n\u2022 Symptomatic Hypertension\n \n\u2022 Secondary Hypertension\n \n\u2022 Persistent Hypertension despite non-pharmacological measures\n45\nStepped Care Approach \nAn individualised stepped care approach to the use of anti-hypertensive drugs has been \nrecommended by the National High Blood Pressure Education Program (NHBPEP) \nworking group.283\nStepped care approach:\n\t Step 1",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_210",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "working group.283\nStepped care approach:\n\t Step 1\t\n begin with the recommended dose of desired drug (monotherapy)\nIf BP control is not achieved\n\t Step 2\t\nIncrease dose until maximum dose or desired BP target is reached \nIf BP control is not achieved\n\t Step 3\t\nAdd a second medication with a complementary mechanism of action\n         \t \t\nProceed to highest recommended dose if necessary and desirable\n\t\nIf BP control is not achieved\n\t Step 4\t\nAdd a 3rd anti hypertensive drug of a different class OR\n\t\n\t\nConsult a paediatrician expert in childhood and adolescent hypertension\nEvidence based treatment recommendation is lacking in paediatric patients. It should \nnot be assumed that what works for adults will work well for children and adolescents. It",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_211",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "not be assumed that what works for adults will work well for children and adolescents. It \nis probably advisable to consider several classes of agents including diuretics, \u00df-blocker, \nACEI, ARBs and CCBs as potentially acceptable first line agents.283,286,287\nAppendix 2 contains dosing recommendations for antihypertensive drugs used in \nchildren aged 1\u201317 years old.\nProteinuric Chronic Kidney Diseases283\nNHBPEP Working group recommended ACEIs or ARBs be used preferentially in children \nwith proteinuric CKD.\nObese Hypertensive Children283\nThe diabetogenic potential of diuretics and \u00df-blockers need to be considered \nand should probably be avoided as initial therapy in children who are obese and \nhypertensive.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_212",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and should probably be avoided as initial therapy in children who are obese and \nhypertensive.\nMany drugs now have specific paediatric labelling.288 These have been driven by initiatives \nto ensure that prescribed antihypertensives are efficacious, safe and contain dosing \ninformation. \n46\n9.0\t\nPHARMACOECONOMICS OF HYPERTENSION\nThe public impact and economic burden of hypertension extends far beyond that \nrelated to treating high blood pressure. Hypertension pharmacotherapy should not be \njudged by the direct cost of the drug alone. For example, ARB reduced stroke by 25% as \ncompared to a \u00df-blocker in patients with hypertension and LVH. This corresponded to a \nreduction in the cost per patient directly related to stroke of \u20ac1141 in 2005.289",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_213",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "reduction in the cost per patient directly related to stroke of \u20ac1141 in 2005.289\nIn Malaysia, 43% of persons aged 30 years and above were hypertensive in 20063 \nand about RM342.5 million, RM369.6 million and RM380.9 million was spent on anti-\nhypertensive medicines alone in year 2009, 2010 and 2011, respectively.290 In 2010, \nthere were 36,998 hypertension-related admissions to MOH hospitals.291 The cost per \nadmission of managing hypertension was RM2,927 for those without comorbidity and \ncomplications, RM4,248 for hypertension with comorbidity and complications, and \nRM4,716 for hypertension with major comorbidity and complications in 2005.292 This \namounts to at least RM134 million spent on managing hypertensive patients admitted",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_214",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "amounts to at least RM134 million spent on managing hypertensive patients admitted \nto Ministry of Health hospitals. The above figures are an underestimation. They do not \ninclude the many admissions due to heart failure, myocardial infarction, stroke and renal \nfailure where hypertension was the underlying cause.\nThere were 25,326 admissions for cerebrovascular diseases including stroke to \ngovernment hospitals in 2010.291 The cost of treating stroke without complications \nis RM3,420, with minor complications is RM4,276, and with major complications, is \nRM6,129 per patient per admission in 2005.292 Taking into account the inflation rates over \nthe years, the total cost of managing stroke in government for the year 2010 is estimated \nto be at least RM101.6 million.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_215",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "to be at least RM101.6 million. \nAdmissions in MOH hospitals in 2010 for IHD which is mainly AMI were 52,145. The \ncost of treating acute uncomplicated ST Elevated Myocardial Infarction (STEMI) was \nRM17,290 using step down method.293 This is estimated to be RM901.6 million. In \nanother study, hypertension was present in 47% of STEMI but 70% and 73% of NSTEMI \nand unstable angina patients respectively.294\nHypertension is the second most common identifiable cause of ESRD (6%) in 2011,295 \nwith 5201 new cases in that year. The cost of dialysis in a MOH facility was approximately \nRM33,000 per patient per year in 2005.296 The public, NGO and private sector provided \n31%, 27% and 42% of overall dialysis treatment in 2011, the government provided",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_216",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "31%, 27% and 42% of overall dialysis treatment in 2011, the government provided \n59% of total funding for dialysis channeled through various funding and subsidy \nprogrammes. The total cost to the country was estimated to be RM318.3 million to treat \nhypertensive patients that needed dialysis in year 2011.\nTreating hypertension reduced strokes by approximately 40%, coronary heart disease \nby 16%, and resulted in fewer cases of non-fatal MI, vascular and non-vascular deaths.297 \nEfforts should be focused on increasing public awareness, choice of cost effective \ntreatment and patient drug adherence. The total drug cost incurred to the private and \ngovernment sectors to manage hypertension was RM380.9 million290 in 2010. This",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_217",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "government sectors to manage hypertension was RM380.9 million290 in 2010. This \nshould translate to better rates of hypertension control and reduction in the total cost of \nmanaging its sequelae.\nRecommendations\n\u2022 \nDo not judge hypertension pharmacotherapy by the direct cost of the drug \nalone. (Grade C)\n\u2022 \nThe direct cost of treating hypertension is far outweighed by the cost of \ntreating complications of hypertension. (Grade B)\n\u2022 \nEducate patients on the cost effectiveness of taking and adhering to drug \ntreatment. (Grade C) \n47\n10.0\t\nTYPES OF ANTI-HYPERTENSIVE AGENTS\nAll stated drug dosages are referenced from MIMS 128th edition 2013103 unless otherwise \nindicated. \n10.1\t\nDIURETICS\nThe use of diuretics is well established in the treatment of hypertension. Thiazide diuretics",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_218",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The use of diuretics is well established in the treatment of hypertension. Thiazide diuretics \nare especially cheap and are one of the most widely used anti-hypertensive agents. \nWhen used in patients with essential hypertension and relatively normal renal function, \nthiazides are more potent than loop diuretics. However, in patients with renal insufficiency \n(serum creatinine >200 umol/L or higher), thiazides are less effective and loop diuretics \nshould be used instead.298\nIn the elderly with no co-morbid conditions, diuretics have been shown to not only \nreduce the incidence of fatal and non-fatal strokes but also cardiovascular morbidity and \nmortality.5,65,68,233,299\nDiuretics may be used as initial first-line therapy. They also enhance the efficacy of other",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_219",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Diuretics may be used as initial first-line therapy. They also enhance the efficacy of other \nclasses of anti-hypertensive drugs when used in combination.300-302\nThere has been increasing debate whether pharmacologically defined thiazide diuretics \n(e.g. hydrochlorothiazide) and the thiazide-like diuretics (e.g. chlorthalidone and \nindapamide) which have previously been grouped together as \u201cthiazide diuretics\u201d offer \ncomparable benefits in the treatment of hypertensive patients. Most of the outcome \nstudies have used thiazide-like diuretics, chlorthalidone4,68 and indapamide.93 There \nare no convincing outcome data using thiazide diuretics monotherapy, in particular low \ndose hydrochlorothiazide. A retrospective analysis showed that chlorthalidone reduced",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_220",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "dose hydrochlorothiazide. A retrospective analysis showed that chlorthalidone reduced \ncardiovascular events more so than hydrochlorothiazide in hypertensive patients at high \nrisk of cardiovascular events.303\nIndapamide has also been shown to be an effective BP-lowering agent alone or in \ncombination with other classes of drugs.35,93   In the very elderly patients, it reduced the \nincidence of fatal and non-fatal strokes as well as cardiovascular and all-cause mortality.93\nIn general, diuretics should be used with care in patients with gout as they may \nprecipitate an acute attack. Potassium-sparing diuretics may cause hyperkalaemia \nif given together with ACEIs or ARBs or in patients with underlying renal insufficiency.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_221",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "if given together with ACEIs or ARBs or in patients with underlying renal insufficiency. \nAldosterone antagonists and potassium-sparing diuretics should be avoided in patients \nwith serum potassium >5.0 mmol/L.\nAdverse effects are uncommon, unless high doses are used. These include increased \nserum cholesterol, glucose and uric acid; decreased potassium, sodium and magnesium \nlevels and erectile dysfunction. Serum electrolytes, in particular potassium, should be \nclosely monitored.304-306\nTable 21.\t Recommended Dosing for Diuretics\nDiuretics\t\nStarting Dose*\t\nRecommended\n\t\n\t\nMaximum Daily Dose*\nHydrochlorothiazide\t\n12.5 mg od\t\n50 mg od\nChlorthalidone\t\n50 mg od\t\n100 mg od\nAmiloride/hydrochlorothiazide 5 mg/50 mg\t\n1 tablet od\t\n2 tablets od\nIndapamide SR\t\n1.5 mg od\t\n1.5 mg od\nIndapamide",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_222",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "1 tablet od\t\n2 tablets od\nIndapamide SR\t\n1.5 mg od\t\n1.5 mg od\nIndapamide\t\n2.5 mg od\t\n2.5 mg od\n* Referenced from 132th Edition, MIMS, 2013\n48\n10.2\t\nBETA-BLOCKERS (\u00df-BLOCKERS)\nBeta-blockers have long been established in the treatment of hypertension. They are \nparticularly useful in hypertensive patients with effort angina, tachyarrhythmias or \nprevious myocardial infarction where they have been shown to reduce cardiovascular \nmorbidity and mortality. Certain \u00df-blockers have been shown to be beneficial in patients \nwith heart failure. (Table 8)\nBeta-blockers are absolutely contraindicated in patients with uncontrolled asthma \nand relatively contraindicated in other forms of obstructive airways disease (including",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_223",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and relatively contraindicated in other forms of obstructive airways disease (including \ncontrolled bronchial asthma). It is also absolutely contraindicated in patients with severe \nperipheral vascular disease and heart block (2nd and 3rd degree).\nThey are generally well tolerated. Adverse effects reported include dyslipidaemia, \nmasking of hypoglycaemia, an increased incidence of new onset diabetes mellitus. \nDespite that a recent long-term follow-up of a study in newly diagnosed type 2 diabetes \nshowed that the benefit of \u00df-Blocker persisted and is even better than an ACEI.307 (Level \nII-2) Other reported adverse events include erectile dysfunction, cold extremities and \nnightmares (especially for lipophilic \u00df-Blockers), increase triglyceride levels and reduce",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_224",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "nightmares (especially for lipophilic \u00df-Blockers), increase triglyceride levels and reduce \nHDL levels (especially for non-selective \u00df-blockers). Use of \u00df-blockers during pregnancy \nis cautioned.\nWith the advent of newer anti-hypertensive agents with better efficacy and better \nsafety profile, concern has been voiced over their widespread use in the treatment of \nhypertension.308,309 In a major landmark study, an ARB was shown to be superior than \n\u00df-Blocker in patients with high risk hypertension and ECG LVH.87 This prompted a meta \nanalysis on the use of \u00df-blockers in the treatment of hypertension.69 Beta-blocker therapy \ndid not reduce the risk for first myocardial infarction compared to other drugs but was",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_225",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "did not reduce the risk for first myocardial infarction compared to other drugs but was \nassociated with a significant 16% higher risk for stroke when compared to non-\u00df-blocker \ntherapy and that atenolol in particular was associated with a significant 26% increase \nin the risk of stroke when compared to other anti-hypertensive agents. Beta-blockers \nlower brachial systolic blood pressure but not the aortic pressure compared to other \ndrugs. Heart rate is reduced but peripheral resistance is increased, thus increasing the \narterial wave reflection during systole rather than diastole.310 (Level I) Similarly, another meta \nanalysis71 and a systematic review also showed that \u00df-blockers were associated with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_226",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "analysis71 and a systematic review also showed that \u00df-blockers were associated with \na significant increase in their withdrawal due to side effects.311 However a more recent \nmeta analyses showed that \u00df-blocker is as effective as other drugs in improving clinical \noutcome.73-76\nNational Institute for Clinical Excellence (NICE) UK Guideline20 in 2011 and JNC VIII 77 did \nnot place \u00df-blockers as first line in their recommendation of anti-hypertensive therapy. It \nis however still recommended as first line by other guidelines.22,78,79\nTable 22.\t Recommended Dosing for \u00df-blockers\n\u00df-blockers\t\nStarting Dose*\t\nRecommended Maximum Daily Dose*\nAcebutolol\t\n200 mg bd\t\n400 mg bd\nAtenolol\t\n50 mg od\t\n100 mg od\nBetaxolol\t\n10 mg od\t\n40 mg od\nBisoprolol\t\n5 mg od\t\n10 mg od\nMetoprolol\t\n50 mg bd\t\n200 mg bd",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_227",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Betaxolol\t\n10 mg od\t\n40 mg od\nBisoprolol\t\n5 mg od\t\n10 mg od\nMetoprolol\t\n50 mg bd\t\n200 mg bd\nPropranolol\t\n40 mg bd\t\n320 mg bd\nNebivolol\t\n5 mg od\t\n10 mg od\n* Referenced from 132th Edition, MIMS, 2013\n49\n10.3\t\nCALCIUM CHANNEL BLOCKERS (CCBs)\nCalcium channel blockers are structurally and functionally heterogenous class of drug. \nThey all cause vasodilation, which decreases peripheral resistance. \nThey are shown to be safe and effective in lowering blood pressure, both as first-\nline agents and in combination with other classes of antihypertensive drugs. With \nfew exceptions, they have no undesirable metabolic effects and their safety profile in \nhypertension is good. Dihydropyridine CCBs are particularly effective in reducing isolated",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_228",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hypertension is good. Dihydropyridine CCBs are particularly effective in reducing isolated \nsystolic hypertension.203,312,313,314 They are also effective in reducing cerebrovascular event \ncompared with other active therapies in primary prevention.314\nFor long-term use, short acting CCBs are no longer recommended and should \nbe phased out. The use of short acting CCB should be confined to certain types of \nhypertensive crisis.315\n Long acting CCB is to be preferred for long term use. Its generic \nformulations are now widely available. Long acting CCB is particularly useful in treating \nhypertensive IHD.316 This is partly because CCB improves endothelial nitric oxide and \ncause an increase flow mediated endothelial function.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_229",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "cause an increase flow mediated endothelial function.\nThere is a growing body of evidence to suggest that dihydropyridine CCB and RAAS \nblocker have additional beneficial effects when used in combination.90,317 A landmark \nsingle pill combination trial showed that combination of ACEI and dihydropiridine CCB \nwas more effective in preventing cardiovascular events than combination of ACEI with \nhydrochlorothiazide.92\nTable 23.\t Recommended Dosing for CCBs\nDihydropridines\t\nStarting Dose*\t\nRecommended Maximum Daily Dose*\namlodipine\t\n5 mg od\t\n10 mg od\nfelodipine\t\n5 mg od\t\n10 mg od\nisradipine\t\n2.5 mg bd\t\n10 mg bd\nlacidipine\t\n2 mg od\t\n6 mg od\nlercanidipine\t\n10 mg od\t\n20 mg od\nnifedipine\t\n10 mg tid\t\n20 mg tid\nNon-dihydropridines\t\ndiltiazem\t\n30 mg tid\t\n120 mg tid\ndiltiazem SR\t\n100 mg od\t\n200 mg od",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_230",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "20 mg tid\nNon-dihydropridines\t\ndiltiazem\t\n30 mg tid\t\n120 mg tid\ndiltiazem SR\t\n100 mg od\t\n200 mg od\nverapamil\t\n80 mg tid\t\n160 mg tid\nverapamil SR\t\n240 mg od\t\n240 mg od\n* Referenced from 132th Edition, MIMS, 2013\n10.4\t\nACE INHIBITORS (ACEIs)\nAngiotensin \nconverting \nenzyme \ninhibitors \nare \nwell \nrecognised \nas \neffective \nantihypertensive agents which can lower cardiovascular risk and reduce mortality and \nmorbidity in hypertensives and those at high cardiovascular risk.36,318 They are generally \nwell tolerated and do not have adverse effects on lipid and glucose metabolism. Their \nsafety profile is good. Angiotensin converting enzyme inhibitors have also been shown to \nreduce mortality and morbidity in patients with congestive heart failure319,320 and in post",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_231",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "reduce mortality and morbidity in patients with congestive heart failure319,320 and in post \nmyocardial infarction patients with reduced left ventricular ejection fraction.321-324\n\t\nIn the diabetic patient, ACEIs have been shown to reduce cardiovascular mortality.123 \nIn addition, they have been shown to prevent the onset of microalbuminuria, reduce \nproteinuria and retard the progression of renal disease. Angiotensin converting enzyme \ninhibitors have also been shown to reduce proteinuria and retard progression of non-\ndiabetic renal disease.325\n50\nIn patients with established vascular disease but normal left ventricular function, \nACEIs reduce mortality, myocardial infarction, stroke and new-onset congestive heart",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_232",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ACEIs reduce mortality, myocardial infarction, stroke and new-onset congestive heart \nfailure.36,326 These benefits are probably independent of their effects on left ventricular \nfunction and blood pressure. \nAdverse effects include cough and, rarely, angioedema. In patients with renovascular \ndisease or renal impairment, deterioration in renal function may occur. Serum creatinine \nand potassium should be checked before initiation and during treatment. In elderly and \nrenal impaired patients, serum creatinine and potassium should be checked within \ntwo weeks after initiation or increase in dose. Any increase in serum creatinine and/or \npotassium should be verified and monitored. If there is hyperkalemia (>5.6 mmol/L) or a",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_233",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "potassium should be verified and monitored. If there is hyperkalemia (>5.6 mmol/L) or a \nrise of serum creatinine of more than 30% from baseline within two months, the dose of \nthe ACEI should be reduced or discontinued. \n \nThis class of drug may increase foetal and neonatal mortality and therefore are \ncontraindicated in pregnancy, and should be avoided in those in child-bearing age.  \t\nTable 24.\t Recommended Dosing for ACEIs\nACEIs\t\nStarting Daily Dose*\t\nRecommended Maximum Daily Dose*\nCaptopril\t\n25 mg bd\t\n50 mg tds\nEnalapril\t\n2.5 mg od\t\n20 mg bd\nLisinopril\t\n5 mg od\t\n80 mg od\nPerindopril\t\n2 mg od\t\n8 mg od\nRamipril\t\n2.5 mg od\t\n10 mg od\nImidapril\t\n2.5 mg od\t\n10 mg od\n*Referenced from 132th Edition, MIMS, 2013 \n10.4.1\t\nCombination Therapy with ACEI",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_234",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "10 mg od\n*Referenced from 132th Edition, MIMS, 2013 \n10.4.1\t\nCombination Therapy with ACEI\nThe combination of an ACEI and a dihydropyridine CCB is preferred over the combination \nof an ACEI and a thiazide diuretic in patients with hypertension and high CV risk.92 This \ncombination is also better than combination of \u00df-blockers and diuretics in hypertensive \npatients with moderate risk and no obvious cardiovascular disease.90\n10.5\t\nANGIOTENSIN RECEPTOR BLOCKERS (ARBs)\nAngiotensin Receptor Blockers are drugs which specifically block angiotensin II \nreceptors. Unlike ACEIs, persistent dry cough is less of a problem. As such ARBs are \nrecommended in ACEI intolerant patients. As with ACEIs, they are contraindicated in \npregnancy. It may be used with caution in bilateral renal artery stenosis.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_235",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "pregnancy. It may be used with caution in bilateral renal artery stenosis. \nAngiotensin Receptor Blockers can be recommended for moderate to high-risk patients \nwith coronary artery disease as an alternative in ACEI intolerant patients.327\nAngiotensin Receptor Blockers are effective in preventing progression of diabetic \nnephropathy110,328 and may reduce the incidence of major cardiac events in patients with \nheart failure329,330 hypertensive LVH87 and diastolic heart failure.176\nThe Blood Pressure Lowering Treatment Trialist Collaboration (BPLTTC) in a meta \nanalysis of 21 randomised trial331 found that there were no clear differences between ACE \ninhibitors and ARBs for the outcomes of stroke and heart failure. \n51\nTable 25.\t Recommended Dosing for ARBs\nARBs\t\nStarting Dose*",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_236",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "51\nTable 25.\t Recommended Dosing for ARBs\nARBs\t\nStarting Dose*\t\nRecommended Maximum Daily Dose*\nCandesartan\t\n8 mg od\t\n16 mg od\nIrbesartan\t\n150 mg od\t\n300 mg od\nLosartan\t\n50 mg od\t\n100 mg od\nTelmisartan\t\n20 mg od\t\n80 mg od\nValsartan\t\n80 mg od\t\n160 mg od\nOlmesartan\t\n20 mg od\t\n40 mg od\n* Referenced from 132th Edition, MIMS, 2013\nThe safety profiles of ARB are very similar to those of ACEI except for a lower incidence \nof cough. There was an initial concern of increased risk of cancer with ARB therapy. \nHowever a recent meta analysis did not provide causal evidence for an increased \nrisk.332,333\nARBs and Risk of MI \nThere is some concern from ARB trials that there is an excess of MI125 and total mortality334",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_237",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "There is some concern from ARB trials that there is an excess of MI125 and total mortality334 \nbut none of these outcomes were statistically significant. In addition, in the largest ARB \ntrial on CV protection, there was no statistically significant increase in MI or total mortality \ncompared to ACEI.326 This is supported by a recent meta analysis. This meta analysis \nshowed that the use of ARB in hypertensive patients does not adversely affect all cause \nmortality. All cause mortality on the other hand was reduced with ACEI.335\nIn patients with LV dysfunction post MI, ARB has also been shown to be non-inferior to \nACEI.336\nCombination of ACEI and ARB\nThe combination of ACEI and ARBs is not recommended in hypertensive with normal \nrenal function.78,326",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_238",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "renal function.78,326\nThis combination may be considered in hypertensive patients with significant residual \nproteinuria after maximal monotherapy, and will require nephrologist supervision.\n10.6\t\nDIRECT RENIN INHIBITORS (DRIs)\nDirect Renin Inhibitors (DRIs) is a new class of anti-hypertensive agent. This class of \ndrug block the RAAS at the first and rate-limiting step of the cascade by preventing \nrenin from cleaving angiotensinogen to angiotensin I. This will result in excessive renin \nconcentration but not in the Plasma Renin Activity (PRA). \nOf this class of drugs, currently only aliskiren is orally active and has a long half-life.337 It \nis therefore effective in producing a sustained lowering of BP.338 Aliskiren was found to \nexhibit potency comparable with ARB and ACEI.339",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_239",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "exhibit potency comparable with ARB and ACEI.339\nAliskiren may be combined with the other classes of anti-hypertensive drugs for added \nBP lowering. The combination of aliskiren and hydrochlorothiazide decreased seated \nSBP by 3.5 to 13.5 mmHg and decreased seated DBP by 2.1 to 7.3 mmHg.340 The \ncombination resulted in a significantly higher responder rates compared with those of \nthe component monotherapies.340 There was no significant difference in BP lowering \nbetween a combination of aliskiren and amlodipine 5 mg compared with amlodipine 10 \nmg.341 Aliskiren is not recommended for combination with other classes of RAAS blockers \nfor control of blood pressure.\n52\nAliskiren has been found to be safe and well tolerated with an adverse effect profile similar",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_240",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "52\nAliskiren has been found to be safe and well tolerated with an adverse effect profile similar \nto placebo. The most common side effect is diarrhea (2.3%) and is more common with \ndoses higher than 300 mg daily. Other reported adverse effects included cough (1.1%), \nrash (1%), elevated uric acid (0.4%), gout (0.2%), and renal stones (0.2%). \nTable 26.\t Recommended Dosing for DRI\nDRI\t\nStarting Dose*\t\nRecommended Maximum Daily Dose*\nAliskiren\t\n150 mg/day\t\n300 mg/day\n* Referenced from 132th Edition, MIMS, 2013\nDoses greater than 300 mg daily result in no additional BP lowering and increased \nadverse effects. Dosage need not be adjusted in elderly patients.\nInitial studies in humans with diabetic nephropathy342,343 and heart failure344 have used",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_241",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Initial studies in humans with diabetic nephropathy342,343 and heart failure344 have used \nthe addition of aliskiren on top of another RAAS blocker (ACEI or ARB). Using albuminuria \nreduction and BNP as surrogate markers respectively, the early results were promising. \nHowever, a later study on a larger number of patients with diabetic nephropathy using \naliskiren and a ACEI or ARB was stopped prematurely because of increased adverse \nevents compared with an ACEI or ARB alone.345,346\nIn view of the above adverse events, it is not recommended that aliskiren be added to an \nACEI or an ARB in patients with diabetes. \n10.7\t\nMISCELLANEOUS DRUGS\n10.7.1\t\nThe \u2202-Blockers and the Combined \u2202, \u00df-Blockers\nThe peripheral \u22021-adrenergic blockers lower BP by reducing peripheral resistance. They",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_242",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The peripheral \u22021-adrenergic blockers lower BP by reducing peripheral resistance. They \nalso reduce prostatic and urethral smooth muscle tone and provide symptomatic relief \nfor patients with early benign prostatic hyperplasia (BPH).347 They should be the treatment \nof choice for hypertensive patients with BPH. The use of non-specific \u2202-blockers \nlike phentolamine and phenoxybenzamine has been restricted to the treatment of \nphaechromocytoma.\nIn addition, \u2202-blockers have favourable effects on lipid metabolism. However postural \nhypotension is a known side effect, especially at initiation of therapy.348,349 It should be \nused cautiously in the elderly if indicated.\nCombined \u2202 and \u00df-blockers offer enhanced neurohormonal blockade. Labetalol",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_243",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Combined \u2202 and \u00df-blockers offer enhanced neurohormonal blockade. Labetalol \nhas been in use for over 20 years and is safe in pregnancy (Refer to chapter 8 on \nHypertension in Pregnancy). The intravenous formulation is useful in hypertensive \nemergencies, including pre-eclampsia and eclampsia.350\nCarvedilol has been shown to be effective in hypertension and also to improve mortality \nand morbidity in patients with heart failure.351-353 In addition, it has no adverse effects on \ninsulin resistance and lipid metabolism.354 However, its safety in pregnancy has not been \nestablished. \nTable 27.\t Recommended Dosing for \u2202-blockers\n\u2202-blockers\t\nStarting Dose*\t\nRecommended Maximum Daily Dose*\nDoxazosin\t\n1 mg\t\n16mg od\nPrazosin\t\n0.5 mg nocte\t\n20mg in divided doses\nTerazosin\t\n1 mg\t\n5mg od",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_244",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Doxazosin\t\n1 mg\t\n16mg od\nPrazosin\t\n0.5 mg nocte\t\n20mg in divided doses\nTerazosin\t\n1 mg\t\n5mg od\n* Referenced from 132th Edition, MIMS, 2013\n53\nTable 28.\t Recommended Dosing for \u2202, \u00df-blockers\n\u2202, \u00df-blockers\t\nStarting Dose*\t\nMaximum Dose*\nLabetolol **\t\n100 mg bd\t\n2.4 gm 3-4 times a day\nCarvedilol ***\t\n12.5 mg od\t\n50 mg od\n*\t\nReferenced from 132th Edition, MIMS, 2013\n**\t\nIn the elderly start with 50 mg bd\n***\t\nThe dosage of carvedilol for patients with heart failure and angina pectoris is different from the doses \t\n\t\n\t\nindicated above. \n10.7.2\t\nCentrally Acting Agents\nThe centrally acting agents available in this country are alpha-methyldopa, clonidine and \nmoxonidine. The common side effects of the centrally acting agents include drowsiness,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_245",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "moxonidine. The common side effects of the centrally acting agents include drowsiness, \ndry mouth, headache, dizziness and mood change. Moxonidine is less likely to cause \nthese reactions. The side-effects may decrease after a few weeks of continued \ntreatment. In general, treatment should begin with the lowest possible dose to minimise \nthe side-effects.\nAlpha-methyldopa has been in use for many years. It is the drug of choice for hypertension \nin pregnancy. It may be considered for resistant hypertension in combination with other \nclasses of anti-hypertensive agents.355\nClonidine should NOT be withdrawn suddenly because rebound hypertension may \noccur.356 The use of clonidine is discouraged because safer and more potent drugs are \navailable.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_246",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "occur.356 The use of clonidine is discouraged because safer and more potent drugs are \navailable.\nMoxonidine is an orally administered imidazoline compound with selective agonist activity \nat imidazoline II receptors. It acts centrally to reduce peripheral sympathetic activity, thus \ndecreasing peripheral vascular resistance. It can be used as monotherapy in patients \nwith mild to moderate hypertension or in combination with other anti-hypertensive \nagents. Studies have suggested that it may improve the metabolic profile of patients with \nimpaired glucose tolerance or diabetes. Absorption is rapid and unaffected by food.357 \nRebound hypertension on cessation of the drug is less likely compared to clonidine \nbut abrupt withdrawal is not recommended. When used with a \u00df-blocker the chance",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_247",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "but abrupt withdrawal is not recommended. When used with a \u00df-blocker the chance \nof a rebound is higher and it is recommended that the \u00df-blocker be stopped first, and \nmoxonidine then tailed down a few days later. It has been shown to increase mortality in \npatients with HF and therefore contraindicated.358\nIn patients with renal impairment the dose needs to be reduced as follows:\nTable 29.\t Recommended dosing for Centrally Acting Agent\n\t\n(Creatinine Clearance 30-60 ml/min): \nCentrally Acting Agent\t\nStarting Dose*\t\nMaximum Dose*\nMoxonidine\t\n\u2264200 mcg in single dose\t\n400 mcg in divided doses\n* Referenced from 132th Edition, MIMS, 2013103\nIf the creatinine clearance is <30 ml/min moxonidine should not be used.\n54\nTable 30.\t Recommended Dosing for Centrally Acting Agents\nDrug\t\nStarting dose",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_248",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "54\nTable 30.\t Recommended Dosing for Centrally Acting Agents\nDrug\t\nStarting dose\t\nMaximum dose\n\u2202-methyldopa* \n125 mg bd \n500 mg tds\nClonidine\t\n500 mcg tds\t\n4 mg tds\nMoxonidine \n\u2022 200 mcg od  \n\u2022 600 mcg in divided doses\n \n\u2022 To be avoided if GFR <30 \n\u2022 400 mcg in divided dose (GFR 30\u201360)\n \n \n\u2022 To be avoided if GFR <30\n* For dosage in pregnancy, refer to chapter on pregnancy\n10.7.3\t\nDirect Vasodilators\nThe direct vasodilators include hydralazine and minoxidil. Hydralazine is only available \nin parenteral formulation for hypertensive emergencies (Refer to Hypertensive \nEmergencies and Hypertension in Pregnancy). Minoxidil is used for refractory \nhypertension. The usefulness of this class of drugs is limited by their side-effects,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_249",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hypertension. The usefulness of this class of drugs is limited by their side-effects, \nincluding headache, compensatory tachycardia, and salt and water retention. Hirsuitism \nis a troublesome side-effect with long-term use of minoxidil. These drugs should only be \nprescribed by physicians familiar their usage.\nTable 31.\t Recommended Dosing for Direct Vasodilators\nDrug\t\nStarting Dose\t\nMaximum dose\nMinoxidil\t\n5 mg od\t\n50 mg od\nHydralazine\t\n10 mg qid \t\n50 mg qid \n55\n11.0\t\nRESISTANT HYPERTENSION\nResistant hypertension is defined as uncontrolled hypertension (>140/90 mmHg) with \ngood medication adherence in spite of the concurrent use of three anti-hypertensive \nagents (including a diuretic) in adequate doses.22,24 Based on this definition, prevalence",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_250",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "agents (including a diuretic) in adequate doses.22,24 Based on this definition, prevalence \nof resistant hypertension from a survey by the Institute of Health Management, Ministry \nof Health is 12%.359 A survey in primary care in Selangor also revealed a similar prevalence \nof around 12%.360 In a large study, prevalence of resistance hypertension was reported \nto be 15%.68 These figures are likely to be an overestimate because many of the patients \nare not necessarily on diuretics.  \nBefore labeling a patient as having resistant hypertension, it is important that \nthe practitioner ascertain that:\n\t\na.\t\nthe patient adheres to medication (by definition at  least 80%)  \n\t\nb.\t the blood pressure is measured appropriately\n\t\nc.\t\nthe patient does not have \u2018office hypertension\u2019",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_251",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "c.\t\nthe patient does not have \u2018office hypertension\u2019\n\t\nd.\t an appropriate combination and dosage of drugs is prescribed, namely \n\t\n\t\n3 drugs including a RAAS blocker, a calcium channel blocker and a diuretic\n\t\ne.\t the patient is not taking any substances which may antagonise the \t \t\n\t\n\t\n\t\nhypertensive effects of the drugs taken (eg NSAID, sympathomimetics, \n\t\n\t\nliquorice, oral contraceptives )\nIt is therefore important that a thorough review of the patient\u2019s history, physical \nexamination and investigations be done including estimation of renal function \nincluding glomerular filtration rate (eGFR). A home or ambulatory blood pressure \nmeasurement should be done to exclude isolated office hypertension. (Refer to chapter",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_252",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "measurement should be done to exclude isolated office hypertension. (Refer to chapter \n2 on Measurement of Blood pressure).The prevalence of isolated office resistant \nhypertension ranges from 35%\u2013 44% 361,362 \nOnce a patient is confirmed to have true resistant hypertension, consider referral for \nexclusion of secondary causes (Refer to chapter 3 on Diagnosis and Assessment).\nExcluding Secondary Hypertension \nAlthough the prevalence of secondary hypertension is around 5%, its prevalence is \nhigher in patients with resistant hypertension. Depending on series, prevalence of \nsecondary hypertension among patients with resistant hypertension can be as high as \n66%, with obstructive sleep apnoea, accounting for most of it.363,364 In two large series,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_253",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "66%, with obstructive sleep apnoea, accounting for most of it.363,364 In two large series, \nprimary aldosteronism was diagnosed in 11% of patients with resistant hypertension.365,366 \nSubsequent investigations arranged should be guided by symptoms present, \nexamination findings elicited and results from preliminary investigations. It is prudent that \nany investigations to be ordered or arranged must be rational with cost effectiveness in \nmind. \nTreatment options in resistant primary hypertension\na.\t Non-pharmacological Management\nNon-pharmacological approaches (therapeutic lifestyle modification) must be re-\nemphasised. (Refer to chapter 5 on Non-Pharmacological Management) \nb. \tPharmacological Management\nA fourth drug should be added to the combination of RAAS blocker, CCB and diuretic.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_254",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "A fourth drug should be added to the combination of RAAS blocker, CCB and diuretic.\n56\nDrugs tested in randomised controlled trials include spironolactone. A review of \n5 prospective trials showed that spironolactone can reduce BP in patients with \nresistant hypertension by an additional 22/10 mmHg.367 Alpha methyldopa has also \nbeen tested as an efficacious treatment for resistant hypertension.368 Some patients \nmay require more than four drugs to achieve BP control. \nc.\t Renal Denervation  \nOver the last 2 years a new form of treatment has been available in the form of \ntransluminal ablation of renal artery (renal denervation or RDN) and the treatment is \nnow available in a few centres in Malaysia. It began with a successful proof of concept",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_255",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "now available in a few centres in Malaysia. It began with a successful proof of concept \ntrial369 and has been subsequently shown to be efficacious in a small randomised trial \n370 and slightly bigger case report.371 Being a new mode of invasive intervention, strict \ncriteria needs to be observed before it can be performed. \n\t\nPatients eligible for this treatment must have the following \t\n \t\n\t\n\t\ncharacteristics: 372\n\t\ni. \t\nabsence of false resistant hypertension by doing Ambulatory Blood \n\t\n\t\nPressure or Home BP Monitoring\n\t\nii. \t\nabsence of  secondary resistant hypertension\n\t\niii. \t absence of  obstructive sleep apnea, high salt intake, BP raising drugs \t\n\t\n\t\n\t\nand severe obesity \n\t\niv. \t absence of suspicious renal  vascular pathology or anomaly especially",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_256",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "iv. \t absence of suspicious renal  vascular pathology or anomaly especially \n\t\n\t\nrenal artery stenosis, multiple renal arteries or main renal artery diameter \n\t\n\t\nof less than 4mm \n\t\nv. \t Near normal renal function (eGFR >45ml/min/1.73m2)\nIt is important that a prudent approach to selecting patients for RDN be in place to \navoid unnecessary procedures. A multidisciplinary team (physician, cardiologist, \nendocrinologist and nephrologist) is recommended that will collectively select the \nright patients for this procedure. \nAdvantages of RDN besides lowering BP, includes improving components of \nmetabolic syndrome, sleep apnea and overall sympathetic drive. A larger clinical trial \nis currently being conducted in patients with resistant hypertension which include a",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_257",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "is currently being conducted in patients with resistant hypertension which include a \nsham procedure as a control.373\nRecommendations\n\u2022 Ensure that patients are treated with at least 3 drugs (inclusive of a diuretic)  \n \n\t\nbefore diagnosing resistant hypertension. (Grade C) \n\u2022 Consider drug non adherence and secondary hypertension before labeling a  \n \n\t\npatient to have resistant hypertension. (Grade C)\n\u2022 Consider referring for renal denervation in patients with true resistant   \n \n\t\nhypertension. (Grade C)\n57\n12.0 \t\nASPIRIN IN HYPERTENSION \nAlthough the benefits of aspirin in secondary CV prevention is incontrovertible, that \nfor primary prevention remains controversial.374 A recent large meta analysis suggest",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_258",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "for primary prevention remains controversial.374 A recent large meta analysis suggest \nthat for primary prevention, the risk of significant bleeding outweigh the benefits of CV \nprotection.375 In patients with hypertension a large RCT showed that low dose aspirin (75 \nmg daily) reduced major CV events especially for MI but had no effect on the incidence \nof stroke. Non-fatal major bleeds were however twice as common with aspirin.231 \nSubgroup analysis of this large trial showed that patients who benefited most are those \nwith well treated hypertensive at higher baseline CV risk or higher baseline BP. 231 The \nbenefits of low dose aspirin was also most convincing in patients with well controlled BP \nand  moderate rise in serum creatinine (>114 umol/L). 376\nRecommendations",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_259",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and  moderate rise in serum creatinine (>114 umol/L). 376\nRecommendations\n\u2022 Consider using antiplatelet in patients with higher baseline BP (Grade B)\n\u2022 Treat patients BP to target once they are on antiplatelets (Grade A)   \n58\n13.0\t\nLIPID LOWERING IN HYPERTENSION\nJust like for aspirin, the use of lipid lowering drugs (particularly statin) is well established \nin patients with high CV risk with or without hypertension. For primary prevention  in \nhypertensive patients, the result have been mixed. In the ALLHAT study high dose \npravastatin failed to show any mortality and cardiovascular benefits in high risk hypertensive \nwith mildly elevated blood pressure.377 The lack of benefits remains after long term follow",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_260",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "with mildly elevated blood pressure.377 The lack of benefits remains after long term follow \nup.378 The level of lipid lowering achieved was however very modest. On the other hand, \nin the ASCOT study low dose atorvastatin in medium risk hypertensive patients with \nmoderately elevated blood pressure showed substantially significant cardiovascular \nevents reduction379, although just like with pravastatin there was no mortality benefits. \nOn long term follow up ,the benefit of atorvastatin remains, but this time the benefits \ninclude a reduction in all cause mortality,  suggesting a legacy effect.380Taking stock of \nthese two conflicting studies, a subsequent meta analysis including other statin trials with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_261",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "these two conflicting studies, a subsequent meta analysis including other statin trials with \na large number of patients recruited showed benefits of statin therapy on cardiovascular \nmortality and morbidity.381 (Level I) in the hypertensive population.\nRecommendations\n\u2022 Initiate statin therapy for primary prevention in patients with concurrent  \n \n\t\nhypertension and mildly elevated cholesterol. (Grade A) \n\u2022 Start statin if LDL-C is > 2.6mmol/L in high risk and > 3.4 mmol/L in medium risk\n\t\nhypertensive patients (Grade A)\n\u2022 The choice of statin is not as important as the level of cholesterol lowering  \n \n\t\nachieved. (Grade B).\n59\nAPPENDICES\nAppendix 1: Estimated BP values after 2 weeks of age in infants from 26 to 44 \nweeks postconceptual age.\nPostconceptual age\t\n50th percentile",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_262",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "weeks postconceptual age.\nPostconceptual age\t\n50th percentile\t\n75th percentile\t\n99th percentile\n44 Weeks\t\n\t\n\t\nSBP\t\n88\t\n105\t\n110\nDBP\t\n50\t\n68\t\n73\nMAP\t\n63\t\n80\t\n85\n42 Weeks\t\n\t\n\t\nSBP\t\n85\t\n98\t\n102\nDBP\t\n50\t\n65\t\n70\nMAP\t\n62\t\n76\t\n81\n40 Weeks\t\n\t\n\t\nSBP\t\n80\t\n95\t\n100\nDBP\t\n50\t\n65\t\n70\nMAP\t\n60\t\n75\t\n80\n38 Weeks\t\n\t\n\t\nSBP\t\n77\t\n92\t\n97\nDBP\t\n50\t\n65\t\n70\nMAP\t\n59\t\n74\t\n79\n36 weeks\t\n\t\n\t\nSBP\t\n72\t\n87\t\n92\nDBP\t\n50\t\n65\t\n70\nMAP\t\n57\t\n72\t\n71\n34 Weeks\t\n\t\n\t\nSBP\t\n70\t\n85\t\n90\nDBP\t\n40\t\n55\t\n60\nMAP\t\n50\t\n65\t\n70\n32 Weeks\nSBP\t\n68\t\n83\t\n88\nDBP\t\n40\t\n55\t\n60\nMAP\t\n48\t\n62\t\n69\n30 Weeks\t\n\t\n\t\nSBP\t\n65\t\n80\t\n85\nDBP\t\n40\t\n55\t\n60\nMAP\t\n48\t\n65\t\n68\n28 Weeks\t\n\t\n\t\nSBP\t\n60\t\n65\t\n80\nDBP\t\n38\t\n50\t\n54\nMAP\t\n45\t\n58\t\n63\n26 Weeks\t\n\t\n\t\nSBP\t\n55\t\n72\t\n77\nDBP\t\n30\t\n50\t\n56\nMAP\t\n38\t\n57\t\n63\n60\nAppendix 2 : Recommended dosages for selected anti-hypertensive agents for",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_263",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "56\nMAP\t\n38\t\n57\t\n63\n60\nAppendix 2 : Recommended dosages for selected anti-hypertensive agents for \nthe management of hypertension in children and adolescents\nDrugs\t\nDoses\t\nFrequency\nAngiotensin-Converting Enzyme Inhibitors\nCaptopril\t\n0.3 \u2013 0.5 mg/kg\t\nBD or TDS\nEnalapril\t\n0.08 \u2013 0.6 mg/kg \t\nOnce daily or BD\nAngiotensin-Receptor Blockers\nIrbesartan\t\n6 \u2013 12 years : 75 \u2013 150 mg/day\t\nOnce daily\n\t\n>13 years : 150 \u2013 300 mg/day\nLosartan\t\n0.7 \u2013 1.4 mg/kg\t\nOnce daily\nCalcium Channel Blockers\nAmlodipine\t\n0.06 \u2013 0.3 mg/kg\t\nOnce daily\n\t\n6 \u2013 17 years : 2.5 \u2013 5 mg\nNifedipine\t\n0.25 \u2013 0.5 mg/kg\t\nTDS or QID\nBeta Adrenergic Blockers\t\nAtenolol\t\n0.5 \u2013 2 mg/kg\t\nOnce daily or BD\nMetoprolol\t\n0.5 \u2013 2 mg/kg\t\nBD\nPropranolol\t\n1 \u2013 2 mg/kg\t\nBD or TDS\nDiuretics\nFrusemide\t\n0.5 \u2013 2 mg/kg\t\nOnce daily or BD",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_264",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "BD\nPropranolol\t\n1 \u2013 2 mg/kg\t\nBD or TDS\nDiuretics\nFrusemide\t\n0.5 \u2013 2 mg/kg\t\nOnce daily or BD\nHydrochlorothiazide\t\n0.5 \u2013 1 mg/kg\t\nOnce daily\nSpironolactone\t\n1 mg/kg\t\nOnce daily\n61\nREFERENCES\n1.\t\nInstitute for Public Health (IPH) 2011. National Health and Morbidity Survey 2011 (NHMS 2011). Vol. II: \nNon-Communicable Diseases; 2011. ISBN 978-967-3887-68-2\n2.\t\nSelvarajah S, Haniff J, GH Tee, et al. Clustering of cardiovascular risk factors in a middle-income country: \na call for urgency. European Journal of Preventive Cardiology 2013 Apr;20(2):368-75\n3.\t\nInstitute of Public Health (IPH) 2008. The Third National Health and Morbidity Survey 2006 Vol 2. Ministry \nof Health Malaysia pg 199\u2013316 ISBN 978-983-3887-30-9\n4.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_265",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "of Health Malaysia pg 199\u2013316 ISBN 978-983-3887-30-9\n4.\t\nKostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older \npersons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212-6\n5.\t\nSHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older \npersons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly \nProgram (SHEP). JAMA 1991;265:3255-64 \n6.\t\nStaessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory \nblood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial \nInvestigators. JAMA 1999;282:539-46 \n7.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_266",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Investigators. JAMA 1999;282:539-46 \n7.\t\nBurt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from \nthe Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13 \n8.\t\nFranklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. \nThe Framingham Heart Study. Circulation 1997;96:308-15 \n9.\t\nFranklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease \nrisk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-9\n10.\t\nMancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement \nby physician and nurse. Hypertension 1987;9:209-215\n11.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_267",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "by physician and nurse. Hypertension 1987;9:209-215\n11.\t\nMancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or \nmasked hypertension. Hypertension 2009;54(2):226-32\n12.\t\nMancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat \nand masked hypertension. Nat Rev Cardiol. 2011;8(12):686-93 \n13.\t\nQuinn RR, Hemmelgarn BR, Padwal RS, et al. The 2010 Canadian Hypertension Education Program \nrecommendations for the management of hypertension: part I - blood pressure measurement, diagnosis \nand assessment of risk. Can J Cardiol 2010;26(5):241-8\n14.\t\nNiiranen TJ, Hanninen MR, Johansson J et al. Home-measured blood pressure is a stronger predictor",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_268",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Niiranen TJ, Hanninen MR, Johansson J et al. Home-measured blood pressure is a stronger predictor \nof cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 2010 Jun; 55(6); \n1346-52\n15.\t\nAsayama K, Ohkubo T, Hara A, et al. Repeated evening home blood pressure measurement improves \nprognostic significance for stroke: a 12-year follow-up of the Ohasama study. Blood Press Monit \n2009;14(3):93-8 \n16.\t\nStergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: \na systematic review. Am J Hypertens 2011 Feb;24(2):123-34\n17.\t\nEguchi K, Kuruvilla S, Ishikawa J, et al. Correlations between different measures of clinic, home, and \nambulatory blood pressure in hypertensive patients. Blood Press Monit 2011;16(3):142-8   \n18.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_269",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ambulatory blood pressure in hypertensive patients. Blood Press Monit 2011;16(3):142-8   \n18.\t\nStergiou GS, Tzamouranis D, Nasothimiou EG, et al. Are there really differences between home and \ndaytime ambulatory blood pressure? Comparison using a novel dual-mode ambulatory and home \nmonitor. J Hum Hypertens 2010;24(3):207-12 \n19.\t\nParati G, Stergiou GS, Asmar R, et al. European Society of Hypertension practice guidelines for home \nblood pressure monitoring. J Hum Hypertens 2010;24(12):779-85\n20.\t\nNational Institute for Health and Excellence Clinical Guideline 127: Hypertension. August 2011 (available \nat: http://publications.nice.org.uk/hypertension-cg127/guidance. (Accessed 8 September 2013) \n21.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_270",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "at: http://publications.nice.org.uk/hypertension-cg127/guidance. (Accessed 8 September 2013) \n21.\t\nInternational Society for Chronobiology. 2013 ambulatory blood pressure monitoring recommendations \nfor the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated \nrisk, and attainment of therapeutic goals. Chronobiol Int. 2013 April; 30 (3):355-410   \n22.\t\n2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the \nmanagement of arterial hypertension of the European Society of Hypertension (ESH) and the European \nSociety of Cardiology (ESC)  Eur Heart J 2013 Jul; 34 (28):2159-219\n23.\t\nCheong AT, Tong SF, Sazlina SG et al. Blood Pressure Control Among Hypertensive Patients With and",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_271",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Cheong AT, Tong SF, Sazlina SG et al. Blood Pressure Control Among Hypertensive Patients With and \nWithout Diabetes Mellitus in Six Public Primary Care Clinics in Malaysia. Asia Pac J Public Health 2013 \nMar 27 (Epub ahead of print)\n24.\t\nChobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, \nDetection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252 \n62\n25.\t\nLewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular \nmortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet \n2002;360:1903-1913 \n26.\t\nVasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_272",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-\nhypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-86 \n27.\t\nJulius S, Nesbitt SD, Egan BM, et al for the Trial of Preventing Hypertension (TROPHY) Study \nInvestigators. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. N Engl J \nMed 2006;354:1685-1697 \n28.\t\nGreenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with \nprehypertension in the United States, 1999-2000. Arch Int Med 2004;164:2113-2134 \n29.\t\nGrotto I, Grossman E, Huerta M, et al. Prevalence of Prehypertension and Associated Cardiovascular \nRisk Profiles Among Young Israeli Adults. Hypertension 2006;48(2):254-259 \n30.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_273",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Risk Profiles Among Young Israeli Adults. Hypertension 2006;48(2):254-259 \n30.\t\nKanauchi M, Kanauchi K, Hashimoto T, et al. Metabolic syndrome and new category \u2018pre-hypertension\u2019 \nin a Japanese population. Curr Med Res Opin 2004;20:1365-1370 \n31.\t\nZhang Y, Lee ET, Devereux RB, et al. Prehypertension, Diabetes, and Cardiovascular Disease Risk in a \nPopulation-Based Sample. The Strong Heart Study. Hypertension 2006;47:410-414\n32. \t Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type \n2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97\n33.\t\nKlahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_274",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "the progression of chronic renal disease. N Engl J Med1994;330:877-884\n34.\t\nJafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure \ncontrol, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann \nIntern Med 2003; 139: 244-252 \n35.\t\nReboldi G, Angeli F, de Simone G et al. Tight versus Standard Blood Pressure Control in Patients with \nHypertension with and without Cardiovascular Disease. Hypertension 2013 Dec 16 [Epub ahead of print]\n36.\t\nThe Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting \nenzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-153 \n37.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_275",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "37.\t\nThe EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease \nInvestigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable \ncoronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA \nstudy). Lancet 2003;362:782-788 \n38.\t\nLuders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the \nangiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure-a \nprospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens \n2008;26:1487-1496 \n39.\t\nSilaste ML, Junes R, Rantala AO, et al. Dietary and other non-pharmacological treatments in patients",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_276",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "with drug-treated hypertension and control subjects. J Intern Med 2000;247:318-324 \n40.\t\nSiebenhofer A, Jeitler K, Berghold A et al. Long-term effects of weight reducing diets in hypertensive \npatients. Cochcrane Database Syst Rev 2011 Sep 7;(9):CD008264\n41.\t\nTaylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: \na meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 2011;24(8):843-53 \n42.\t\nGraudal NA, Hubeck-Graudal T, J\u00fcrgens G. Effects of low-sodium diet vs. high-sodium diet on blood \npressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J \nHypertens 2012;25(1):1-15 \n43.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_277",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Hypertens 2012;25(1):1-15 \n43.\t\nJ\u00fcrgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, \naldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev 2004, Issue 1. \nArt. No.: CD004022. DOI: 10.1002/14651858.CD004022.pub2 \n44.\t\nHe FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane \nDatabase Syst Rev 2004, Issue 3. Art. No.: CD004937. DOI: 10.1002/14651858.CD004937 \n45.\t\nThe Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium \nreduction intervention on blood pressure and hypertension incidence in overweight people with high-normal \nblood pressure.  The Trials of Hypertension Prevention, Phase II. Arch Intern Med 1997;157(6):657-667.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_278",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "46.\t\nGraudal NA, Galloe AM, Garred P.  Effects of sodium restriction on blood pressure, renin, aldosterone, \ncatecholamines, cholesterols and triglyceride: A meta-analysis. JAMA 1998;279(17):1383-1391. \n47.\t\nNorimah AK Jr, Safiah M, Jamal K,et al. Food Consumption Patterns: Findings from the Malaysian Adult \nNutrition Survey (MANS). Malays J Nutr 2008;14(1):25-39 \n48.\t\nXin X,He J, Frontini MG et al. Effects of alcohol reduction on blood pressure: a meta-analysis of \nrandomized controlled trials. Hypertension 2001 Nov; 38(5):1112-7\n49.\t\nMorgan TO. Hypertension: Dietary and Lifestyle Measures in a Nutshell. Medical Progress 2000;26(7):5-9 \n50.\t\nHalbert JA, Silagy CA, Finucane P, et al. The effectiveness of exercise training in lowering blood pressure: a",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_279",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "meta-analysis of randomised controlled trials of 4 weeks or longer. J Hum Hypertens 1997;11:641-649 \n63\n51.\t\nPetrella RJ. How effective is exercise training for treatment of hypertension? Clin J Sport Med 1998 \nJul;8(3):224-31\n52.\t\nCornelissen VA, Fgard RH, Coeckelberghs E. Impact of resistance training on blood pressure and \nother cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension 2011 \nNov;58(5):950-8 \n53.\t\nOwen A,Wiles J,Swaine I. Effect of isometric exercise on resting blood pressure: a meta analysis. J Hum \nHypertens 2010 Dec;24(12):796-800\n54.\t\nRogers MW, Probst MM, Gruber JJ, et al. Differential effects of exercise training intensity on blood \npressure and cardiovascular responses to stress in borderline hypertensive humans. J Hypertens",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_280",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "pressure and cardiovascular responses to stress in borderline hypertensive humans. J Hypertens \n1996;14(11):1369-1375 \n55.\t\nEbrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-\npharmacological interventions. J Public Health Med 1998;20:441-448 \n56.\t\nDong JY,Qin LQ, Zhang Z. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis \nof randomized, double blind, placebo-controlled trials. Am Heart J 2011 Dec;162(6):959-65 \n57.\t\nDickinson HO, Beyer FR, Ford GA, et al. Relaxation therapies for the management of primary hypertension \nin adults. Cochrane Database Syst Rev 2008, Issue 1. Art. No.: CD004935. DOI: 10.1002/14651858.\nCD004935.pub2 \n58.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_281",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "CD004935.pub2 \n58.\t\nDickinson HO, Nicolson D, Cook JV, et al. Calcium supplementation for the management of primary \nhypertension in adults. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD004639. DOI: \n10.1002/14651858.CD004639.pub2 \n59.\t\nBeyer FR, Dickinson HO, Nicolson D, et al. Combined calcium, magnesium and potassium \nsupplementation for the management of primary hypertension in adults. Cochrane Database  Syst Rev \n2006, Issue 3. Art. No.: CD004805. DOI: 10.1002/14651858.CD004805.pub2 \n60.\t\nDickinson HO, Nicolson D, Campbell F, et al. Magnesium supplementation for the management of \nprimary hypertension in adults. Cochrane Database Syst Rev 2006, Issue 3. Art. No.: CD004640. DOI: \n10.1002/14651858.CD004640.pub2 \n61.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_282",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "10.1002/14651858.CD004640.pub2 \n61.\t\nDickinson HO, Nicolson D, Campbell F, et al. Potassium supplementation for the management of \nprimary hypertension in adults. Cochrane Database Syst Rev 2006, Issue 3. Art. No.: CD004641. DOI: \n10.1002/14651858.CD004641.pub2 \n62.\t\nDickinson HO,Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure : a \nsystematic review of randomsied controlled trials. J Hypertens 2006 Feb; 24(2):215-33\n63.\t\nBlood Pressure Lowering Treament Trialists\u2019 Collaboration. Effects of different blood pressure lowering \nregimens on major cardiovascular events: results of prospectively-designed overviews of randomised \ntrials. Lancet 2003;362:1527-35 \n64.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_283",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "trials. Lancet 2003;362:1527-35 \n64.\t\nHansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs \nin elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with \nHypertension-2 study. Lancet 1999;354:1751-6 \n65.\t\nBrown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-\nblind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS \nstudy: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72 \n66.\t\nHansson L, Lindholm LH, Nishanen L, et al. Effect of angiotension-converting-enzyme inhibition \ncompared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_284",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the \nCaptopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6 \n67.\t\nWing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme \ninhibitors and diuretics for hypertension in the elderly. N Eng J Med 2003;348:583-92 \n68.\t\nDavis BR, Cutler JA, Gordon DJ, et al. Major outcomes in high-risk hypertensive patients randomized \nto angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive \nand Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. (Errata \nin 2003;289:178 and 2004; 291:2196.) \n69.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_285",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in 2003;289:178 and 2004; 291:2196.) \n69.\t\nLindholm LH, Carlberg B, Samuelsson O. Should \u00df-blockers remain first choice in the treatment of \nprimary hypertension? A meta-analysis. Lancet 2005;366:1545-53 \n70.\t\nKhan N, McAlister FA. Re examining the efficacy of beta-blockers for the treatment of hypertension: a \nmeta-analysis CMAJ 2006 Jun 6;174(12):1737-42\n71.\t\nBradley HA,Wiysomge CS, Volmink JA et al. How strong is the evidence for the use of beta-blockers \nas first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006 Nov; \n24(11):2131-41\n72.\t\nWiysonge CS, Bradley HA,Mayosi BM et al. Beta-Blockers for Hypertension. Cochcrane Database Syst \nRev 2007 Jan 24;(1): CD002003\n73.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_286",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Rev 2007 Jan 24;(1): CD002003\n73.\t\nLaw MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular \ndisease: meta-analysis of 147 randomised trials in the contect of expectations from prospective \nepidemiological studies. BMJ 2009 May 19; 338:b1665\n64\n74.\t\nChrysant SG,Chrysant GS. Current status of beta blockers for the treatment of hypertension:an update. \nDrugs Today 2012 May;48(5):353-66\n75.\t\nWright JM, Musini VM. First\u2013line drugs for hypertension. Cochcrane Dayabase Syst Rev 2009 Jul 8; (3): \nCD001841\n76.\t\nWiysonge CS, Bradley HA, Volmink J. Beta-Blockers for Hypertension. Cochcrane Database Syst Rev \n2012 Nov 14;11: CD002003\n77.\t\nPaul A. James, Suzanne Oparil, Barry C. Carter et al 2014. Evidence-based Guideline for The",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_287",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "77.\t\nPaul A. James, Suzanne Oparil, Barry C. Carter et al 2014. Evidence-based Guideline for The \nManagement of High Blood Pressure in Adults. Report from the panel member appointed to the Eight \nJoint National Committee (JNC 8 ) JAMA. Dec 18,2013:E1-E14\n78.\t\nHackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program \nrecommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and \ntreatment of hypertension. Can J Cardiol 2013 May;29 (5):528-42\n79.\t\nOgihara T, Kikuchi K, Matuoka H et al. The Japanese Society of Hypertension Guidelines for the \nManagement of Hypertension (JSH 2009). Hypertens Res 2009 Jan;32(1):3-107 \n80.\t\nBangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_288",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication \ncompliance: a meta-analysis. Am J Med 2007;120:713-19 \n81.\t\nAjay K.G., Arshad S. and Neil R.P. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations \nof Antihypertensive Agents: A Meta-Analysis. Hypertension 2010;55:399-407 \n82.\t\nAlan H.G., Jan N.B., Barry L.C., George L.B. Position Article Combination therapy in hypertension, J Am \nSoc Hypertens 2010;4(2) :90\u201398 \n83.\t\nFeldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated \nhypertension: a cluster randomized, controlled trial. Hypertension 2009;53: 646\u201353 \n84.\t\nBrown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium-channel blocker amlodipine",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_289",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "84.\t\nBrown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium-channel blocker amlodipine \ncombination as an initial treatment strategy for hypertension. Lancet 2011;9762(377):312-320.\n85.\t\nDickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly ; a comparison of \nfixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am \nJ Cardiovasc Drugs 2008;8(1):45-50\n86.\t\nPROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering \nregimen among 6105 individuals with previous stroke or transientis chaemic attack. Lancet 2001; 358: \n1033\u201341\n87.\t\nDahlof B, Devereux RB, Kjeldsen SE, et al.Losartan Intervention for Endpoint reduction in hypertension \nstudy (LIFE). Lancet 2002;359:1004-1010\n88.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_290",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "study (LIFE). Lancet 2002;359:1004-1010\n88.\t\nPepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist \nhypertension treatment strategy for patients with coronary artery disease. The International Verapamil-\nTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290(21):2805\u20132816\n89.\t\nJulius S, Weber MA, Kjeldsen SE, et al. The Valsartan Anti-hypertensive Long-Term Use Evaluation \n(VALUE) Trial. Outcomes in Patients Receiving Monotherapy. Hypertension 2006;48:385-391 \n90.\t\nDahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive \nregimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazideas",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_291",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazideas \nrequired, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-\nBPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895\u2013906.\n91.\t\nPatel A. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide \non macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE \ntrial): a randomised controlled trial. Lancet 2007;370:829-840 \n92.\t\nKenneth Jamerson, Michael A. Weber, George L. Bakris et al. ACCOMPLISH Trial Investigators. \nBenazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med \n2008;359:2417-28.\n93.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_292",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "2008;359:2417-28.\n93.\t\nNigel S. Beckett, Ruth Peters, Astrid E. Fletcher et al. Treatment of Hypertension in Patients 80 Years of \nAge or Older, N Engl J Med 2008;358(18):1887-98\n94.\t\nMoser M, Setaro JF. Resistant or difficult to control hypertension. N Engl J Med 2006;355:385-92    \n95.\t\nvan den Born BJ, Beutler JJ, Gaillard CA et al. Dutch guideline for the management of hypertensive \ncrisis- 2010 revision. Neth J Med 2011 May;69(5):248-55\n96.\t\nGonzalez Pachheco H , Morales Victorino N, Nunez Urquiza JP et al. Patients with hypertensive crises \nwho are admitted to a coronary care unit: clinical characteristics and outcomes. J Clin Hypertens 2013 \nMarc;15(3):210-4\n97.\t\nEditorial. Severe symptomless hypertension. Lancet 1989;334:1369-1370 \n98.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_293",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Marc;15(3):210-4\n97.\t\nEditorial. Severe symptomless hypertension. Lancet 1989;334:1369-1370 \n98.\t\nPergolini M The Management of hypertensive crises: a clinical review. Clin Ter 2009:160(2):151-7\n99.\t\nMarik PE, Rivera R. Hypertensive emergencies: an update. Curr Opin Crit Care 2011 Dec;17(6):569-80\n100.\t Elliot WJ. Hypertensives emergencies. Crit Care Clin 2001;17:435-451 \n101.\t Peacock WF 4th, Hilleman DE, Levy PD et al. A systematic review of nicardipine vs labetalol for the \nmanagement of hypertensive crises. Am J Emerg Med 2012 Jul: 30(6):981-93\n65\n102.\t Editorial. Thought for autoregulation in the hypertensive patient. Lancet 1979;314:510\n103.\t Messerli FH, Kowey P, Grodzicki T. Sublingual nifedipine for hypertensive emergencies. Lancet 1991;338: \n881-3",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_294",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "881-3\n104.\t ADA Position paper 2013. Diabetes Care 2013 Jan;36(1):S1-S110 \n105.\t Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on \ndiabetic nephropathy. N Engl J Med 1993;329:1456-1462 \n106.\t Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme \ninhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; \n156:286-289\n107.\t Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with \ndiabetes: a meta-regression analysis. Ann Int Med 1993;118:129-138 \n108.\t Heeg JE, de Jong PE, Van de Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_295",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Inhibition by lisinopril. Kidney Int 1989;36(2):272-9 \n109.\t Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of \ndiabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878\n110.\t Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes \nin patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869. \n111.\t Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist \nirbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60 \n112.\t Mogensen CE, Neldam S, Takkanen I, et al. Randomised controlled trial of dual blockade of renin-",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_296",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent \ndiabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-1444  \n113.\t Gaede P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment \npreserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant \n2004;19:2784-8 \n114.\t Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and \ndiabetes: a consensus approach. Am J Kidney Dis 2000;36:646-661 \n115.\t UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and \nmicrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_297",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713 \n116.\t Russell M, Fleg JL, Galloway WJ et al. Examination of lower targets for low-density lipoprotein cholesterol \nand blood pressure in diabetes\u2013the Stop Athersclerosis in Native Diabetics Study (SANDS). Am Heart J. \n2006;152:867-875\n117.\t Charlton Wilson, Chun-Chih Huang Nawar Shara et al. Cost-effectiveness of lower targets for blood \npressure and LDL Cholesterol in Diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS). \nJ Clin Lipidol 2010 May;4(3):165-172\n118. \t The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N \nEngl J Med. 2010;362(17):1575-1582",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_298",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Engl J Med. 2010;362(17):1575-1582 \n119.\t Cooper-Dehoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular \noutcomes among hypertensive patients with diabetes and coronary artery disease.  JAMA 2010;304(1): \n61-68 \n120. \t Perkovic V, de Galan BE, Ninomiya T, et al. Lowering Blood Pressure Reduces Renal Events in Type 2 \nDiabetes. J Am Soc Nephrol 2009;20(4):883-892\n121.  \tBarnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting enzyme inhibition \nin type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61 \n122.  \tRuggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med \n2004;351:1941-51",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_299",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "2004;351:1941-51 \n123.  \tHeart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular \nand microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-\nHOPE substudy. Lancet 2000;355:253-9 \n124.  \tStrippoli GFM, Craig M, Schena FP, Craig JC. Antihypertensive agents for preventing diabetic kidney \ndisease.The Cochrane Library 2010, Issue 2.  \n125.  \tHaller H, Ito S, Izzo Jr JL, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 \nDiabetes. N Engl J Med 2011;364:907-917 \n126.  \tAlberti KG, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement \nof the International Diabetes Federation task Force on Epidemiology and Prevention; National Heart, Lung,",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_300",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis \nSociety; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645 \n127.  \tThird Report of National Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment \nof High Blood Cholesterol in Adults (ATP Treatment Panel III) Final Report National Institutes of Health NIH \nPublication No 02-5215, September 2002\n128.  \tTan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment \nPanel definition of the Metabolic Syndrome to Asians? Diabetes Care 2004;27:1182-1186 \n66\n129.  \tKahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_301",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "from the American Diabetes Association and the European Association for the Study of Diabetes. \nDiabetes Care 2005;28:2289-2304 \n130.  \tGrundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the metabolic syndrome: An \nAmerican Heart Association/National Heart Lung and Blood Institute Scientific Statement. Circulation \n2005;112:2735-2752 \n131.  \tGrundy SM. Metabolic Syndrome: Connecting and reconciling the Cardiovascular and Diabetes Worlds. \nJ Am Coll Cardiol 2006;47:1093-1100 \n132.  \tWan Mohamed WN, Ismail AA, Sharifuddin A, et al. Prevalence metabolic syndrome and its risk factors \nin adult Malaysian: Results of a nationwide survey. Diab Res Clin Prac 2011;91:239-245\n133.  \tAzwany YN., Wan Bebakar W.M., Kamarul Imran M, et al. Clustering of metabolic syndrome factors in",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_302",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Malaysian population: Asian Criteria revisited. International Journal of Collaborative Research on Internal \nMedicine & Public Health, 2011;3(8):655-664 \n134.\t Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men.16 \nyear MRFIT findings. JAMA 1997;277:1293-1298 \n135.  \tMadhavan S, Stockwell D, Cohen H, et al. Renal function during antihypertensive treatment.Lancet \n1995;345:749-751\n136.  \tChronic Kidney Disease Work Group. K/DOQI clinical practice guidelines for chronic kidney disease: \nEvaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney \n2002;39:S1-S266\n137.  \tAppel LJ, Wright JT Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_303",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "disease. N Engl J Med. 2010 Sep 2;363(10):918-29 \n138.  \tRuggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-\ndiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005 Mar \n12;365(9463):939-46 \n139.  \tGansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood pressure lowering \nagents: meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-1974 \n140.\t Giatras I, Lau J, Levey AS, et al. Effect of angiotensin-converting enzyme inhibitors on the progression of \nnondiabetic renal disease:a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-345",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_304",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "nondiabetic renal disease:a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-345\n141.  \tGISEN Group.  Randomised placebo-controlled trial of effect of ramipril on decline of glomerular filtration \nrate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-\n1863 \n142.  \tLaverman GD, Navis G, Henning RH, et al. Dual renin-angiotensin system blockade at optimal doses for \nproteinuria. Kidney Int. 2002;62:1020-1025 \n143.\t Nielsen S, Dollerup J, Nielsen B, ET AL. Losartan reduces albuminuria in patients with essential \nhypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997;12:19-23 \n144.  \tKunz R, Friedrich C, Wolpers M and Mann JE. Meta-analysis : Effect of Monotherapy and Combination",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_305",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med \n2008:148:30-48   \n145.  \tBakris GL, Weir MR. Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine; \nis this a cause for concern? Arch intern Med 2000;160(5):685-93 \n146.  \tNational Kidney Foundation K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive \nAgents in Chronic Kidney Disease. Am J Kidney Dis 2004;43(suppl 1):S1-S290 \n147.  \tTaal MW, Brenner BM. Evolving strategies for renoprotection: non-diabetic chronic renal disease. Curr \nOpin Nephrol Hypertens 2001;10:523-531 \n148.  \tNavaneethan SD, Nigwekar SU, Sehgal AR et al. Aldosterone antagonists for preventing the progression",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_306",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009 Mar;4(3): \n542-51 \n149.  \tTextor S C, Lerman L. State of the Art: Renovascular Hypertension and Ischaemic Nephropathy. Am J \nHypertens 2010;23(11):1159-1169 \n150.  \tBabool K, Evans C, Moore RH. Incidence of end-stage renal disease in medically treated patients with \nsevere bilateral atherosclerotic renovascular disease. Am J Kidney 1998;31:971\u2013977 \n151.  \tMailloux LU, Napolitano B, Belluci AG, et al. Renal vascular disease causing end-stage renal disease, \nincidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney 1994;24:622\u2013\n629 \n152. \t Pedersen EB. New tools in diagnosing renal artery stenosis. Kidney Int 2000;57:2657-2677",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_307",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "152. \t Pedersen EB. New tools in diagnosing renal artery stenosis. Kidney Int 2000;57:2657-2677  \n153.  \tOlbricht CJ, Paul K, Prokop M, et al. Minimally invasive diagnosis of renal artery stenosis by spiral \ncomputed tomography angiography. Kidney Int 1995;48:1332-1337 \n154.  \tNordmann AJ, Woo K , Parkes R, et al. Balloon angioplasty or medical therapy for hypertensive patients \nwith atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. Am J Med \n2003;114:44-50 \n155. \t Watson PS, Hadjipetrou P, Cox SV, et al. Effect of renal artery stenting on renal function and size in \npatients with atherosclerotic renovascular disease. Circulation 2000;102:671-1677  \n67\n156.\t Robert DS, Stephen CT. Renal artery stenosis, N Engl J Med 2001;344:431-442",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_308",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "67\n156.\t Robert DS, Stephen CT. Renal artery stenosis, N Engl J Med 2001;344:431-442  \n157.  \tBax L, Woittiez AJ, Kouwenberg HJ, et al. Stent Placement in Patients with atherosclerotic renal \nartery stenosis and impaired renal function: a randomized trial. Ann Int Med. 2009;150:2099 Jun \n16;150(12):840-8\n158.\t Gupta D, Chaudhary K, Nistala R. Stenting renal artery stenosis: What is the fuss all about? Rev Recent \nClin Trials. 2010 Jan;5(1);28-34\n159.  \tThe ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J \nMed. 2009;361:1953\u20131962  \n160.  \tCooper CJ, Murphy TP, Cutlip DE, et al. Stenting and Medical Therapy for Athersosclerotic Renal-Artery \nStenosis. N Engl J Med 2013; DOI:10.1056/NEJM oa1310789.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_309",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Stenosis. N Engl J Med 2013; DOI:10.1056/NEJM oa1310789. \n161.  \tJadranka BP. Renal transplant artery stenosis. Nephrol Dial Transpl  2003,18 Suppl 5:74-77 \n162.  \tJaff MR, White CJ. Vascular Disease. Diagnostic and Therapeutic Approaches. Cardiotext Publishing \n2011.  \n163.\t Slovut DP, Olin JW. Current concepts: Fibromuscular dysplasia. N Engl J Med. 2004; 350:1862\u20131871 \n164.\t Yap YG, Duong T, Bland JM, et al. Prognostic value of blood pressure measured during hospitalization \nafter acute myocardial infarction: an insight from survival trials. J Hypertens 2007;25:307\u2013313. \n165.  \tDomanski MJ, Mitchell GF, Norman JE, et al. Independent prognostic information provided by \nsphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_310",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left \nventricular dysfunction. J Am Coll Cardiol 1999;33:951\u2013958. \n166. \t Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative \noverview updated until 1 March 2003. J Hypertens, 2003 Jun;21(6):1055-76\n167. \t Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure \nsoon after myocardial infarction? A meta-regression analysis of randomized trials. Eur J Heart Failure \n2000 Sep; 2(3):333-40 \n168.\t Flather MD, Yusuf S, Kober L et al. Long \u2013 term ACE-inhibitor therapy in patients with heart failure or left",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_311",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "ventricular dysfunction: a sytematic overview of data from individual patient. ACE\u2013inhibitor Myocardial \ninfarction Collaborative Group. Lancet 2000 May 6:355(9215):1575-81  \n169.\t Werner C, Baumhakel M, Teo KK et al. RAS blockade with ARB and ACE inhibitor: current perspective \non rationale and patient selection. Clin Res Cardiol 2008 Jul; 97(7):418-31  \n170. \t McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis : beta-blocker dose, heart rate reduction and \ndeath in patients with heart failure. Ann Intern Med 2009 Jun 2:150(11):784-94\n171. \t Fauchier L, Pierra B, de Labriollet A et al. Comparison of the beneficial effect of beta-blockers on mortality \nin patients with ischaemic and non-ischaemic systolic heart failure: a meta-analysis of randomized",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_312",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in patients with ischaemic and non-ischaemic systolic heart failure: a meta-analysis of randomized \ncontrolled trials. Eur J Heart Failure 2007 Nov, 9 (11):1136-9\n172.\t Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin\u2013converting enzyme inhibitors and \nbeta blockers in the management of left ventricular systolic dysfunction according to race, gender and \ndiabetes status: a meta analysis of major clinical trials. J Am Coll Cardiol 2003 May 7;41(9):1529-38\n173. \t Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction : a systematic review \nof randomized clinical trials. Eur Heart J 2009 Feb;30(4):409-72\n174. \t Heran BS, Musini VM, Bassett K et al. Angiotensin receptor blockers for heart failure. Cochrane Database \nSyst Rev 2012 April 18.4:CD003040",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_313",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Syst Rev 2012 April 18.4:CD003040 \n175. \t Demers C,Mody A, Teo KK. ACE inhibitors in heart failure: what more do we need to know? Am J \nCardiovasc Drugs 2005:5(6):351-9\n176.\t Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and \npreserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81 \n177. \t Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection \nfraction. N Engl J Med 2008;359:2456-2467\n178.  \tAl-Mallah MH, Tleyjeh IM, Abd-Latif AA et al. Angiotensin\u2013converting enzyme inhibitors in coronary \nartery disease and preserved left ventricular systolic function : a systematic review and meta-analysis of",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_314",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "randomized controlled trials. J Am Coll Cardiol 2006 April 18;47 (8):1575-83\n179.  \tKannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing \nconditions for atrial fibrillation: population based estimates. Am J Cardiol 1998;82:2N\u20139N.  \n180.\t Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur \nHeart J 2007;28:752\u2013759.\n181. \t Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial recurrence in hypertensive \npatients. J Cardiovasc Pharmacol 2006;47:46\u201350 \n182.  \tMadrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with \nlong-lasting persistent atrial fibrillation. Circulation 2002;106:331\u20136",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_315",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "long-lasting persistent atrial fibrillation. Circulation 2002;106:331\u20136 \n183.  \tDucharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic \nchronic heart failure by candesartan in the Candesaran in Heart failure: Assessment of Reduction in \nMortality and morbidity (CHARM) program. Am Heart J 2006; 151:985\u201391\n68\n184.  \tMaggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with \nheart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548\u201357 \n185. \t Zhang Y, Zhang P, Mu Y et al. The role of renin-angiotensin system blockade therapy in the prevention",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_316",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "of atrial fibrillation : a meta analysis of randomized controlled trials. Clin Pharmacol Ther 2010 Oct; 88(4): \n521-31\n186. \t Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting \nenzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832\u2013\n1839.  \n187. \t Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade \nuse in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med 2007 Jun; 261 \n(6):577-86  \n188.\t de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial  fibrillation : a \nmeta-analysis. Arch Intern Med 2005 Feb 14; 165(3):258-62",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_317",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "meta-analysis. Arch Intern Med 2005 Feb 14; 165(3):258-62\n189. \t Selvin E,Erlinger T. Prevalence of risk factors for peripheral arterial disease in the United Staes. Result \nfrom the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004;110:738-743 \n190. \t Elizabeth Selvin, Alan T. Hirsch. Contemporary Risk Factor Control and Walking Dysfunction in individuals \nwith Peripheral Artery Disease: NHANES 1999-2004. Atherosclerosis 2008 December 201(2):425-433\n191. \t Clement DL. Treatment of hypertension in patients with peripheral arterial disease: an update. Curr \nHypertens Rep 2009 Aug;11(4):271-6\n192.  \tTravis M Falconer, John W Eikboom, Graeme J Hankey et al. Management of peripheral arterial disease",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_318",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in the elderly: focus on cilostazol. Clin Interv Aging 2008 March; 3(1):17-23\n193. \t Diez J, Gonzalez A, Lopez B et al. Effects of antihypertensive agents on the left ventricle: clinical \nimplication. Am J Cardiovasc Drugs 2001;1(4):263-73\n194. \t Fagard RH,Celis H,Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta \nanalysis of randomized comparative studies. Hypertension 2009 Nov;54(5):1084-91  \n195.  \tMackay J, Mensah G. The Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health \nOrganization 2004.  (http://www.who.int/cardiovascular diseases/resources/atlas/en/)   \n196.  \tLawes CM, Rodgers A, Bennett DA, et al. Asia Pacific Cohort Studies Collaboration: Blood pressure and",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_319",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "cardiovascular diseases in the Asia Pacific region. J Hypertens 2003;21:707-716 \n197.  \tAsia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia \nPacific region. A pooled analysis. Hypertension 2003;42:69-75 \n198.  \tMartiniuk AL, Lee CM, Lawes CM, et al. For the Asia-Pacific Cohort Studies Collaboration. Hypertension: \nits prevalence and population attributable fraction for mortality from cardiovascular disease in the Asia-\nPacific region. J Hypertens 2007;25:73-79 \n199.  \tWorld Health Organization. http/www.who.int (global burden of stroke)     \n200.  \tVenketasubramaniam N. The epidemiology of stroke in ASEAN countries \u2013 A review. Neurol J SEA \n1998;3:9-14 \n201.  \tHealth Fact 2009. Ministry of Health, Malaysia",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_320",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "1998;3:9-14 \n201.  \tHealth Fact 2009. Ministry of Health, Malaysia \n202.  \tChalmers J, Todd A, Chapman N, et al: International Society of Hypertension Writing Group. International \nSociety of Hypertension Writing Group. International Society of Hypertension (ISH): Statement on Blood \nPressure Lowering and Stroke Prevention. J Hypertens 2003;21:651\u2013663 \n203.  \tLiu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients \nwith isolated systolic hypertension. Systolic Hypertension in China (Sys-China) Collaborative Group. J \nHypertens 1998;16:1823-1829 \n204.  \tStaessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_321",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe \n(Syst-Eur) Trial Investigators. Lancet 1997;350:757-764 \n205.\t O\u2019Brien ET, Beevers DG, Marshall H. ABC of Hypertension. BMJ. 3rd edition 1995;1-92 \n206.  \tNational High Blood Pressure Education Program Working Group report on primary prevention of \nhypertension. Arch Intern Med 1993;153:186-208 \n207.  \tLiu L, Zhao Y, Liu G, et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a \nrandomized long-term placebo controlled trial in Chinese hypertensive patients. J Hypertens \n2005;23:2157-2172 \n208.  \tSpengos K, Tsivgoulis G, Zakopoulos N. Blood Pressure Management in Acute Stroke:  A Long-Standing \nDebate. Eur Neurol 2006;55:123\u2013135",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_322",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Debate. Eur Neurol 2006;55:123\u2013135 \n209.  \tCAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomized placebo controlled trial of \nearly aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641\u20131649 \n210.\t International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of \naspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. \nLancet 1997;349:1569\u20131581 \n211.  \tKidwell CS, Saver JL, Mattiello J, et al. Thrombolytic reversal of acute human cerebral Ischaemic injury \nshown by diffusion/perfusion magnetic resonance imaging. Ann Neurol.  2000;47:621\u2013469 \n69\n212.  \tPhillips SJ. Pathophysiology and management of hypertension in acute Ischaemic stroke. Hypertension",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_323",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "1994;23:131\u2013136 \n213.  \tAdams HP Jr, Adams RJ, Brott T, et al. Stroke Council of the American Stroke Association. Guidelines for \nthe early management of patients with Ischaemic stroke: A scientific statement from the Stroke Council \nof the American Stroke Association. Stroke 2003;34:1056\u20131083 \n214.  \tAdams H, Adams R, Del Zoppo G, Goldstein LB. Stroke Council of the American Heart Association; \nAmerican Stroke Association (2005). Guidelines for the early management of patients with Ischaemic \nstroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart \nAssociation / American Stroke Association. Stroke 2005;36:916\u2013923 \n215.  \tBroderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of  spontaneous intracerebral",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_324",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hemorrhage: a statement for healthcare professionals from a  special writing group of the Stroke Council, \nAmerican Heart Association. Stroke 1999;30: 905\u2013915 \n216.  \tWahlgren NG, MacMahon DG, de Keyser J, et al. INWEST Study Group: Intravenous  Nimodipine West \nEuropean Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc \nDis 1994;4:204\u2013210 \n217.  \tHacke W, Kaste M, Bogousslavsky J, et al. European Stroke Initiative Executive Committee and the EUSI \nWriting Committee. European Stroke Initiative Recommendations for Stroke Management\u2013Update 2003. \nCerebrovasc Dis 2003;16:311-337 \n218. \t Sakamoto Y, Koga M, Yamagami H et al. Systolic blood pressure after intravevous antihypertensive",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_325",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "treatment and clinical outcomes in hyperacute intraceberal hemorrhage: the stroke acute management \nwith urgent risk-factor assessment and improvement intracerebral hemorrhagic study. Stroke 2013 \nJuly;44(70):1846-51\n219. \t Anderson CS, Heeley E, Huang Y et al. Rapid blood-presure lowering in patients with acute intracerebral \nhaemorrhage. N Engl J Med. 2013 Jun 20:368(25): 2355-65 \n220.  \tWarlow C, Sudlow C, Dennis M, et al. Stroke. Lancet 2003;362:1211-1224 \n221.  \tKein R, Steinke W, Daffertshofer  M et al. Stroke recurrence in patients with symptomatic vs asymptomatic \nmiddle cerebral artery disease. Neurology 2005 Sep 27: 65(6):859-64\n222. \t Wolfe CD, Crichton SL, Heuschmann PU et al. Estimates of outcomes up to ten years after stroke:",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_326",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "analysis from prospective South London Stroke Register. PLoS Med 2011 May:8(5);E1001033 \n223.  \tStaessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update \nincluding the 2003\u20132004 secondary prevention trials. Hypertens Res 2005; 28:385\u2013407 \n224.  \tLawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published \nreviews. Stroke. 2004;35:776 \u2013785 \n225.  \tSchrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, Eprosartan compared \nwith Nitrendipine for secondary prevention. Principal results of a prospective randomized controlled \nstudy (MOSES). Stroke 2005;36:1218-1226 \n226.  \tYusuf S, Diener HC, Sacco RL, et al. ProFESS Study Group. Telmisartan to Prevent Recurrent Stroke and",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_327",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Cardiovascular Events. N Engl J Med 2008; 359:1225-1237 \n227.  \tSandset EC, Bath MWP, Boysen G, Jatuzis D. SCAST Study Group. The angiotensin-receptor blocker \ncandesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. \nLancet 2011;377(9767):741-750 \n228.  \tReboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting  enzyme inhibitors \nand angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. \nJ Hypertens 2008;26(7):1282-1289  \n229.  \tSPS3 Study Group. Benavente OR,Coffy CS,Conwif R et al. Blood-pressure targets in patients with \nrecent lacunar stroke: the SPS3 randomsied trial. Lancet 2013 Aug 10;382 (9891):507-15",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_328",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "recent lacunar stroke: the SPS3 randomsied trial. Lancet 2013 Aug 10;382 (9891):507-15 \n230.  \tNational High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. \nNational High Blood Pressure Education Program Working Group. Hypertens 1994;23:275-285 \n231.  \tHansson L, Julius S, Carruthers SG et al. Effects of intensive blood pressure lowering and low dose \naspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) \nrandomised trial. Lancet 1998;351:1755-62 \n232.  \tZhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. \nHypertension 2006;48;187-195 \n233.\t Tuomilehto J. Medical Research Council trial of treatment of hypertension in older adults: principal",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_329",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "results. MRC Working Party. BMJ 1992;304:405-412 \n234.  MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five \nrandomized trials in elderly hypertensive. Clin Exp Hypertens 1993;15:967-978 \n235.\t Gianni M, Bosch J, Pogue J et al. Effect of long term ACE Inhibitor Therapy in elderly vascular disease \npatients. Eur Heart J 2007 Jun;28(11):1382-8 \n236.\t Sean P, Kennedy, Brian A Lawlor, Rose Anne Kenny et al. Blood Pressure and Dementia - a \nComprehensive Review. Ther Adv Neurol Disord. 2009, July;2(4):241-260\n70\n237.\t Whelton PK, Appel LJ, Espeland MA, et al. Sodium restriction and weight loss in the treatment of \nhypertension in older persons: A randomised controlled trial of non-pharmacologic interventions in the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_330",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "elderly (TONE). JAMA 1998;279(11):839-846 \t\n238.  \tBrown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive \ndisorders of pregnancy: statement from the International Society for the Study of Hypertension in \nPregnancy (ISSHP). Hypertension in Pregnancy 2001;20(1):ix-xiv \n239.  \tReport of the National High Blood Pressure Education Program Working Group on High Blood Pressure \nin Pregnancy. Am J Obstet Gynecol 2000;183:S1-22 \n240.  \tWHO Technical Report Series 1996; No. 862 \n241.  \tDavey DA. Hypertensive disorders of pregnancy. In Dewhurst\u2019s Textbook of Obstetrics and Gynaecology \nfor Postgraduates Whitfield CR (editor), 5th edition, 1995;175-227 \n242.  \tMontan S. Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 2004;16:111-",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_331",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "115 \n243.  \tThe Royal College of Obstetricians and Gynaecologists & Royal College of Midwives. Hypertension in \npregnancy: the management of hypertensive disorders during pregnancy. NICE Clinical Guideline 2011 \n244.  \tDuley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its \ncomplications. Cochrane Database of Systematic Reviews 2007;(2)CD004659. \n245.  \tRoberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on \nHypertension During Pregnancy. Hypertension 2003;41:437-445 \n246. \t Magee LA, Helewa M, Moutquin J-M, von Dadelszen P. Diagnosis, evaluation and management of the \nhypertensive disorders of pregnancy. J Obstet Gyneacol Canada 2008;30(3)Suppl.1:S1-48",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_332",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "hypertensive disorders of pregnancy. J Obstet Gyneacol Canada 2008;30(3)Suppl.1:S1-48 \n247.  \tVillar J on behalf of the WHO Calcium Supplementation for the Prevention of Preeclampsia Trial Group. \nWorld Health Organization randomized trial of calcium supplementation among low calcium intake \npregnant women. Am J Obstet Gynecol 2006;194:639-649. \n248.  \tImdad A, Jabeen A, Bhutta ZA (2011). Role of calcium supplementation during pregnancy in reducing \nrisk of developing gestational hypertensive disorders: a meta-analysis of studies from developing \ncountries. BMC Public Health 2011;11(Suppl.3):S18 DOI:10.1186/1471-2458-11-S3-S18\n249.  \tMakrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_333",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. The Cochrane Library \n2006; Issue 3\n250.  \tMeher S, Duley L. Garlic for preventing pre-eclampsia and its complications. The Cochrane Library 2006; \nIssue 3 \n251.  \tThaver D, Saeed MA, Bhutta ZA. Pyridoxine (vitamin B6) supplementation in pregnancy. The Cochrane \nLibrary 2006; Issue 3 \n252.  \tPoston L, Briley AL, Seed PT, et al. VIP Trial Consortium. Vitamin C and vitamin E in   pregnant women \nat risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006;367(9517):1119-20 \n253.   McCaw-Binns AM, Ashley DE, Knight LP, et al. Strategies to prevent eclampsia in a   developing country: \nI. Reorganization of maternity services. Int J Obstet Gynecol 2004;87:286-294",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_334",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "I. Reorganization of maternity services. Int J Obstet Gynecol 2004;87:286-294 \n254.\t MacGillivray I, McCaw-Binns AM, Ashley DE, et al. Strategies to prevent eclampsia in a developing \ncountry: II. Use of a maternal pictorial card. Int J Obstet Gynecol 2004; 87(3) : 295-300 \n255.  \tRoyal College of Obstetricians and Gynaecologists (RCOG), Guideline No.10 (A), March 2006. The \nmanagement of severe pre-eclampsia / eclampsia. \n256.  \tMagee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: \na meta-analysis. BMJ 2003;327(7421):955-960 \n257.  \tBrown MA, Buddle ML, Farrel T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment \nof severe hypertension in pregnancy. Am J Obstet Gynecol 2002;187:1046-1050",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_335",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "of severe hypertension in pregnancy. Am J Obstet Gynecol 2002;187:1046-1050 \n258.  \tThe Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence \nfrom the Collaborative Eclampsia Trial. Lancet 1995;345:1455-1463 \n259.  \tThe Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from \nmagnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-\n1890 \n260.  \tDoyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for \nneuroprotection of the fetus (Review). The Cochrane Library 2010; Issue 1.\n261.  \tFerrazanni S, De Carolis S, Pomini F, et al. The duration of hypertension in the puerperium of preeclamptic",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_336",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "women: relationship with renal impairment and week of delivery. Am J Obstet Gynecol 1994;171(2): 506-\n512. \n262.  \tMatthys LA, Coppage KH, Lambers DS, et al. Delayed postpartum preeclampsia: an experience of 151 \ncases. Am J Obstet Gynecol 2004;190:1464-6 \n263. \t Goldenberg RL, McClure EM, MacGuire ER, et al. Lessons for low-income regions  following the \nreduction in hypertension-related maternal mortality in high-income countries. Int J Gynecol Obstet \n2011;113:91-93 \n71\n264.  \tFrishman W, Schlocker SJ, Awad K, Tejani N. Pathophysiology and medical management of systemic \nhypertension in pregnancy. Cardiology in Review 2005;13:274-84 \n265.  \tReproductive Health Supplies Coalition. Magnesium sulphate. Product Brief: Caucus on New and \nUnderused Reproductive Health Technologies 2012",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_337",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Underused Reproductive Health Technologies 2012 \n266.\t Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam infusion in \neclampsia. Cochrane Database Syst Rev 2010 Dec;(12):CD000127\n267. \t Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone \ntherapies. Endocrinol Metab Clin N Am 2011;40:419-432 \n268. \t Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure \nin the pill-free interval. Contraception 1993;47:367-76 \n269. \t Guidelines for management of hypertension: report of the fourth working party of the British Hypertension \nSociety, 2004. BHS IV \n270. \t Department of Reproductive Health. Medical Eligibility Criteria for Contraceptive Use 2009, 4th edition.",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_338",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "World Health Organisation.\n271. \t Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an anti-\nmineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood \npressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21 \n272.  \tHulley S, Grady D, Bush T et al. Randomised trial of estrogen plus progestin for secondary prevention of \ncoronary heart disease in post menopausal women. Heart and Estrogen/progestin Replacement Study \n( HERS) Research Group. JAMA 1998 Aug 19;280(7):605-13.\n273. \t Women\u2019s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal \nwomen with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 2004;291",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_339",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 2004;291\n\t\n(14):1701-1712 \n274. \t White WB, Hanes V, Chauhan V et al. Effects of a new hormone therapy, drospirenone and 17-beta-\nestradiol, in post-menopausal women with hypertension. Hypertension 2006;48: 246-53 \n275.  \tSingh HP, Hurley RM Myers TF. Neonatal hypertension: incidence and risk factors. Am J Hypertens 1992; \n5:51-55 \n276.\t Barrington KJ, Umbilical. Artery catheters in the newborn: effects of catheter materials. Cochrane \nDatabase of Syst Rev: 2010:CD000505 \n277.  \tJM Dionne, CL Abitbol, JT Flynn. Hypertension in infancy: diagnosis, management and outcome. Pediatr \nNephrol 2012;27:17-32",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_340",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Nephrol 2012;27:17-32 \n278.   Nwanko M, Lorenz J, Gardiner J A. standard protocol for blood pressure measurements in the newborn. \nPediatrics 1997(10):99  \n279.\t Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy.\n\t\nJ Pediatr 1988;112:805-810 \n280.\t Guron G, Friberg P. An intact renin angiotensin system is a prerequisite for normal renal development.\n\t\nJ Hypertens 2000;18:123-137 \n281.  \tSorof J, Lai D, Turner J, et al. Overweight ethnicity and the prevalence of hypertension in school aged \nchildren. Pediatrics 2004;113:475-82 \n282.   Jago R, Harrell JS, McMurray RG, et al. Prevalence of abnormal lipid and blood pressure values among \nan ethnically diverse population of eighth grade adolescents and screening implications. Pediatrics",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_341",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "2006;117:2065-73 \n283.  The Fourth Report of the Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and \nAdolescents. National High Blood Pressure Education Program Working Group on High Blood Pressure \nin Children and Adolescents. Pediatrics 2004;114:555-576 \n284.  \tRobinson RF, Batisky DL, Hayes JR, et al. Body Mass Index in primary and secondary pediatric \nhypertension. Pediatr Nephrol 2004;19:1379-1384 \n285.  \tFlynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. \nPediatr Nephrol 2005;20:961-966 \n286.  \tBlande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol 2009;24: \n1939-1949",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_342",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "1939-1949  \n287.  \tFlynn JT, Daniels SR. Pharmacological treatment of hypertension in children and adolescents. J Pediatr \n2006;149:746-754 \n288.  \tFlynn JT. Hypertension in the young: epidemiology, sequelae and therapy. Nephrol Dial Transplant  2009; \n24:370-375 \n289.  \tJonsson B, Carides GW, Burke TA, et al. Cost effectiveness of losartan in patients with hypertension and \nLVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens 2005;23:1425-1431 \n290.  \tIMS Health quarterly pharmaceutical market survey update - data accessed on March 2012. Subscribed \ndata available from IMS Health Malaysia Sdn. Bhd.\n291.  \tHealth Informatic Centre, Ministry of Health 2012  \n72\n292.  \tMN Amrizal, Y Rohaizat, Ahmed Z et al. Casemix Costing in Universiti Kebangsaan Malaysia Hospital",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_343",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "using the Top-Down Approach: Cost Analysis for Cardiology Cases 2005. Malaysia J of Public Health \nMedicine 2007;5(suppl 2):33-44  \n293.  \tAniza I, Syafrawati, Saperi S, et al. Developing the cost for Uncomplicated Acute ST Elevated Myocardial \nInfarction (STEMI Primary Percutaneous Coronary Intervention) Using Step down and Activity Based \nCosting at UKMMC. Malaysian J Community Health 2011: Vol 17 No.1 26-31\n294.  \tChin SP, Jeyaindran S, Azhari R et al. Acute Coronary Syndrome (ACS) Registry \u2013 Leading the Charge \nfor National Cardiovascular Disease (NCVD) Database. Med J Malaysia 2008;63 Supplement:29-36  \n295.  \tLim YN, Ong LM and Goh BL. Eighteen Report of the Malaysian Dialysis and Transplant  Registry, 2011. \nKuala Lumpur, 2011",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_344",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Kuala Lumpur, 2011  \n296. \t Hooi LS, Lim TO, Goh A et al. Economic Evaluation of Centre Haemodialysis and Continuous Ambulatory \nPeritoneal Dialysis in Ministry of Health Hospitals, Malaysia. Nephrology 2005;10:25\u201332  \n297.  \tCollins R, MacMahon S. Blood pressure, antihypertensives drug treatment and the risks of stroke and of \ncoronary heart disease. British Medical Bulletin 1994;50:272-98 \n298. \t Vasavada N, Saha C, Agarwal R. A double blind randomised crossover trial of two loop diuretics in \nchronic kidney disease. Kidney Int 2003;64:632\n299.  \tDahlof B, Lindholm LH, Hansson L, et al.  Morbidity and mortality in the Swedish Trial in Old Patients with \nHypertension (STOP-Hypertension).  Lancet 1991;338:1281-1285",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_345",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Hypertension (STOP-Hypertension).  Lancet 1991;338:1281-1285 \n300. \t Sulaiman MM, Rahman ARA, Noor AR. Effectiveness of combination of therapy with or without diuretics \nin the treatment of essential hypertensive. Asia Pacific Journal of Pharmacology 2001;15:17-24 \n301.  \tFrishman, WH, Bryzinski, BS, Coulson, LR, et al. A multifactorial trial design to assess combination \ntherapy in hypertension. Arch Intern Med 1994;154:1461\n302.  \tStergiou GS, Makris T, Papavasiliou M, et al. Comparison of antihypertensive effects of an angiotensin-\nconverting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not \ncontrolled by angiotensin receptor blocker monotherapy. J Hypertens 2005;23:883",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_346",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "controlled by angiotensin receptor blocker monotherapy. J Hypertens 2005;23:883\n303.\t Dorsch MP, Brenda W. Gillespie BW, Erickson SR, et al. Chlorthalidone Reduces Cardiovascular Events \nCompared With Hydrochlorothiazide : A Retrospective Cohort  Analysis. Hypertension 2011;57:689-694 \n304.\t Carlsen, JE, Kober, L, Torp-Pedersen, et al. Relation between dose of bendrofluazide, antihypertensive \neffect, and adverse biochemical effects. BMJ 1990;300:975 \n305.\t Wasswertheil-Smoller, S, Blaufox, MD, Oberman, A, et al. Effect of antihypertensives on sexual function \nand quality of life: The TAIM study. Ann Intern Med 1991;114:613\n306.\t Siscovick, DS, Ragunathan, TE, Psaty, BM, et al. Diuretic therapy for hypertension and the risk of primary",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_347",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "cardiac arrest. N Engl J Med 1994 Jun 30;330(26):1852-7\n307. \t Holman RR, Paul SK, Bethel MA, et al. Long term follow-up after tight control of blood pressure in type \n2 diabetes. N Engl J Med 2008;359:1565-76 \n308. \t Beevers DG. Beta-Blockers for Hypertension: Time to call a halt. J Hum Hypertens 1998;12:807-10 \n309. \t Messerli FH, Beevers DG, Franklin SS, Pickering TG. Beta-Blockers in  Hypertension- the emperor has \nno clothes: An open center to present and  prospective drafters of new guidelines for the treatment of \nHypertension. Am J Hypertens. 2003;16(10):870-3 \n310. \t Wiliams B, Levy PS, Thom SM, et al. Differential impact of blood pressure lowering drugs on central \nblood pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation [CAF\u00c9]",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_348",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "study. Circulation 2006;113:1213-1225 \n311. \t Conlin PR. Four-Year persistence patterns among patients initiating therapy with the angiotensin II \nreceptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001;23:1999-2010 \n312.\t Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-\nterm reductions in blood pressure: overview of randomised drug trials in their epidemiological context. \nLancet 1990;335:827-838 \n313.\t Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14: \n1237-1245 \n314. \t Messerli FH, Noll G, Lindholm LH, et al. The role of dihydropyridine calcium channel blockers in the",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_349",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "treatment of hypertension and cardiovascular disease\u2013An update. European Cardiology 2006;2(1):16-20 \n315.\t Messerli FH, Grossman E. The use of sublingual nifedipine: a continuing concern. Arch Intern Med \n1999;159:2259-2260 \n316. \t Bangalore S, Parkar S, Messerli FH. Long-Acting Calcium Antagonists in Patients with Coronary Artery \nDisease: A Meta-Analysis. Am J Med 2009;122(4):356-365 \n317.  \tSiragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric \noxide, cGMP, and TNF-\u2202 production after cardiac ischemia. J Cardiovasc Pharmacol 2006; 47:636\u2013642 \n318.  \tFerrari R. Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular \nprotection. Eur Heart J 2008;10(suppl G):G13-G20",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_350",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "protection. Eur Heart J 2008;10(suppl G):G13-G20 \n319.  The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. \nResults of the Cooperative North Scardinarian Enalapril Survey Study (CONSENSUS): N Engl J Med \n1987;4:316:1429-35 \n73\n320.\t The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in \nasymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327:685-91. \n321.\t Effect of Ramipril and morbidity of survivors of acute myocardial with clinical evidence of heart failure. \nThe Acute Infarction Ramipril Efficacy Efficacy (AIRE) study investigators. Lancet 1993;2;342:821-8",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_351",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "The Acute Infarction Ramipril Efficacy Efficacy (AIRE) study investigators. Lancet 1993;2;342:821-8\n322.\t GISSI-3: Effects of Lisinopril and transdermal glyceryl tritrate singly and together on 6-week mortality and \nventricular function after acute myocardial infarction. Lancet 1994; 343:115-22\n323.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate and intraveneous \nmagnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 Collaborative \nGroup. Lancet 1995; 345:609-85 \n324.  \tThe effect of the Angiotensin-Converting-enzyme inhibitor Zofenorpil on mortality and morbidity after \nanterior myocardial infarction. The Survival Infarction Long term Evaluation (SMILE) study investigators. \nN Engl J Med 1995;2:332: 80-5",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_352",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "N Engl J Med 1995;2:332: 80-5 \n325.  \tChiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin converting enzyme inhibition and renal protection in \nnondiabetic patients:The data of the meta-analyses. J Am Soc Nephrol 2005;16:S58\u2013S63 \n326.\t Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. \nN Engl J Med 2008;358:1547-59 \n327.  \tYusuf S, Teo KK, Anderson C, et al. Effects of the angiotensin receptor blocker telmisartan on \ncardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A \nrandomised controlled trial. Lancet 2008;372(9644):1174-83 \n328.  \tBerl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_353",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-549 \n329.  \tMcMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart \nfailure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the \nCHARM\u2013Added trial. Lancet 2003;362:767-71 \n330.\t Jay Cohn, Gianni Tognori for Valsartan Heart Failure Trial Investigator. A Randomised Trial of the \nAngiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. N Engl J Med. 2001; 345:1667-1675.\n331.  \tBlood Pressure Lowering Treatment Trialist\u2019s Collaboration Turnbull F, Neal B, Pfeffer M, et al. Blood \npressure-dependent and independent effects of agent that inhibit the renin-angiotensin system. J \nHypertens 2007;25:951-8",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_354",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Hypertens 2007;25:951-8 \n332.  \tSipahi I, Debanne S, Rowland D, et al. Angiotensin receptor blockade and risk of cancer: meta-analysis \nof randomised controlled trials. Lancet Oncol 2010;11:627-36 \n333.  \tBangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-\nanalyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol \n2011;12:65-82 \n334.  \tMcMurray JJ, Holman RR, Haffner SM, et al. for the NAVIGATOR study group. Effect of valsartan on the \nincidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490 \n335.  \tvan Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_355",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system \ninhibitors involving 158,998 patients. Eur Heart J 2012;33(16):2088-97\n336.\t Pfeffer MA, McMurray JJV, Velazquez EJ, et al. for the Valsartan in Acute Myocardial Infarction Trial \ninvestigators (VALIANT). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, \nleft ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906\n337.\t Wood JM, Maibaum J, Rahuel J, et. al Structure-based design of Aliskren, a novel orally effective renin \ninhibitors. Biochen Biophys Res Commun, 2003;308:698-705 \n338.  Kelly DJ, Wilkinson-Berka JL, Gilbert RE. Renin inhibition; new potential for an old therapeutic target. \nHypertension 2005; 46:471-472",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_356",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Hypertension 2005; 46:471-472\n339.   Luft FC, Weinberger MH. Antihypertensive therapy with aliskiren. Kidney Int. 2008; 73(6): 679-83 \n340.  \tVillamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive \nefficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217\u201326 \n341.  \tDrummond W, Munger MA, Rafique EM, et al. Antihypertensive efficacy of the oral direct renin inhibitor \naliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens. \n2007;9(10):742-50 \n342.  \tUresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone \nor in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_357",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst \n2007;8(4):190-8\n343.  \tHans-Henrik Parving, for the AVOID Study Investigators. Aliskiren Combined with Losartan in Type 2 \nDiabetes and Nephropathy. N Engl J Med 2008;358(23):2433-46  \n344.  \tMcMurray JJ for Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators Effects of the oral \ndirect renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1(1):17-24 \n345. \t Hans-Henrik Parving, Barry M. Brenner, John JV McMurray et al for the ALTITUTE Investigators \nCardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med. 2012;367:2004-13.\n74",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_358",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "74\n346. \t NOVARTIS Media Release. Basel, December 20, 2011. Novartis announces termination of ALTITUDE \nstudy with Rasilez\u00ae/Tekturna\u00ae in high-risk patients with diabetes and renal impairment.(http://www.\nnovartis.com/newsroom/media-releases/en/2011/1572562.shtml), Accessed Jan 2013 \n347.  \tGillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia \nin patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-\nresponse multicenter study. J Urol 1995;154:110-115\n348.  \tKoch-Weser J, Graham R, Pettinger W. Drug therapy: prazosin. N Engl J Med 1979 ; 300 : 232-236\n349.  \tNeaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results.Treatment",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_359",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "of Mild Hypertension Study Research Group. JAMA 1993; 270:713-724\n350.  \tLund-Johansen P. Short- and long-term (six-year) hemodynamic effects of labetalol in essential \nhypertension. Am J Med 1983; 75:24-31 \n351.  \tPacker M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with \nchronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355 \n352.  \tKrum H, Coats AJS, Fowler MB, et al. Effects of initiating carvedilol in patients with severe chronic heart \nfailure: result from the COPERNICUS Study. JAMA 2003;289:712-718 \n353.  \tPoole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_360",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): \nrandomised controlled trial. Lancet 2003;362:7-13 \n354. \t Bakris GL, Fonsecs V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type \n2 diabetes and hypertension.JAMA 2004;292:2227-2236 \n355.  \tSalvi RM. Methyldopa. (http://www.inchem.org/documents/pims/pharm/methyldo.htm), accessed Jan \n2013\n356.  \tMerck Manual. Clonidine. (http://www.merck.com/mmpe/lexicomp/clonidine.html), accessed Jan 2013 \n357.  \tFenton C, Keating GM, Lyseng-Williamson KA. Moxonidine, A review of its use in Essential Hypertension \nDrugs 2006;66(4):477-496 \n358.  \tCohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_361",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659\u201367 \n359.  \tMalaysian Institute of Health Management, National Essential Hypertension Audit 2006.  \n360.\t Chia YC. Prevalence of resistant hypertension in a multiethnic cohort of hypertensive patients.\n\t\nJ Hypertens 2012;30 (e-Supplement A), e627  \n361.  \tAkmal HA, Lau GC, Shahrul ZI, et al. The Prevalence of white-coat resistant hypertension (Wc-Rh) \namongst patients referred for cathether-based renal denervation (RDN) procedure for true resistant \nhypertension (TRH) at the National Heart Institute of Malaysia. J Hypertens 2012;30( e-suppl):300 \n362.  \tMuxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_362",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "pattern of resistant hypertension. Blood Press Monit. 2003;8:181\u20135 \n363.  \tPedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary \ncause of hypertension associated with resistant hypertension. Hypertens 2011,58:811-7    \n364. \t Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with \nresistant hypertension and symptoms of sleep apnea. Chest  2004;125:112-117 \n365.   Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in \n1,125 hypertensive patients. J Am Coll Cardiol 2006;48(11):2293-300\n366.  \tDouma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: \na retrospective observational study. Lancet  2008;371:1921-1926",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_363",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "a retrospective observational study. Lancet  2008;371:1921-1926 \n367.  \tMarrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother 2010;44:1762-9 \n368.  \tSermswan A, Archawarak N. Methyldopa supplement for resistant essential hypertension: a prospective \nrandomized placebo control crossover study. J Med Assoc Thai  2003;12:1156-61 \n369. \t Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant \nhyprtension: a multicenter safety and proof- of- principle cohort study. Lancet 2009;373:1275-1281   \n370.  \tSymplicity HTN -2 Investigators: Renal sympathetic denervation in patients with treatment\u2013resistant \nhypertension (The Symplicity HTN -2 Trial ): a randomised controlled trial. Lancet 2010;376:1903-9",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_364",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "371.  \tSymplicity HTN-1 Investigators. Catheter- based renal sympathetic denervation for resistant hypertension. \nDurability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-917 \n372.\t Schmieder RE, Redon J, Grassi G, et al. ESH Postion Paper: Renal Denervation\u2013an interventional \ntherapy of resistant hypertension. J Hypertens 2012;30:837-841 \n373.\t Symplicity HTN-3 Investigators. Renal denervation in patients with uncontrolled hypertension \n(SYMPLICITY HTN-3). (http://clinicaltrials.gov/ct2/show/NCT01418261), accessed Aug 2013.  \n374.\t Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Card 2012;27(5):499-507  \n375.\t Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes:",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_365",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209-16 \n376. \t Zanchetti A, Hansson L, Dahlof B et al. Benefit and harm of low-dose aspirin in well-treated hypertensive \nat different baseline cardiovascular risk. J Hypertens 2002;20(11):2301-2307 \n75\n377.\t ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in \nmoderately hypercholesrolaemic hypertensive patients randomsied to pravastatin vs usual care: The \nAntihypertensive and Lipid \u2013 Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 2002 \nDec 18,288(23):2998-3007\n378. \t Margolis KL, Davis BR, Baimbridge C et al. Long-Term Follow-up of moderately Hypercholesterolaemic",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_366",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive \nand Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLA). J Clin Hypertens 2013 Aug: \n15(8):542-54\n379. \t Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in \nhypertensive patients who have average or lower-than-average cholesterol concentration in the Anglo-\nScandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentered randomized \ncontrolled trial. Lancet 2003;361: 1149-1158\n380. \t Peter S. Sever, Choon L Chang, Ajay K Gupta et al. The Anglo-Scandinavian Cardiac Outcome Trial. 11 \nyear mortality follow-up of the lipid lowering arm in the UK, Eur Heart J 2011.32(20):2525-2532",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "MYS_D1_CPG Hypertension 2013_chunk_367",
        "document_id": "MYS_D1_CPG Hypertension 2013",
        "text": "year mortality follow-up of the lipid lowering arm in the UK, Eur Heart J 2011.32(20):2525-2532 \n381. \t Messerli FH, Pinto L, Tang SS. Impact of systemic hypertension on the cardiovascular benefits of statin \ntherapy- a meta analysis. Am J Cardiol 2008 Feb 1;101(3):319-25\nISBN 978-967-12406-0-1",
        "metadata": {
            "year": "2013",
            "disease_type": "hypertension",
            "source": "clinical_guideline"
        }
    }
]